

Supplementary Tables and Figures

[Figure 1a](#): 2019 Cohort Sample

[Figure 1b](#): Viral LRTI Cohort Sample

[Table 1](#): International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) Diagnostic Codes Utilized to Identify Persistent and New Clinical Sequelae

[Figure 2a](#): Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2020 Comparison Group

[Figure 2b](#): Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2019 Comparison Group

[Figure 2c](#): Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the Viral LRTI Comparison Group

[Figure 2d](#): Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2019 Comparison Group and Exactly Matching Prior Dementia Comorbidity

[Table 2](#): Absolute Standardized Mean Difference After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2020, 2019, and Viral LRTI Comparison Groups

[Table 3](#): First COVID-19 Clinical Diagnosis and PCR Test Timing Among Unmatched SARS-CoV-2 Group with Both Diagnostic Methods

[Figure 3](#): Distribution of Time Difference Between First COVID-19 Clinical Diagnosis and PCR Test Timing Among Unmatched SARS-CoV-2 Group with Both Diagnostic Methods

[Table 4a](#): Cumulative Incidence and Risk Difference per 100 Individuals for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and Comparison Groups

[Table 4b](#): Incidence Rates and Hazard Ratio for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and Comparison Groups

[Table 4c](#): Cumulative Incidence and Risk Difference per 100 Individuals for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and 2019 Comparison Group Before and After Exactly Matching Prior Dementia Comorbidity

[Table 4d](#): Incidence Rates and Hazard Ratio for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and 2019 Comparison Group Before and After Exactly Matching Prior Dementia Comorbidity

[Table 5a](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

[Table 5b](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

[Table 5c](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

[Table 5d](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

[Table 5e](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

[Table 5f](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

[Table 5g](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

[Table 5h](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

[Table 5i](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

[Table 5j](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

[Table 5k](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

[Table 5l](#): Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

[Table 6a](#): Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and 2020 Comparison Group

[Table 6b](#): Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and 2019 Comparison Group

[Table 6c](#): Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and Viral LRTI Comparison Group

Figure 1a: 2019 Cohort Sample




Figure 1b: Viral LRTI Cohort Sample




Table 1: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) Diagnostic Codes Utilized to Identify Persistent and New Clinical Sequelae

Hypertension	
Hypertension	I10, I11, I12, I13, I14, I15, I16
Pulmonary Hypertension	I27
Cardiovascular Outcomes	
Cardiac Rhythm Disorders	
> Cardiac Arrhythmia	I49
> Tachycardia	I47, R00.0
> Postural Orthostatic Tachycardia Syndrome (POTs)	I49.9
CHF, Cardiomyopathy, Myocarditis	
> Congestive Heart Failure	I50.3, I50.2
> Cardiomyopathy	I42.4, I42.2, I42.3, I42.0, I25.5, I42.1, I43, I42.5, B33.24, A36.81, I42.9, I42.8
> Myocarditis	I40, B33.22, I51.4
Coronary Disease	
> Myocardial Infarction	I21, I22
> Acute Coronary Syndrome	I20.0, I21, I24
Cardiogenic Shock	R57.0
Hypercoagulability, DVT, PE, PAO	
> Hypercoagulability	D68, I82
> Deep Vein Thrombosis	I82
> Pulmonary Embolism	I26.0, I26.9
> Peripheral Arterial Occlusions	E0852, E0952, E1052, E1152, E1352, I7401, I7409, I7410, I7411, I7419, I742, I743, I744, I745, I748, I749, I7501, I7502, I7581, I7589, I96
Stroke and Sequelae	
> Ischemic Stroke and Sequelae	H34.1, I63, I64, I69


> Hemorrhagic Stroke and Sequelae	I60, I61, I62, I69
Mental Health	
Mental Health Diagnosis*	
> Anxiety Disorder	F41.1, F41.3, F41.8, F41.9 <i>Remark: F41.0 is panic disorder, not included.</i>
> Depression Diagnosis	F32, F33
> Post-traumatic Stress Disorder (PTSD)	F43.1
> Mood Disorder	F34, F39
Psychosis	F23, F29
Neurological Outcomes	
Amnesia/Memory Difficulty	R41
Migraine	G43
Peripheral Neuropathy	G62.9, G63
Encephalopathy	G93.4
Seizures	G40
Dementia	G30, G31.0, F02, F01.5, F03
Guillain-Barre Syndrome	G61.0
Diabetes	
Type 2 Diabetes (T2D) Diagnosis	E11
Liver	
Liver Test Abnormality	I85, B18, I86.4, K70, K71, K72, K73, K74, K75, K76
Nephrology Outcomes	
Kidney Injury	
> Chronic Kidney Disease	N18, I12, I13
> Acute Kidney Injury	N17
Pulmonary Outcomes	
Respiratory Failure	
> Acute Respiratory Failure	J96.0

> Chronic Respiratory Failure	J96.1
> Interstitial Lung Disease	J84
Dermatologic Outcomes	
Atopic Dermatitis Diagnosis	L20
Urticaria	L50
Herpesviral Vesicular Dermatitis	B00.1
Other Outcomes	
Sleep Apnea	G47.3
Hematology disorder	
Thrombocytopenia	D69.6, D69.5, D75.82, D69.3, D69.4
Leukopenia	D72.818, D72.819
Anemia	D50.0, D50.8, D50.9, D51, D52, D53
Symptoms	
Myalgia	B33, M79
Fatigue Diagnosis	
> Chronic Fatigue	R53.82
> Fatigue	R53
> Post-viral Fatigue	G93.3
Anosmia	R43.0

Outcomes with ">" indicate inclusion under the grouped outcome above them.


* Only the grouped outcome Mental Health Diagnosis and not the individual outcomes of Anxiety, Depression, PTSD, and Mood Disorder was reported in the analysis and accounted for in the Bonferroni correction.

Figure 2a: Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2020 Comparison Group




The absolute standardized mean differences after propensity score matching was obtained for the matched SARS-CoV-2 and 2020 comparison groups containing 87,337 matched pairs already filtered based on having at least 21 days of observation from the index date.

Figure 2b: Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2019 Comparison Group




The absolute standardized mean differences after propensity score matching was obtained for the matched SARS-CoV-2 and 2019 comparison groups containing 88,070 matched pairs already filtered based on having at least 21 days of observation from the index date.

Figure 2c: Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the Viral LRTI Comparison Group



The absolute standardized mean differences after propensity score matching was obtained for the matched SARS-CoV-2 and vLRTI comparison groups containing 73,490 matched pairs already filtered based on having at least 21 days of observation from the index date.

Figure 2d: Absolute Standardized Mean Difference Before and After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2019 Comparison Group and Exactly Matching Prior Dementia Comorbidity



The absolute standardized mean differences after propensity score matching was obtained for the matched SARS-CoV-2 and 2019 comparison groups containing 63,945 matched pairs already filtered based on having at least 21 days of observation from the index date and having either both none or with prior dementia comorbidity.

Table 2: Absolute Standardized Mean Difference After Propensity Score Matching the SARS-CoV-2 Infection Group with the 2020, 2019, and Viral LRTI Comparison Groups

Matching Variables	SARS-CoV-2 Infected and 2020 Comparison Group	SARS-CoV-2 Infected and 2019 Comparison Group	SARS-CoV-2 Infected and Viral LRTI Comparison Group
Matched Group Size	87,337 vs 87,337	88,070 vs 88,070	73,490 vs 73,490
Age	0.007	0.097	0.011
Gender (Male)	0.003	0.007	0.001
SES Index	0.021	0.012	0.007
Race/Ethnicity			
White	0.011	0.018	0.014
Black	0.011	0.019	0.001
Asian	0.002	0.007	0.009
Hispanic	0.002	0.038	0.002
Native American	0.001	0.005	0.006
Other	0.001	0.006	0.008
Index Month			
January to March	0.003	0.015	0.088
April	0.005	0.014	0.055
May	0.003	0.018	0.041
June	0.002	0.005	0.026
July	0.002	0.003	0.016
August	0.007	0.007	0.006
September	0.005	0.000	0.022
October	0.004	0.002	0.003
November	0.007	0.027	0.047
Prior Comorbidity			
AIDS/HIV	0.004	0.004	0.000
Alcohol Abuse	0.002	0.013	0.001
Blood Loss Anemia	0.004	0.008	0.022
Cerebrovascular Disease	0.007	0.038	0.024
Chronic Pulmonary Disease	0.016	0.013	0.043
Coagulopathy	0.006	0.003	0.024
Congestive Heart Failure	0.007	0.005	0.043

Deficiency Anemia	0.002	0.012	0.045
Dementia	0.006	0.165	0.027
Depression	0.007	0.055	0.008
Diabetes with Chronic Complications	0.020	0.051	0.018
Diabetes without Chronic Complications	0.019	0.038	0.019
Drug Abuse	0.002	0.022	0.005
Fluid and Electrolyte Disorders	0.000	0.019	0.037
Hypertension	0.025	0.046	0.037
Hypothyroidism	0.002	0.020	0.012
Liver Disease	0.003	0.002	0.023
Lymphoma	0.003	0.004	0.022
Metastatic Cancer	0.003	0.007	0.019
Moderate to Severe Liver Disease	0.009	0.000	0.008
Myocardial Infarction	0.000	0.007	0.022
Obesity	0.021	0.015	0.018
Other Neurological Disorders	0.006	0.108	0.006
Paralysis	0.013	0.023	0.003
Peptic Ulcer Disease	0.006	0.001	0.016
Peripheral Vascular Disease	0.002	0.047	0.026
Psychosis	0.004	0.048	0.006
Pulmonary Circulation Disorder	0.006	0.004	0.022
Renal Failure	0.014	0.035	0.016
Rheumatoid Arthritis	0.009	0.007	0.023
Solid Tumor without Metastasis	0.004	0.005	0.030
Valvular Disease	0.011	0.006	0.049
Weight Loss	0.007	0.024	0.014
Prior Conditions			
Alzheimer's Dementia	0.007	0.160	0.024
Asthma	0.011	0.001	0.027
Cystic Fibrosis	0.001	0.003	0.001

Immunodeficiency	0.003	0.007	0.014
Pulmonary Fibrosis	0.003	0.003	0.007
Sickle Cell Disease	0.003	0.006	0.002
Smoking	0.002	0.014	0.024
Thalassemia	0.004	0.002	0.002
Type 1 Diabetes	0.012	0.005	0.016
Type 2 Diabetes	0.024	0.041	0.017
Prior Inpatient Length of Stay	0.021	0.002	0.020
Prior PCP Visit Days	0.029	0.038	0.089
Prior Cardiologist Visit Days	0.002	0.079	0.104
Prior Nephrologist Visit Days	0.014	0.073	0.060
History of Individual Clinical Sequelae			
Hypertension	0.022	0.044	0.046
Pulmonary Hypertension	0.007	0.011	0.026
Cardiac Arrhythmia	0.000	0.014	0.041
Tachycardia	0.002	0.015	0.037
POTs	0.003	0.020	0.025
Congestive Heart Failure	0.008	0.014	0.041
Cardiomyopathy	0.007	0.011	0.033
Myocarditis	0.004	0.002	0.005
Myocardial Infarction	0.006	0.025	0.023
Acute Coronary Syndrome	0.004	0.024	0.023
Cardiogenic Shock	0.001	0.005	0.011
Hypercoagulability	0.000	0.001	0.027
Deep Vein Thrombosis	0.001	0.005	0.020
Pulmonary Embolism	0.001	0.010	0.015
Peripheral Arterial Occlusions	0.010	0.011	0.013
Ischemic Stroke	0.001	0.010	0.011
Hemorrhagic Stroke	0.001	0.010	0.002
Sequelae Cerebrovascular Disease	0.005	0.023	0.001
Anxiety	0.001	0.016	0.017

Depression	0.004	0.050	0.008
PTSD	0.001	0.002	0.006
Mood Disorder	0.001	0.013	0.000
Psychosis	0.012	0.021	0.002
Amnesia/Memory Difficulty	0.014	0.068	0.007
Migraine	0.004	0.004	0.007
Peripheral Neuropathy	0.003	0.014	0.009
Encephalopathy	0.015	0.005	0.017
Seizure	0.006	0.014	0.002
Dementia	0.013	0.144	0.020
Alzheimer	0.009	0.108	0.017
Guillain-Barre Syndrome	0.001	0.003	0.004
Type 2 Diabetes	0.021	0.042	0.020
Liver Test Abnormality	0.000	0.001	0.021
Chronic Kidney Disease	0.013	0.033	0.023
Acute Kidney Injury	0.004	0.020	0.037
Acute Respiratory Failure	0.008	0.024	0.025
Chronic Respiratory Failure	0.004	0.014	0.016
Interstitial Lung Disease	0.003	0.004	0.009
Atopic Dermatitis	0.002	0.005	0.010
Urticaria	0.004	0.001	0.009
Herpesviral Vesicular Dermatitis	0.000	0.003	0.000
Sleep Apnea	0.014	0.001	0.029
Thrombocytopenia	0.005	0.005	0.019
Leukopenia	0.002	0.006	0.009
Anemia	0.009	0.009	0.039
State			
TX	0.015	0.118	0.027
FL	0.011	0.121	0.046
CA	0.019	0.139	0.043
NC	0.009	0.070	0.006
NY	0.005	0.063	0.004
AZ	0.004	0.085	0.023
IL	0.010	0.060	0.025

GA	0.016	0.032	0.014
NJ	0.014	0.017	0.001
WI	0.024	0.079	0.005

Matching Variables lists down all 120 covariates exactly used for matching.


This table only includes matched SARS-CoV-2 and comparison group pairs both having at least 21 days of observation from the index date.

State only includes the top 10 states of the SARS-CoV-2 group prior to matching.

Table 3: First COVID-19 Clinical Diagnosis and PCR Test Timing Among Unmatched SARS-CoV-2 Group with Both Diagnostic Methods

Category	Count (%)
COVID diagnosis first	5,287 (33%)
PCR test and COVID diagnosis on the same day	3,313 (20%)
PCR test first	7,669 (47%)

Figure 3: Distribution of Time Difference Between First COVID-19 Clinical Diagnosis and PCR Test Timing Among Unmatched SARS-CoV-2 Group with Both Diagnostic Methods



The mean (dashed line) time difference between first COVID-19 clinical diagnosis and PCR test is 1.7 days.

Table 4a: Cumulative Incidence and Risk Difference per 100 Individuals for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and Comparison Groups

Clinical Sequelae	Category	2020 Comparison Group	2019 Comparison Group	Viral LRTI Comparison Group
	Matched Group Size	87,337 vs 87,337	88,070 vs 88,070	73,490 vs 73,490
	Follow-up days: Median (IQR)	64 (23–150)	62 (22–149)	68 (23–155)
Hypertension				
Hypertension	SARS-CoV-2 Group	11.47	13.16	15.41
	Comparison Group	7.04	7.1	14.07
	Risk Difference	4.43 (2.27 to 6.37)	6.06 (3.09 to 9.23)	1.34 (-2.1 to 5.25)
	p-value	<0.001	<0.001	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	1.03	1.03	1.05
	Comparison Group	0.67	0.88	1.54
	Risk Difference	0.36 (0.18 to 0.55)	0.14 (-0.04 to 0.36)	-0.49 (-0.71 to -0.25)
	p-value	<0.001	0.9	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.81	4.8	4.84
	Comparison Group	2.61	3.17	5.23
	Risk Difference	2.19 (1.76 to 2.57)	1.63 (1.19 to 2.06)	-0.39 (-0.81 to 0.19)
	p-value	<0.001	<0.001	1
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.82	2.86	2.85
	Comparison Group	1.76	2.18	3.18
	Risk Difference	1.06 (0.7 to 1.35)	0.68 (0.35 to 1.01)	-0.32 (-0.64 to 0.1)
	p-value	<0.001	<0.001	1
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.89	2.89	2.9
	Comparison Group	1.35	1.53	2.92
	Risk Difference	1.54 (1.19 to 1.87)	1.36 (1.05 to 1.69)	-0.02 (-0.44 to 0.35)
	p-value	<0.001	<0.001	1
> POTs				
> POTs	SARS-CoV-2 Group	1.14	1.17	1.14
	Comparison Group	0.65	0.86	1.29
	Risk Difference	0.49 (0.31 to 0.69)	0.31 (0.12 to 0.54)	-0.15 (-0.38 to 0.08)
	p-value	<0.001	<0.001	1

CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	3.08	3.09	3.22
	Comparison Group	1.75	2.19	5.6
	Risk Difference	1.33 (0.96 to 1.67)	0.9 (0.55 to 1.27)	-2.38 (-2.85 to -1.9)
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.72	2.75	2.86
	Comparison Group	1.51	1.98	4.99
	Risk Difference	1.21 (0.87 to 1.51)	0.77 (0.45 to 1.07)	-2.13 (-2.54 to -1.73)
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	1.13	1.13	1.13
	Comparison Group	0.76	0.84	1.72
	Risk Difference	0.37 (0.17 to 0.57)	0.29 (0.07 to 0.51)	-0.59 (-0.91 to -0.34)
	p-value	<0.001	<0.001	1
> Myocarditis	SARS-CoV-2 Group	0.04	0.04	0.03
	Comparison Group	0.01	0.01	0.01
	Risk Difference	0.03 (0 to 0.07)	0.03 (0 to 0.07)	0.02 (-0.01 to 0.06)
	p-value	0.11	0.16	1
Coronary Disease	SARS-CoV-2 Group	1.64	1.7	1.59
	Comparison Group	0.82	1.11	2.12
	Risk Difference	0.82 (0.61 to 1.06)	0.59 (0.35 to 0.84)	-0.53 (-0.83 to -0.22)
	p-value	<0.001	<0.001	1
> Myocardial Infarction	SARS-CoV-2 Group	1.34	1.41	1.31
	Comparison Group	0.66	0.89	1.77
	Risk Difference	0.69 (0.49 to 0.9)	0.52 (0.28 to 0.75)	-0.45 (-0.76 to -0.18)
	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.63	1.69	1.57
	Comparison Group	0.81	1.1	2.11
	Risk Difference	0.81 (0.61 to 1.02)	0.59 (0.28 to 0.83)	-0.54 (-0.85 to -0.29)
	p-value	<0.001	<0.001	1
Cardiogenic Shock	SARS-CoV-2 Group	0.14	0.12	0.14
	Comparison Group	0.07	0.1	0.22
	Risk Difference	0.06 (0 to 0.13)	0.02 (-0.05 to 0.08)	-0.08 (-0.18 to 0.01)
	p-value	0.05	1	1

Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.45	3.48	3.43
	Comparison Group	1.2	1.64	3.26
	Risk Difference	2.25 (1.97 to 2.6)	1.85 (1.51 to 2.21)	0.17 (-0.23 to 0.54)
	p-value	<0.001	<0.001	1
> Hypercoagulability	SARS-CoV-2 Group	2.37	2.39	2.36
	Comparison Group	0.9	1.25	2.33
	Risk Difference	1.47 (1.2 to 1.73)	1.14 (0.87 to 1.44)	0.03 (-0.29 to 0.38)
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.66	1.68	1.64
	Comparison Group	0.5	0.74	1.55
	Risk Difference	1.16 (0.96 to 1.36)	0.94 (0.74 to 1.14)	0.1 (-0.16 to 0.38)
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.26	1.28	1.22
	Comparison Group	0.27	0.34	1.08
	Risk Difference	0.99 (0.82 to 1.16)	0.94 (0.79 to 1.1)	0.14 (-0.05 to 0.34)
	p-value	<0.001	<0.001	0.69
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.4	0.44	0.4
	Comparison Group	0.22	0.28	0.48
	Risk Difference	0.18 (0.06 to 0.3)	0.16 (0.04 to 0.27)	-0.08 (-0.21 to 0.07)
	p-value	<0.001	<0.001	1
Stroke and Sequelae	SARS-CoV-2 Group	2.21	2.29	2.3
	Comparison Group	1.28	1.7	2.64
	Risk Difference	0.92 (0.66 to 1.19)	0.59 (0.3 to 0.89)	-0.33 (-0.66 to -0.01)
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.96	2.03	2.06
	Comparison Group	1.15	1.52	2.3
	Risk Difference	0.81 (0.57 to 1.03)	0.52 (0.26 to 0.79)	-0.24 (-0.54 to 0.09)
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.32	1.36	1.38
	Comparison Group	0.7	0.96	1.6

	Risk Difference	0.62 (0.44 to 0.84)	0.4 (0.2 to 0.6)	-0.22 (-0.47 to 0.03)
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.78	5.78	5.89
	Comparison Group	3.28	4.12	5.94
	Risk Difference	2.5 (2.04 to 3.04)	1.66 (1.21 to 2.22)	-0.06 (-0.63 to 0.51)
	p-value	<0.001	<0.001	1
Psychosis	SARS-CoV-2 Group	0.31	0.37	0.35
	Comparison Group	0.11	0.22	0.31
	Risk Difference	0.2 (0.11 to 0.28)	0.15 (0.02 to 0.27)	0.04 (-0.07 to 0.18)
	p-value	<0.001	<0.001	1
Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	4.92	5.41	5.53
	Comparison Group	2.28	3.46	5.39
	Risk Difference	2.63 (2.23 to 3.13)	1.94 (1.45 to 2.37)	0.14 (-0.44 to 0.63)
	p-value	<0.001	<0.001	1
Migraine	SARS-CoV-2 Group	0.33	0.32	0.31
	Comparison Group	0.27	0.3	0.34
	Risk Difference	0.06 (-0.05 to 0.16)	0.02 (-0.1 to 0.16)	-0.03 (-0.17 to 0.08)
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.99	0.99	0.93
	Comparison Group	0.8	1	1.16
	Risk Difference	0.19 (-0.01 to 0.38)	-0.01 (-0.22 to 0.2)	-0.23 (-0.45 to 0.02)
	p-value	0.11	1	1
Encephalopathy	SARS-CoV-2 Group	2.76	2.84	2.77
	Comparison Group	0.89	1.3	2.54
	Risk Difference	1.87 (1.58 to 2.17)	1.53 (1.28 to 1.83)	0.23 (-0.12 to 0.56)
	p-value	<0.001	<0.001	1
Seizure	SARS-CoV-2 Group	0.54	0.56	0.57
	Comparison Group	0.26	0.44	0.58
	Risk Difference	0.28 (0.16 to 0.4)	0.12 (-0.02 to 0.27)	-0.02 (-0.17 to 0.15)
	p-value	<0.001	0.37	1
Dementia	SARS-CoV-2 Group	2.5	2.89	2.97

	Comparison Group	1.01	1.55	2.26
	Risk Difference	1.49 (1.21 to 1.77)	1.34 (0.98 to 1.67)	0.71 (0.3 to 1.08)
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.02	0.02
	Comparison Group	0	0	0.02
	Risk Difference	0.02 (0 to 0.05)	0.02 (0 to 0.04)	0 (-0.03 to 0.02)
	p-value	<0.001	0.11	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.82	2.97	3.05
	Comparison Group	1.43	1.73	2.51
	Risk Difference	1.39 (1 to 1.82)	1.24 (0.72 to 1.74)	0.55 (-0.04 to 1.08)
	p-value	<0.001	<0.001	0.05
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.82	1.85	1.82
	Comparison Group	1.27	1.46	1.96
	Risk Difference	0.55 (0.29 to 0.8)	0.39 (0.09 to 0.64)	-0.14 (-0.44 to 0.21)
	p-value	<0.001	<0.001	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.24	6.64	6.75
	Comparison Group	3.65	4.78	7.03
	Risk Difference	2.59 (2.03 to 3.12)	1.86 (1.29 to 2.47)	-0.28 (-0.98 to 0.39)
	p-value	<0.001	<0.001	1
> Chronic Kidney Disease	SARS-CoV-2 Group	4.07	4.38	4.4
	Comparison Group	3.13	4	5.16
	Risk Difference	0.94 (0.48 to 1.38)	0.38 (-0.14 to 0.98)	-0.76 (-1.29 to -0.15)
	p-value	<0.001	0.58	1
> Acute Kidney Injury	SARS-CoV-2 Group	4.49	4.59	4.7
	Comparison Group	1.76	2.49	5.02
	Risk Difference	2.74 (2.39 to 3.07)	2.1 (1.71 to 2.46)	-0.32 (-0.81 to 0.07)
	p-value	<0.001	<0.001	1
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	8.96	9.15	9.03
	Comparison Group	1.41	2.03	6.64

	Risk Difference	7.55 (7.18 to 8.01)	7.12 (6.66 to 7.55)	2.39 (1.79 to 2.94)
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	7.94	8.04	8.04
	Comparison Group	1.01	1.5	4.77
	Risk Difference	6.93 (6.56 to 7.29)	6.54 (6.18 to 6.88)	3.27 (2.76 to 3.75)
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.37	1.39	1.41
	Comparison Group	0.29	0.46	1.78
	Risk Difference	1.08 (0.88 to 1.27)	0.93 (0.77 to 1.13)	-0.38 (-0.62 to -0.12)
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.29	1.39	1.29
	Comparison Group	0.44	0.61	1.74
	Risk Difference	0.85 (0.67 to 1.03)	0.79 (0.61 to 0.98)	-0.45 (-0.78 to -0.23)
	p-value	<0.001	<0.001	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.27	0.25	0.28
	Comparison Group	0.26	0.3	0.32
	Risk Difference	0 (-0.12 to 0.12)	-0.05 (-0.17 to 0.06)	-0.04 (-0.15 to 0.09)
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.19	0.18	0.21
	Comparison Group	0.11	0.19	0.23
	Risk Difference	0.08 (0 to 0.17)	-0.01 (-0.09 to 0.07)	-0.02 (-0.14 to 0.08)
	p-value	0.05	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.08	0.09	0.1
	Comparison Group	0.03	0.07	0.07
	Risk Difference	0.05 (0.01 to 0.1)	0.02 (-0.04 to 0.09)	0.03 (-0.02 to 0.1)
	p-value	<0.001	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.52	1.52	1.44
	Comparison Group	1.02	1.43	2.13
	Risk Difference	0.5 (0.22 to 0.74)	0.09 (-0.17 to 0.35)	-0.69 (-0.99 to -0.33)

	p-value	<0.001	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.92	0.95	0.85
	Comparison Group	0.6	0.57	1.03
	Risk Difference	0.32 (0.14 to 0.5)	0.38 (0.2 to 0.56)	-0.18 (-0.39 to 0.03)
	p-value	<0.001	<0.001	1
Leukopenia	SARS-CoV-2 Group	0.32	0.29	0.3
	Comparison Group	0.14	0.13	0.24
	Risk Difference	0.17 (0.09 to 0.28)	0.16 (0.08 to 0.26)	0.06 (-0.04 to 0.16)
	p-value	<0.001	<0.001	1
Anemia	SARS-CoV-2 Group	3.27	3.3	3.28
	Comparison Group	1.95	2.19	3.3
	Risk Difference	1.33 (0.97 to 1.68)	1.11 (0.74 to 1.52)	-0.02 (-0.43 to 0.39)
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.06	8.11	8.13
	Comparison Group	5.81	6.99	9.09
	Risk Difference	2.25 (1.57 to 2.95)	1.12 (0.38 to 1.86)	-0.95 (-1.71 to -0.19)
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	10.62	10.74	10.84
	Comparison Group	4.83	6.36	10.86
	Risk Difference	5.8 (5.19 to 6.57)	4.39 (3.7 to 5.21)	-0.03 (-0.85 to 0.89)
	p-value	<0.001	<0.001	1
> Fatigue	SARS-CoV-2 Group	10.49	10.61	10.7
	Comparison Group	4.83	6.35	10.84
	Risk Difference	5.66 (5.03 to 6.27)	4.26 (3.54 to 4.9)	-0.15 (-1.02 to 0.82)
	p-value	<0.001	<0.001	1
> Chronic Fatigue	SARS-CoV-2 Group	0.37	0.37	0.38
	Comparison Group	0.27	0.42	0.42
	Risk Difference	0.1 (-0.02 to 0.2)	-0.05 (-0.16 to 0.08)	-0.04 (-0.2 to 0.1)
	p-value	0.26	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.24	0.25	0.23
	Comparison Group	0.01	0.02	0.04
	Risk Difference	0.22 (0.16 to 0.29)	0.22 (0.16 to 0.3)	0.18 (0.11 to 0.26)
	p-value	<0.001	<0.001	<0.001

Anosmia	SARS-CoV-2 Group	0.07	0.07	0.06
	Comparison Group	0.03	0.03	0.04
	Risk Difference	0.03 (-0.01 to 0.08)	0.04 (-0.01 to 0.08)	0.02 (-0.02 to 0.07)
	p-value	0.74	0.26	1

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (index date + 21 days), which is 141 days after index date.

Confidence intervals were calculated based on the Bonferroni correction, i.e., $(1 - 0.05/N)$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 4b: Incidence Rates and Hazard Ratio for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and Comparison Groups

Clinical Sequelae	Category	2020 Comparison Group	2019 Comparison Group	Viral LRTI Comparison Group
	Matched Group Size	87,337 vs 87,337	88,070 vs 88,070	73,490 vs 73,490
	Follow-up days: Median (IQR)	64 (23–150)	62 (22–149)	68 (23–155)
Hypertension				
Hypertension	SARS-CoV-2 Group	512/1496.24 (0.3422)	356/919.19 (0.3873)	402/886.01 (0.4537)
	Comparison Group	347/1706.54 (0.2033)	213/992.2 (0.2147)	373/910.69 (0.4096)
	Hazard Ratio (CI)	1.7 (1.36 to 2.14)	1.88 (1.41 to 2.5)	1.1 (0.87 to 1.39)
	p-value	<0.001	<0.001	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	577/19321.56 (0.0299)	594/19431.36 (0.0306)	521/17314.9 (0.0301)
	Comparison Group	420/21440.24 (0.0196)	538/21106.98 (0.0255)	877/18591.78 (0.0472)
	Hazard Ratio (CI)	1.5 (1.22 to 1.86)	1.19 (0.98 to 1.44)	0.62 (0.52 to 0.75)
	p-value	<0.001	0.1	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	2380/15954.22 (0.1492)	2378/15901.87 (0.1495)	2131/14448.12 (0.1475)
	Comparison Group	1370/17721.64 (0.0773)	1671/17252.28 (0.0969)	2429/15325.02 (0.1585)
	Hazard Ratio (CI)	1.92 (1.72 to 2.15)	1.54 (1.39 to 1.71)	0.92 (0.83 to 1.01)
	p-value	<0.001	<0.001	1
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	1493/17373.85 (0.0859)	1521/17412.78 (0.0873)	1340/15689.08 (0.0854)
	Comparison Group	1021/19281.45 (0.0530)	1251/18889.14 (0.0662)	1614/16754.37 (0.0963)
	Hazard Ratio (CI)	1.61 (1.41 to 1.84)	1.31 (1.16 to 1.49)	0.87 (0.77 to 0.99)
	p-value	<0.001	<0.001	1
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	1633/18177.04 (0.0898)	1635/18209.86 (0.0898)	1429/16377.76 (0.0873)
	Comparison Group	813/20229.32 (0.0402)	936/19820.75 (0.0472)	1497/17536.58 (0.0854)
	Hazard Ratio (CI)	2.21 (1.92 to 2.54)	1.89 (1.65 to 2.16)	1 (0.89 to 1.13)
	p-value	<0.001	<0.001	1
> POTs				
> POTs	SARS-CoV-2 Group	686/19391.46 (0.0354)	697/19465.86 (0.0358)	602/17386.11 (0.0346)
	Comparison Group	436/21560.1 (0.0202)	548/21227.65 (0.0258)	717/18755.67 (0.0382)
	Hazard Ratio (CI)	1.73 (1.41 to 2.12)	1.38 (1.14 to 1.66)	0.89 (0.74 to 1.07)
	p-value	<0.001	<0.001	1

CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	1554/16258.01 (0.0956)	1557/16162.34 (0.0963)	1432/14618.44 (0.0980)
	Comparison Group	935/17995.61 (0.0520)	1138/17441.78 (0.0652)	2612/15309.72 (0.1706)
	Hazard Ratio (CI)	1.81 (1.58 to 2.08)	1.46 (1.28 to 1.66)	0.55 (0.5 to 0.62)
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	1450/17031.25 (0.0851)	1456/16902.5 (0.0861)	1342/15269.62 (0.0879)
	Comparison Group	853/18873.87 (0.0452)	1097/18282.16 (0.0600)	2453/16037.09 (0.1530)
	Hazard Ratio (CI)	1.85 (1.61 to 2.13)	1.42 (1.24 to 1.62)	0.55 (0.49 to 0.62)
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	624/18683.02 (0.0334)	617/18770.49 (0.0329)	559/16821.39 (0.0332)
	Comparison Group	464/20666.19 (0.0225)	501/20381.55 (0.0246)	942/18016.64 (0.0523)
	Hazard Ratio (CI)	1.47 (1.2 to 1.79)	1.32 (1.09 to 1.61)	0.62 (0.52 to 0.73)
	p-value	<0.001	<0.001	1
> Myocarditis	SARS-CoV-2 Group	25/20451.18 (0.0012)	27/20536.11 (0.0013)	17/18291.06 (0.0009)
	Comparison Group	5/22697.18 (0.0002)	9/22405.85 (0.0004)	12/19802.42 (0.0006)
	Hazard Ratio (CI)	5.36 (1.06 to 27.03)	3.19 (0.9 to 11.32)	1.58 (0.45 to 5.57)
	p-value	0.02	0.06	1
Coronary Disease	SARS-CoV-2 Group	1014/19134.15 (0.0530)	1049/19201.05 (0.0546)	851/17172.38 (0.0496)
	Comparison Group	532/21220.03 (0.0251)	720/20890.08 (0.0345)	1239/18415.78 (0.0673)
	Hazard Ratio (CI)	2.08 (1.75 to 2.48)	1.57 (1.34 to 1.83)	0.72 (0.62 to 0.83)
	p-value	<0.001	<0.001	1
> Myocardial Infarction	SARS-CoV-2 Group	853/19474.26 (0.0438)	891/19563.16 (0.0455)	723/17471.01 (0.0414)
	Comparison Group	425/21594.03 (0.0197)	578/21284.78 (0.0272)	1040/18770.43 (0.0554)
	Hazard Ratio (CI)	2.18 (1.8 to 2.65)	1.65 (1.39 to 1.97)	0.72 (0.62 to 0.85)
	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1005/19140.97 (0.0525)	1043/19205.98 (0.0543)	841/17180.32 (0.049)
	Comparison Group	528/21224.37 (0.0249)	714/20893.73 (0.0342)	1234/18421.19 (0.067)
	Hazard Ratio (CI)	2.08 (1.74 to 2.48)	1.57 (1.34 to 1.84)	0.71 (0.61 to 0.83)
	p-value	<0.001	<0.001	1
Cardiogenic Shock	SARS-CoV-2 Group	89/20391.16 (0.0044)	88/20482.64 (0.0043)	75/18243.14 (0.0041)
	Comparison Group	51/22634.76 (0.0023)	69/22341.75 (0.0031)	138/19733.61 (0.0070)
	Hazard Ratio (CI)	1.9 (1.06 to 3.39)	1.37 (0.81 to 2.33)	0.57 (0.35 to 0.91)
	p-value	0.007	1	1

Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2077/18141.41 (0.1145)	2094/18049.31 (0.1160)	1796/16242.88 (0.1106)
	Comparison Group	708/20183.03 (0.0351)	952/19687.71 (0.0484)	1728/17310.2 (0.0998)
	Hazard Ratio (CI)	3.19 (2.76 to 3.67)	2.36 (2.08 to 2.69)	1.08 (0.96 to 1.2)
	p-value	<0.001	<0.001	0.81
> Hypercoagulability	SARS-CoV-2 Group	1413/18678.28 (0.0756)	1428/18627.56 (0.0767)	1241/16729.79 (0.0742)
	Comparison Group	538/20775.54 (0.0259)	759/20338.78 (0.0373)	1275/17922.64 (0.0711)
	Hazard Ratio (CI)	2.86 (2.42 to 3.37)	2.03 (1.75 to 2.35)	1.02 (0.89 to 1.16)
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1029/19382.08 (0.0531)	1039/19374.24 (0.0536)	888/17318.41 (0.0513)
	Comparison Group	310/21542.3 (0.0144)	463/21159.16 (0.0219)	896/18632.26 (0.0481)
	Hazard Ratio (CI)	3.59 (2.9 to 4.44)	2.4 (2 to 2.89)	1.03 (0.88 to 1.21)
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	882/19906.58 (0.0443)	902/19967.13 (0.0452)	745/17811.18 (0.0418)
	Comparison Group	182/22089.27 (0.0082)	215/21759.37 (0.0099)	643/19200.91 (0.0335)
	Hazard Ratio (CI)	5.14 (3.93 to 6.71)	4.41 (3.44 to 5.66)	1.19 (0.99 to 1.42)
	p-value	<0.001	<0.001	0.04
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	255/20110.56 (0.0127)	275/20161.43 (0.0136)	221/17979.03 (0.0123)
	Comparison Group	148/22320.59 (0.0066)	181/21999.07 (0.0082)	269/19409.56 (0.0139)
	Hazard Ratio (CI)	1.88 (1.34 to 2.64)	1.64 (1.19 to 2.25)	0.87 (0.64 to 1.17)
	p-value	<0.001	<0.001	1
Stroke and Sequelae	SARS-CoV-2 Group	1318/17972.2 (0.0733)	1328/17602.23 (0.0754)	1176/15898.62 (0.0740)
	Comparison Group	744/19974.35 (0.0372)	979/19239.95 (0.0509)	1443/17105.47 (0.0844)
	Hazard Ratio (CI)	1.92 (1.66 to 2.24)	1.46 (1.27 to 1.68)	0.85 (0.75 to 0.97)
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1189/18146.25 (0.0655)	1198/17810.78 (0.0673)	1067/16068.55 (0.0664)
	Comparison Group	674/20179.02 (0.0334)	876/19471.46 (0.0450)	1270/17301.62 (0.0734)
	Hazard Ratio (CI)	1.92 (1.64 to 2.25)	1.47 (1.27 to 1.7)	0.88 (0.77 to 1.01)
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	836/19009.58 (0.044)	851/18777.63 (0.0453)	756/16903.41 (0.0447)
	Comparison Group	443/21125.82 (0.021)	615/20525.44 (0.0300)	934/18250.9 (0.0512)

	Hazard Ratio (CI)	2.04 (1.68 to 2.47)	1.48 (1.24 to 1.76)	0.85 (0.72 to 1)
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	2319/13114.98 (0.1768)	2188/12296.92 (0.1779)	2015/11387.88 (0.1769)
	Comparison Group	1469/14630.55 (0.1004)	1630/13397.87 (0.1217)	2086/12158.7 (0.1716)
	Hazard Ratio (CI)	1.76 (1.58 to 1.97)	1.46 (1.31 to 1.63)	1.01 (0.91 to 1.12)
	p-value	<0.001	<0.001	1
Psychosis	SARS-CoV-2 Group	206/20127.49 (0.0102)	240/20090.12 (0.0119)	202/17978.1 (0.0112)
	Comparison Group	82/22358.86 (0.0037)	146/21916.95 (0.0067)	173/19453.05 (0.0089)
	Hazard Ratio (CI)	2.74 (1.78 to 4.22)	1.77 (1.25 to 2.5)	1.24 (0.88 to 1.75)
	p-value	<0.001	<0.001	1
Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	2538/16342.15 (0.1553)	2578/15008.48 (0.1718)	2410/14048.53 (0.1715)
	Comparison Group	1243/18224.08 (0.0682)	1754/16295.79 (0.1076)	2438/15023.94 (0.1623)
	Hazard Ratio (CI)	2.26 (2.02 to 2.53)	1.59 (1.43 to 1.76)	1.03 (0.94 to 1.14)
	p-value	<0.001	<0.001	1
Migraine	SARS-CoV-2 Group	198/19916.2 (0.0099)	193/19979.72 (0.0097)	170/17829.44 (0.0095)
	Comparison Group	180/22078.72 (0.0082)	201/21782.62 (0.0092)	213/19266.3 (0.0111)
	Hazard Ratio (CI)	1.21 (0.86 to 1.71)	1.04 (0.75 to 1.45)	0.86 (0.61 to 1.21)
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	571/19099.24 (0.0299)	569/19082.88 (0.0298)	484/17070.33 (0.0284)
	Comparison Group	498/21185.52 (0.0235)	612/20796.75 (0.0294)	650/18362.93 (0.0354)
	Hazard Ratio (CI)	1.26 (1.03 to 1.55)	1.01 (0.83 to 1.22)	0.79 (0.65 to 0.96)
	p-value	0.004	1	1
Encephalopathy	SARS-CoV-2 Group	1766/19109.67 (0.0924)	1803/18840.72 (0.0957)	1542/16987.23 (0.0908)
	Comparison Group	569/21228.42 (0.0268)	847/20520.7 (0.0413)	1411/18263.94 (0.0773)
	Hazard Ratio (CI)	3.36 (2.87 to 3.93)	2.28 (1.99 to 2.61)	1.14 (1.01 to 1.29)
	p-value	<0.001	<0.001	0.008
Seizure	SARS-CoV-2 Group	334/19742.58 (0.0169)	349/19723.05 (0.0177)	311/17632.61 (0.0176)
	Comparison Group	168/21924.95 (0.0077)	280/21524.97 (0.0130)	344/19083.15 (0.0180)
	Hazard Ratio (CI)	2.17 (1.59 to 2.97)	1.35 (1.04 to 1.76)	0.95 (0.74 to 1.24)
	p-value	<0.001	0.005	1
Dementia	SARS-CoV-2 Group	1290/16834.55 (0.0766)	1315/14705.27 (0.0894)	1266/14164.28 (0.0894)

	Comparison Group	623/18785.25 (0.0332)	755/16007.51 (0.0472)	1053/15308.37 (0.0688)
	Hazard Ratio (CI)	2.27 (1.93 to 2.66)	1.87 (1.61 to 2.18)	1.26 (1.1 to 1.45)
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	15/20444.92 (0.0007)	15/20527.07 (0.0007)	9/18284.48 (0.0005)
	Comparison Group	3/22691.62 (0.0001)	3/22396.38 (0.0001)	10/19792.42 (0.0005)
	Hazard Ratio (CI)	5.31 (0.67 to 42.37)	5.23 (0.64 to 42.64)	0.92 (0.2 to 4.21)
	p-value	0.21	0.24	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	728/8569.02 (0.0850)	704/7599.69 (0.0926)	695/7323.44 (0.0949)
	Comparison Group	415/9683.7 (0.0429)	450/8421.53 (0.0534)	591/7794.21 (0.0758)
	Hazard Ratio (CI)	1.96 (1.6 to 2.4)	1.72 (1.41 to 2.1)	1.23 (1.02 to 1.48)
	p-value	<0.001	<0.001	0.005
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1005/18332.09 (0.0548)	1019/18324.53 (0.0556)	881/16510.34 (0.0534)
	Comparison Group	755/20396.72 (0.0370)	875/20015.15 (0.0437)	1067/17801.14 (0.0599)
	Hazard Ratio (CI)	1.47 (1.25 to 1.72)	1.26 (1.08 to 1.47)	0.88 (0.76 to 1.02)
	p-value	<0.001	<0.001	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	2509/12181.34 (0.2060)	2541/11569.58 (0.2196)	2322/10850.95 (0.2140)
	Comparison Group	1487/13505.21 (0.1101)	1753/12339.32 (0.1421)	2363/11063.82 (0.2136)
	Hazard Ratio (CI)	1.85 (1.66 to 2.06)	1.54 (1.39 to 1.71)	0.99 (0.9 to 1.09)
	p-value	<0.001	<0.001	1
> Chronic Kidney Disease	SARS-CoV-2 Group	1628/12809.25 (0.1271)	1663/12298.47 (0.1352)	1525/11508.12 (0.1325)
	Comparison Group	1305/14180.41 (0.0920)	1545/13142.37 (0.1176)	1824/11846.24 (0.1540)
	Hazard Ratio (CI)	1.36 (1.21 to 1.54)	1.14 (1.02 to 1.28)	0.84 (0.75 to 0.95)
	p-value	<0.001	0.004	1
> Acute Kidney Injury	SARS-CoV-2 Group	2807/17697.95 (0.1586)	2868/17517.41 (0.1637)	2522/15811.42 (0.1595)
	Comparison Group	1055/19684.35 (0.0536)	1419/18962.33 (0.0748)	2568/16715.62 (0.1536)
	Hazard Ratio (CI)	2.89 (2.57 to 3.25)	2.16 (1.94 to 2.4)	1.02 (0.93 to 1.11)
	p-value	<0.001	<0.001	1
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	5917/17945.69 (0.3297)	5997/17834.79 (0.3363)	5054/15881.47 (0.3182)
	Comparison Group	849/19898.64 (0.0427)	1228/19365.8 (0.0634)	3456/16753.5 (0.2063)

	Hazard Ratio (CI)	7.55 (6.7 to 8.51)	5.27 (4.76 to 5.83)	1.53 (1.42 to 1.64)
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	5676/18936.03 (0.2997)	5760/18908 (0.3046)	4880/16901.73 (0.2887)
	Comparison Group	647/21014.51 (0.0308)	956/20579.4 (0.0465)	2708/18013.61 (0.1503)
	Hazard Ratio (CI)	9.4 (8.21 to 10.77)	6.45 (5.75 to 7.22)	1.9 (1.75 to 2.05)
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	844/19752.53 (0.0427)	855/19813.77 (0.0432)	758/17607.11 (0.0431)
	Comparison Group	201/21901.35 (0.0092)	288/21557.88 (0.0134)	968/18889.4 (0.0512)
	Hazard Ratio (CI)	4.53 (3.5 to 5.87)	3.17 (2.53 to 3.96)	0.82 (0.69 to 0.96)
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	776/19590.21 (0.0396)	817/19639.86 (0.0416)	685/17458.74 (0.0392)
	Comparison Group	276/21727.79 (0.0127)	410/21402.35 (0.0192)	954/18779.13 (0.0508)
	Hazard Ratio (CI)	3.07 (2.43 to 3.86)	2.15 (1.76 to 2.63)	0.75 (0.64 to 0.89)
	p-value	<0.001	<0.001	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	161/20054.1 (0.0080)	158/20144.34 (0.0078)	152/17948.95 (0.0085)
	Comparison Group	184/22272.08 (0.0083)	195/21982.88 (0.0089)	185/19418.73 (0.0095)
	Hazard Ratio (CI)	0.97 (0.68 to 1.38)	0.88 (0.62 to 1.26)	0.88 (0.61 to 1.26)
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	119/20206.41 (0.0059)	111/20289.79 (0.0055)	113/18059.84 (0.0063)
	Comparison Group	76/22438.32 (0.0034)	132/22140.13 (0.0060)	140/19562.39 (0.0072)
	Hazard Ratio (CI)	1.73 (1.06 to 2.81)	0.91 (0.59 to 1.4)	0.87 (0.57 to 1.32)
	p-value	0.006	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	46/20379.13 (0.0023)	49/20459.65 (0.0024)	48/18220.66 (0.0026)
	Comparison Group	26/22617.21 (0.0011)	46/22320.38 (0.0021)	41/19731.31 (0.0021)
	Hazard Ratio (CI)	1.94 (0.87 to 4.35)	1.16 (0.59 to 2.27)	1.25 (0.62 to 2.5)
	p-value	0.17	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	749/16816.92 (0.0445)	755/16830.42 (0.0449)	644/15215.91 (0.0423)
	Comparison Group	541/18503.12 (0.0292)	749/18230.44 (0.0411)	1051/16227.64 (0.0648)
	Hazard Ratio (CI)	1.5 (1.25 to 1.81)	1.08 (0.91 to 1.28)	0.64 (0.54 to 0.75)

	p-value	<0.001	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	591/19549.66 (0.0302)	600/19618.55 (0.0306)	479/17508.41 (0.0274)
	Comparison Group	367/21710.18 (0.0169)	353/21374.12 (0.0165)	583/18889.97 (0.0309)
	Hazard Ratio (CI)	1.75 (1.41 to 2.18)	1.82 (1.46 to 2.27)	0.86 (0.71 to 1.06)
	p-value	<0.001	<0.001	1
Leukopenia	SARS-CoV-2 Group	203/20220.2 (0.0100)	192/20296.89 (0.0095)	166/18074.44 (0.0092)
	Comparison Group	101/22431.99 (0.0045)	96/22136.37 (0.0043)	155/19565.48 (0.0079)
	Hazard Ratio (CI)	2.19 (1.47 to 3.28)	2.15 (1.42 to 3.24)	1.15 (0.79 to 1.67)
	p-value	<0.001	<0.001	1
Anemia	SARS-CoV-2 Group	1652/16932.12 (0.0976)	1659/16780.08 (0.0989)	1490/15169.48 (0.0982)
	Comparison Group	1095/18907.59 (0.0579)	1207/18336.4 (0.0658)	1598/16229.73 (0.0985)
	Hazard Ratio (CI)	1.67 (1.47 to 1.9)	1.49 (1.32 to 1.69)	0.98 (0.87 to 1.11)
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	2911/12051.42 (0.2415)	2743/11165.02 (0.2457)	2407/10026.35 (0.2401)
	Comparison Group	2352/13479.15 (0.1745)	2539/12120.13 (0.2095)	2838/10584.02 (0.2681)
	Hazard Ratio (CI)	1.39 (1.27 to 1.52)	1.17 (1.07 to 1.28)	0.88 (0.8 to 0.96)
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	4386/13042.3 (0.3363)	4144/11999.75 (0.3453)	3638/10810.39 (0.3365)
	Comparison Group	2114/14571.52 (0.1451)	2518/13088.68 (0.1924)	3703/11390.83 (0.3251)
	Hazard Ratio (CI)	2.35 (2.16 to 2.56)	1.82 (1.68 to 1.98)	1.02 (0.94 to 1.1)
	p-value	<0.001	<0.001	1
> Fatigue	SARS-CoV-2 Group	4334/13054.03 (0.332)	4100/12012.6 (0.3413)	3597/10824.22 (0.3323)
	Comparison Group	2115/14585.12 (0.145)	2518/13102.79 (0.1922)	3699/11408.48 (0.3242)
	Hazard Ratio (CI)	2.32 (2.13 to 2.53)	1.8 (1.66 to 1.95)	1.01 (0.93 to 1.09)
	p-value	<0.001	<0.001	1
> Chronic Fatigue	SARS-CoV-2 Group	235/20020.05 (0.0117)	235/20029.17 (0.0117)	207/17855.78 (0.0116)
	Comparison Group	170/22226.87 (0.0076)	264/21858.93 (0.0121)	244/19322.21 (0.0126)
	Hazard Ratio (CI)	1.52 (1.09 to 2.12)	0.96 (0.72 to 1.3)	0.9 (0.66 to 1.23)
	p-value	<0.001	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	151/20418.41 (0.0074)	153/20496.78 (0.0075)	128/18258.85 (0.0070)
	Comparison Group	8/22663.59 (0.0004)	14/22362.27 (0.0006)	33/19761.26 (0.0017)
	Hazard Ratio (CI)	20.03 (6.04 to 66.4)	11.52 (4.58 to 29)	4.07 (2.14 to 7.73)
	p-value	<0.001	<0.001	<0.001

Anosmia	SARS-CoV-2 Group	41/20428.55 (0.002)	48/20510.01 (0.0023)	37/18267.84 (0.0020)
	Comparison Group	23/22673.24 (0.001)	14/22375.2 (0.0006)	29/19775.72 (0.0015)
	Hazard Ratio (CI)	1.97 (0.83 to 4.68)	3.75 (1.37 to 10.25)	1.41 (0.62 to 3.21)
	p-value	0.25	<0.001	1

Denominator for incidence of each outcome is person-year for individuals at-risk starting at the start of the post-acute phase (index date + 21 days).

Confidence intervals were calculated based on the Bonferroni correction, i.e., (1 - 0.05/N) confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 4c: Cumulative Incidence and Risk Difference per 100 Individuals for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and 2019 Comparison Group Before and After Exactly Matching Prior Dementia Comorbidity

Clinical Sequelae	Category	2019 Comparison	2019 Comparison with Balanced Dementia
	Matched Group Size	88,070 vs 88,070	63,945 vs 63,945
	Outcome Observation Period (Days): Median (IQR)	62 (22 - 149)	63 (22 - 150)
Hypertension			
Hypertension	SARS-CoV-2 Group	13.16	12.55
	2019 Comparison Group	7.1	6.79
	Risk Difference	6.06 (3.09 to 9.23)	5.76 (2.64 to 8.77)
	p-value	<0.001	<0.001
Pulmonary Hypertension			
Pulmonary Hypertension	SARS-CoV-2 Group	1.03	1.03
	2019 Comparison Group	0.88	0.88
	Risk Difference	0.14 (-0.04 to 0.36)	0.15 (-0.05 to 0.39)
	p-value	0.9	0.8
Cardiology			
Cardiac Rhythm Disorders			
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.8	4.6
	2019 Comparison Group	3.17	2.96
	Risk Difference	1.63 (1.19 to 2.06)	1.64 (1.03 to 2.17)
	p-value	<0.001	<0.001
> Cardiac Arrhythmia			
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.86	2.81
	2019 Comparison Group	2.18	2.05
	Risk Difference	0.68 (0.35 to 1.01)	0.76 (0.39 to 1.21)
	p-value	<0.001	<0.001
> Tachycardia			
> Tachycardia	SARS-CoV-2 Group	2.89	2.77
	2019 Comparison Group	1.53	1.42
	Risk Difference	1.36 (1.05 to 1.69)	1.35 (0.97 to 1.66)
	p-value	<0.001	<0.001
> POTs			
> POTs	SARS-CoV-2 Group	1.17	1.12
	2019 Comparison Group	0.86	0.79
	Risk Difference	0.31 (0.12 to 0.54)	0.33 (0.12 to 0.57)
	p-value	<0.001	<0.001

CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	3.09	3.1
	2019 Comparison Group	2.19	2.05
	Risk Difference	0.9 (0.55 to 1.27)	1.04 (0.61 to 1.46)
	p-value	<0.001	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	2.75	2.71
	2019 Comparison Group	1.98	1.84
	Risk Difference	0.77 (0.45 to 1.07)	0.87 (0.58 to 1.27)
	p-value	<0.001	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	1.13	1.14
	2019 Comparison Group	0.84	0.85
	Risk Difference	0.29 (0.07 to 0.51)	0.28 (0 to 0.52)
	p-value	<0.001	0.05
> Myocarditis	SARS-CoV-2 Group	0.04	0.05
	2019 Comparison Group	0.01	0.02
	Risk Difference	0.03 (0 to 0.07)	0.03 (-0.01 to 0.09)
	p-value	0.16	0.64
Coronary Disease	SARS-CoV-2 Group	1.7	1.68
	2019 Comparison Group	1.11	1.06
	Risk Difference	0.59 (0.35 to 0.84)	0.62 (0.33 to 0.93)
	p-value	<0.001	<0.001
> Myocardial Infarction	SARS-CoV-2 Group	1.41	1.39
	2019 Comparison Group	0.89	0.83
	Risk Difference	0.52 (0.28 to 0.75)	0.56 (0.35 to 0.81)
	p-value	<0.001	<0.001
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.69	1.67
	2019 Comparison Group	1.1	1.06
	Risk Difference	0.59 (0.28 to 0.83)	0.61 (0.31 to 0.85)
	p-value	<0.001	<0.001
Cardiogenic Shock	SARS-CoV-2 Group	0.12	0.13
	2019 Comparison Group	0.1	0.09
	Risk Difference	0.02 (-0.05 to 0.08)	0.04 (-0.04 to 0.12)
	p-value	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.48	3.41

	2019 Comparison Group	1.64	1.57
	Risk Difference	1.85 (1.51 to 2.21)	1.84 (1.55 to 2.21)
	p-value	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	2.39	2.29
	2019 Comparison Group	1.25	1.19
	Risk Difference	1.14 (0.87 to 1.44)	1.1 (0.82 to 1.45)
	p-value	<0.001	<0.001
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.68	1.57
	2019 Comparison Group	0.74	0.68
	Risk Difference	0.94 (0.74 to 1.14)	0.89 (0.66 to 1.14)
	p-value	<0.001	<0.001
> Pulmonary Embolism	SARS-CoV-2 Group	1.28	1.25
	2019 Comparison Group	0.34	0.31
	Risk Difference	0.94 (0.79 to 1.1)	0.94 (0.76 to 1.12)
	p-value	<0.001	<0.001
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.44	0.45
	2019 Comparison Group	0.28	0.27
	Risk Difference	0.16 (0.04 to 0.27)	0.18 (0.05 to 0.31)
	p-value	<0.001	<0.001
Stroke and Sequelae	SARS-CoV-2 Group	2.29	2.09
	2019 Comparison Group	1.7	1.41
	Risk Difference	0.59 (0.3 to 0.89)	0.68 (0.35 to 1.03)
	p-value	<0.001	<0.001
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	2.03	1.87
	2019 Comparison Group	1.52	1.24
	Risk Difference	0.52 (0.26 to 0.79)	0.62 (0.34 to 0.93)
	p-value	<0.001	<0.001
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.36	1.23
	2019 Comparison Group	0.96	0.76
	Risk Difference	0.4 (0.2 to 0.6)	0.47 (0.21 to 0.74)
	p-value	<0.001	<0.001
Mental Health			

Mental Health Diagnosis	SARS-CoV-2 Group	5.78	5.29
	2019 Comparison Group	4.12	3.58
	Risk Difference	1.66 (1.21 to 2.22)	1.7 (1.15 to 2.37)
	p-value	<0.001	<0.001
Psychosis	SARS-CoV-2 Group	0.37	0.25
	2019 Comparison Group	0.22	0.1
	Risk Difference	0.15 (0.02 to 0.27)	0.15 (0.06 to 0.26)
	p-value	<0.001	<0.001
Neurologic			
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.41	4.62
	2019 Comparison Group	3.46	2.5
	Risk Difference	1.94 (1.45 to 2.37)	2.12 (1.66 to 2.53)
	p-value	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.32	0.37
	2019 Comparison Group	0.3	0.33
	Risk Difference	0.02 (-0.1 to 0.16)	0.04 (-0.1 to 0.19)
	p-value	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.99	1.01
	2019 Comparison Group	1	1.01
	Risk Difference	-0.01 (-0.22 to 0.2)	0 (-0.23 to 0.23)
	p-value	1	1
Encephalopathy	SARS-CoV-2 Group	2.84	2.47
	2019 Comparison Group	1.3	1.02
	Risk Difference	1.53 (1.28 to 1.83)	1.44 (1.13 to 1.75)
	p-value	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.56	0.5
	2019 Comparison Group	0.44	0.34
	Risk Difference	0.12 (-0.02 to 0.27)	0.15 (0 to 0.32)
	p-value	0.37	0.05
Dementia	SARS-CoV-2 Group	2.89	2.54
	2019 Comparison Group	1.55	1.18
	Risk Difference	1.34 (0.98 to 1.67)	1.36 (1.05 to 1.66)
	p-value	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.02
	2019 Comparison Group	0	0.01

	Risk Difference	0.02 (0 to 0.04)	0.02 (-0.01 to 0.06)
	p-value	0.11	0.8
Diabetes			
Type 2 Diabetes	SARS-CoV-2 Group	2.97	2.96
	2019 Comparison Group	1.73	1.63
	Risk Difference	1.24 (0.72 to 1.74)	1.33 (0.8 to 1.9)
	p-value	<0.001	<0.001
Liver			
Liver Test Abnormality	SARS-CoV-2 Group	1.85	1.85
	2019 Comparison Group	1.46	1.51
	Risk Difference	0.39 (0.09 to 0.64)	0.34 (0.02 to 0.68)
	p-value	<0.001	<0.001
Nephrology			
Kidney Injury	SARS-CoV-2 Group	6.64	6.21
	2019 Comparison Group	4.78	4.37
	Risk Difference	1.86 (1.29 to 2.47)	1.84 (1.17 to 2.46)
	p-value	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	4.38	4.17
	2019 Comparison Group	4	3.72
	Risk Difference	0.38 (-0.14 to 0.98)	0.45 (-0.09 to 1.02)
	p-value	0.58	0.64
> Acute Kidney Injury	SARS-CoV-2 Group	4.59	4.38
	2019 Comparison Group	2.49	2.29
	Risk Difference	2.1 (1.71 to 2.46)	2.09 (1.75 to 2.52)
	p-value	<0.001	<0.001
Respiratory			
Respiratory Failure	SARS-CoV-2 Group	9.15	9.19
	2019 Comparison Group	2.03	1.89
	Risk Difference	7.12 (6.66 to 7.55)	7.3 (6.8 to 7.72)
	p-value	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	8.04	8.07
	2019 Comparison Group	1.5	1.36
	Risk Difference	6.54 (6.18 to 6.88)	6.71 (6.27 to 7.12)
	p-value	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.39	1.43

	2019 Comparison Group	0.46	0.45
	Risk Difference	0.93 (0.77 to 1.13)	0.98 (0.76 to 1.19)
	p-value	<0.001	<0.001
> Interstitial Lung Disease	SARS-CoV-2 Group	1.39	1.45
	2019 Comparison Group	0.61	0.59
	Risk Difference	0.79 (0.61 to 0.98)	0.86 (0.61 to 1.08)
	p-value	<0.001	<0.001
Dermatologic			
Atopic Dermatitis	SARS-CoV-2 Group	0.25	0.25
	2019 Comparison Group	0.3	0.3
	Risk Difference	-0.05 (-0.17 to 0.06)	-0.06 (-0.18 to 0.06)
	p-value	1	1
Urticaria	SARS-CoV-2 Group	0.18	0.18
	2019 Comparison Group	0.19	0.2
	Risk Difference	-0.01 (-0.09 to 0.07)	-0.01 (-0.11 to 0.11)
	p-value	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.09	0.09
	2019 Comparison Group	0.07	0.08
	Risk Difference	0.02 (-0.04 to 0.09)	0.01 (-0.06 to 0.07)
	p-value	1	1
Others			
Sleep Apnea	SARS-CoV-2 Group	1.52	1.5
	2019 Comparison Group	1.43	1.5
	Risk Difference	0.09 (-0.17 to 0.35)	0 (-0.3 to 0.34)
	p-value	1	1
Hematology			
Thrombocytopenia	SARS-CoV-2 Group	0.95	0.94
	2019 Comparison Group	0.57	0.55
	Risk Difference	0.38 (0.2 to 0.56)	0.39 (0.19 to 0.58)
	p-value	<0.001	<0.001
Leukopenia	SARS-CoV-2 Group	0.29	0.27
	2019 Comparison Group	0.13	0.13
	Risk Difference	0.16 (0.08 to 0.26)	0.13 (0.03 to 0.24)
	p-value	<0.001	<0.001

Anemia	SARS-CoV-2 Group	3.3	3.07
	2019 Comparison Group	2.19	2.04
	Risk Difference	1.11 (0.74 to 1.52)	1.02 (0.63 to 1.45)
	p-value	<0.001	<0.001
Symptom			
Myalgia	SARS-CoV-2 Group	8.11	7.88
	2019 Comparison Group	6.99	6.75
	Risk Difference	1.12 (0.38 to 1.86)	1.13 (0.31 to 1.9)
	p-value	<0.001	<0.001
Fatigue Diagnosis	SARS-CoV-2 Group	10.74	10.33
	2019 Comparison Group	6.36	5.73
	Risk Difference	4.39 (3.7 to 5.21)	4.6 (3.8 to 5.42)
	p-value	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	10.61	10.18
	2019 Comparison Group	6.35	5.72
	Risk Difference	4.26 (3.54 to 4.9)	4.45 (3.57 to 5.13)
	p-value	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	0.37	0.38
	2019 Comparison Group	0.42	0.44
	Risk Difference	-0.05 (-0.16 to 0.08)	-0.06 (-0.23 to 0.1)
	p-value	1	1
> Postviral Fatigue	SARS-CoV-2 Group	0.25	0.24
	2019 Comparison Group	0.02	0.03
	Risk Difference	0.22 (0.16 to 0.3)	0.21 (0.14 to 0.3)
	p-value	<0.001	<0.001
Anosmia	SARS-CoV-2 Group	0.07	0.08
	2019 Comparison Group	0.03	0.03
	Risk Difference	0.04 (-0.01 to 0.08)	0.05 (-0.01 to 0.11)
	p-value	0.26	0.11

The 2019 Comparison with Balanced Dementia Group consists of the matched SARS-CoV-2 and 2019 comparison groups already filtered based on having at least 21 days of observation from the index date and having either both none or with prior dementia comorbidity.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (index date + 21 days), which is 141 days after index date.

Confidence intervals were calculated based on the Bonferroni correction, i.e., $(1 - 0.05/N)$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 4d: Incidence Rates and Hazard Ratio for Clinical Sequelae in the Post-Acute Phase by SARS-CoV-2 Infection and 2019 Comparison Group Before and After Exactly Matching Prior Dementia Comorbidity

Clinical Sequelae	Category	2019 Comparison	2019 Comparison with Balanced Dementia
	Matched Group Size	88,070 vs 88,070	63,945 vs 63,945
	Outcome Observation Period (Days): Median (IQR)	62 (22 - 149)	63 (22 - 150)
Hypertension			
Hypertension	SARS-CoV-2 Group	356/919.19 (0.3873)	290/791.83 (0.3662)
	2019 Comparison Group	213/992.2 (0.2147)	176/847.14 (0.2078)
	Hazard Ratio (CI)	1.88 (1.41 to 2.5)	1.83 (1.34 to 2.52)
	p-value	<0.001	<0.001
Pulmonary Hypertension			
Pulmonary Hypertension	SARS-CoV-2 Group	594/19431.36 (0.0306)	438/14234.99 (0.0308)
	2019 Comparison Group	538/21106.98 (0.0255)	389/15461.9 (0.0252)
	Hazard Ratio (CI)	1.19 (0.98 to 1.44)	1.21 (0.96 to 1.52)
	p-value	0.1	0.17
Cardiology			
Cardiac Rhythm Disorders			
Cardiac Rhythm Disorders	SARS-CoV-2 Group	2378/15901.87 (0.1495)	1714/11867.2 (0.1444)
	2019 Comparison Group	1671/17252.28 (0.0969)	1168/12843.29 (0.0909)
	Hazard Ratio (CI)	1.54 (1.39 to 1.71)	1.58 (1.4 to 1.79)
	p-value	<0.001	<0.001
> Cardiac Arrhythmia			
> Cardiac Arrhythmia	SARS-CoV-2 Group	1521/17412.78 (0.0873)	1104/12911.83 (0.0855)
	2019 Comparison Group	1251/18889.14 (0.0662)	876/13988.36 (0.0626)
	Hazard Ratio (CI)	1.31 (1.16 to 1.49)	1.36 (1.17 to 1.58)
	p-value	<0.001	<0.001
> Tachycardia			
> Tachycardia	SARS-CoV-2 Group	1635/18209.86 (0.0898)	1172/13443.85 (0.0872)
	2019 Comparison Group	936/19820.75 (0.0472)	641/14581.65 (0.0440)
	Hazard Ratio (CI)	1.89 (1.65 to 2.16)	1.97 (1.67 to 2.31)
	p-value	<0.001	<0.001
> POTs			
> POTs	SARS-CoV-2 Group	697/19465.86 (0.0358)	491/14325.17 (0.0343)
	2019 Comparison Group	548/21227.65 (0.0258)	368/15596.82 (0.0236)
	Hazard Ratio (CI)	1.38 (1.14 to 1.66)	1.44 (1.15 to 1.81)
	p-value	<0.001	<0.001

CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	1557/16162.34 (0.0963)	1156/12042.25 (0.0960)
	2019 Comparison Group	1138/17441.78 (0.0652)	794/12957.93 (0.0613)
	Hazard Ratio (CI)	1.46 (1.28 to 1.66)	1.55 (1.33 to 1.8)
	p-value	<0.001	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	1456/16902.5 (0.0861)	1069/12569.02 (0.0851)
	2019 Comparison Group	1097/18282.16 (0.0600)	760/13571.09 (0.0560)
	Hazard Ratio (CI)	1.42 (1.24 to 1.62)	1.5 (1.28 to 1.75)
	p-value	<0.001	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	617/18770.49 (0.0329)	462/13780.6 (0.0335)
	2019 Comparison Group	501/20381.55 (0.0246)	370/14918.64 (0.0248)
	Hazard Ratio (CI)	1.32 (1.09 to 1.61)	1.34 (1.06 to 1.69)
	p-value	<0.001	<0.001
> Myocarditis	SARS-CoV-2 Group	27/20536.11 (0.0013)	22/15021.56 (0.0015)
	2019 Comparison Group	9/22405.85 (0.0004)	7/16376.86 (0.0004)
	Hazard Ratio (CI)	3.19 (0.9 to 11.32)	3.35 (0.81 to 13.89)
	p-value	0.06	0.13
Coronary Disease	SARS-CoV-2 Group	1049/19201.05 (0.0546)	767/14110.95 (0.0544)
	2019 Comparison Group	720/20890.08 (0.0345)	508/15335.82 (0.0331)
	Hazard Ratio (CI)	1.57 (1.34 to 1.83)	1.62 (1.34 to 1.95)
	p-value	<0.001	<0.001
> Myocardial Infarction	SARS-CoV-2 Group	891/19563.16 (0.0455)	651/14365.69 (0.0453)
	2019 Comparison Group	578/21284.78 (0.0272)	399/15607.76 (0.0256)
	Hazard Ratio (CI)	1.65 (1.39 to 1.97)	1.75 (1.42 to 2.15)
	p-value	<0.001	<0.001
> Acute Coronary Syndrome	SARS-CoV-2 Group	1043/19205.98 (0.0543)	763/14112.08 (0.0541)
	2019 Comparison Group	714/20893.73 (0.0342)	506/15337.15 (0.0330)
	Hazard Ratio (CI)	1.57 (1.34 to 1.84)	1.62 (1.34 to 1.95)
	p-value	<0.001	<0.001
Cardiogenic Shock	SARS-CoV-2 Group	88/20482.64 (0.0043)	64/14981.79 (0.0043)
	2019 Comparison Group	69/22341.75 (0.0031)	45/16325.16 (0.0028)
	Hazard Ratio (CI)	1.37 (0.81 to 2.33)	1.52 (0.8 to 2.89)
	p-value	1	0.8
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2094/18049.31 (0.1160)	1502/13354.35 (0.1125)

	2019 Comparison Group	952/19687.71 (0.0484)	659/14534.88 (0.0453)
	Hazard Ratio (CI)	2.36 (2.08 to 2.69)	2.44 (2.1 to 2.85)
	p-value	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	1428/18627.56 (0.0767)	1009/13742.25 (0.0734)
	2019 Comparison Group	759/20338.78 (0.0373)	520/14977.1 (0.0347)
	Hazard Ratio (CI)	2.03 (1.75 to 2.35)	2.08 (1.74 to 2.48)
	p-value	<0.001	<0.001
> Deep Vein Thrombosis	SARS-CoV-2 Group	1039/19374.24 (0.0536)	718/14252.28 (0.0504)
	2019 Comparison Group	463/21159.16 (0.0219)	302/15542.63 (0.0194)
	Hazard Ratio (CI)	2.4 (2 to 2.89)	2.54 (2.02 to 3.18)
	p-value	<0.001	<0.001
> Pulmonary Embolism	SARS-CoV-2 Group	902/19967.13 (0.0452)	646/14630.94 (0.0442)
	2019 Comparison Group	215/21759.37 (0.0099)	140/15925.09 (0.0088)
	Hazard Ratio (CI)	4.41 (3.44 to 5.66)	4.85 (3.57 to 6.59)
	p-value	<0.001	<0.001
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	275/20161.43 (0.0136)	202/14772.13 (0.0137)
	2019 Comparison Group	181/21999.07 (0.0082)	128/16109.2 (0.0079)
	Hazard Ratio (CI)	1.64 (1.19 to 2.25)	1.7 (1.17 to 2.46)
	p-value	<0.001	<0.001
Stroke and Sequelae	SARS-CoV-2 Group	1328/17602.23 (0.0754)	924/13308.85 (0.0694)
	2019 Comparison Group	979/19239.95 (0.0509)	607/14508.28 (0.0418)
	Hazard Ratio (CI)	1.46 (1.27 to 1.68)	1.63 (1.37 to 1.94)
	p-value	<0.001	<0.001
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1198/17810.78 (0.0673)	833/13431.61 (0.0620)
	2019 Comparison Group	876/19471.46 (0.0450)	538/14649.43 (0.0367)
	Hazard Ratio (CI)	1.47 (1.27 to 1.7)	1.66 (1.38 to 1.99)
	p-value	<0.001	<0.001
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	851/18777.63 (0.0453)	574/14028.26 (0.0409)
	2019 Comparison Group	615/20525.44 (0.0300)	364/15299.9 (0.0238)
	Hazard Ratio (CI)	1.48 (1.24 to 1.76)	1.68 (1.35 to 2.09)
	p-value	<0.001	<0.001
Mental Health			

Mental Health Diagnosis	SARS-CoV-2 Group	2188/12296.92 (0.1779)	1585/9778.15 (0.1621)
	2019 Comparison Group	1630/13397.87 (0.1217)	1114/10648.11 (0.1046)
	Hazard Ratio (CI)	1.46 (1.31 to 1.63)	1.55 (1.36 to 1.76)
	p-value	<0.001	<0.001
Psychosis	SARS-CoV-2 Group	240/20090.12 (0.0119)	122/14862.71 (0.0082)
	2019 Comparison Group	146/21916.95 (0.0067)	54/16207.73 (0.0033)
	Hazard Ratio (CI)	1.77 (1.25 to 2.5)	2.43 (1.42 to 4.16)
	p-value	<0.001	<0.001
Neurologic			
Amnesia/Memory Difficulty	SARS-CoV-2 Group	2578/15008.48 (0.1718)	1813/12422.42 (0.1459)
	2019 Comparison Group	1754/16295.79 (0.1076)	1038/13501.69 (0.0769)
	Hazard Ratio (CI)	1.59 (1.43 to 1.76)	1.89 (1.66 to 2.14)
	p-value	<0.001	<0.001
Migraine	SARS-CoV-2 Group	193/19979.72 (0.0097)	159/14603.85 (0.0109)
	2019 Comparison Group	201/21782.62 (0.0092)	152/15900.98 (0.0096)
	Hazard Ratio (CI)	1.04 (0.75 to 1.45)	1.13 (0.78 to 1.65)
	p-value	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	569/19082.88 (0.0298)	415/13997.08 (0.0296)
	2019 Comparison Group	612/20796.75 (0.0294)	451/15259.24 (0.0296)
	Hazard Ratio (CI)	1.01 (0.83 to 1.22)	0.99 (0.8 to 1.24)
	p-value	1	1
Encephalopathy	SARS-CoV-2 Group	1803/18840.72 (0.0957)	1179/14202.65 (0.0830)
	2019 Comparison Group	847/20520.7 (0.0413)	489/15471.26 (0.0316)
	Hazard Ratio (CI)	2.28 (1.99 to 2.61)	2.57 (2.16 to 3.07)
	p-value	<0.001	<0.001
Seizure	SARS-CoV-2 Group	349/19723.05 (0.0177)	225/14568.38 (0.0154)
	2019 Comparison Group	280/21524.97 (0.0130)	158/15876.42 (0.0100)
	Hazard Ratio (CI)	1.35 (1.04 to 1.76)	1.54 (1.09 to 2.16)
	p-value	0.005	<0.001
Dementia	SARS-CoV-2 Group	1315/14705.27 (0.0894)	1120/14228.56 (0.0787)
	2019 Comparison Group	755/16007.51 (0.0472)	561/15527.75 (0.0361)
	Hazard Ratio (CI)	1.87 (1.61 to 2.18)	2.15 (1.82 to 2.55)
	p-value	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	15/20527.07 (0.0007)	11/15014.59 (0.0007)
	2019 Comparison Group	3/22396.38 (0.0001)	3/16368.41 (0.0002)

	Hazard Ratio (CI)	5.23 (0.64 to 42.64)	3.84 (0.44 to 33.46)
	p-value	0.24	1
Diabetes			
Type 2 Diabetes	SARS-CoV-2 Group	704/7599.69 (0.0926)	533/5756.93 (0.0926)
	2019 Comparison Group	450/8421.53 (0.0534)	318/6326.39 (0.0503)
	Hazard Ratio (CI)	1.72 (1.41 to 2.1)	1.83 (1.45 to 2.32)
	p-value	<0.001	<0.001
Liver			
Liver Test Abnormality	SARS-CoV-2 Group	1019/18324.53 (0.0556)	755/13361.1 (0.0565)
	2019 Comparison Group	875/20015.15 (0.0437)	648/14594.56 (0.0444)
	Hazard Ratio (CI)	1.26 (1.08 to 1.47)	1.26 (1.06 to 1.5)
	p-value	<0.001	<0.001
Nephrology			
Kidney Injury	SARS-CoV-2 Group	2541/11569.58 (0.2196)	1843/8892.22 (0.2073)
	2019 Comparison Group	1753/12339.32 (0.1421)	1231/9414.03 (0.1308)
	Hazard Ratio (CI)	1.54 (1.39 to 1.71)	1.58 (1.4 to 1.79)
	p-value	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	1663/12298.47 (0.1352)	1209/9325.35 (0.1296)
	2019 Comparison Group	1545/13142.37 (0.1176)	1086/9898.06 (0.1097)
	Hazard Ratio (CI)	1.14 (1.02 to 1.28)	1.17 (1.02 to 1.35)
	p-value	0.004	0.003
> Acute Kidney Injury	SARS-CoV-2 Group	2868/17517.41 (0.1637)	2038/13102.7 (0.1555)
	2019 Comparison Group	1419/18962.33 (0.0748)	959/14170.73 (0.0677)
	Hazard Ratio (CI)	2.16 (1.94 to 2.4)	2.26 (1.99 to 2.57)
	p-value	<0.001	<0.001
Respiratory			
Respiratory Failure	SARS-CoV-2 Group	5997/17834.79 (0.3363)	4433/13189.56 (0.3361)
	2019 Comparison Group	1228/19365.8 (0.0634)	849/14303.53 (0.0594)
	Hazard Ratio (CI)	5.27 (4.76 to 5.83)	5.62 (4.98 to 6.35)
	p-value	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	5760/18908 (0.3046)	4244/13945.56 (0.3043)
	2019 Comparison Group	956/20579.4 (0.0465)	642/15161.58 (0.0423)
	Hazard Ratio (CI)	6.45 (5.75 to 7.22)	7.06 (6.15 to 8.11)
	p-value	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	855/19813.77 (0.0432)	636/14521.3 (0.0438)

	2019 Comparison Group	288/21557.88 (0.0134)	204/15782.77 (0.0129)
	Hazard Ratio (CI)	3.17 (2.53 to 3.96)	3.32 (2.54 to 4.32)
	p-value	<0.001	<0.001
> Interstitial Lung Disease	SARS-CoV-2 Group	817/19639.86 (0.0416)	623/14399.02 (0.0433)
	2019 Comparison Group	410/21402.35 (0.0192)	292/15679.52 (0.0186)
	Hazard Ratio (CI)	2.15 (1.76 to 2.63)	2.3 (1.82 to 2.91)
	p-value	<0.001	<0.001
Dermatologic			
Atopic Dermatitis	SARS-CoV-2 Group	158/20144.34 (0.0078)	118/14741.72 (0.0080)
	2019 Comparison Group	195/21982.88 (0.0089)	146/16067.5 (0.0091)
	Hazard Ratio (CI)	0.88 (0.62 to 1.26)	0.88 (0.58 to 1.32)
	p-value	1	1
Urticaria	SARS-CoV-2 Group	111/20289.79 (0.0055)	84/14838.32 (0.0057)
	2019 Comparison Group	132/22140.13 (0.0060)	105/16174.79 (0.0065)
	Hazard Ratio (CI)	0.91 (0.59 to 1.4)	0.87 (0.53 to 1.41)
	p-value	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	49/20459.65 (0.0024)	36/14960.99 (0.0024)
	2019 Comparison Group	46/22320.38 (0.0021)	34/16309.28 (0.0021)
	Hazard Ratio (CI)	1.16 (0.59 to 2.27)	1.15 (0.52 to 2.52)
	p-value	1	1
Others			
Sleep Apnea	SARS-CoV-2 Group	755/16830.42 (0.0449)	547/12265.01 (0.0446)
	2019 Comparison Group	749/18230.44 (0.0411)	561/13265.74 (0.0423)
	Hazard Ratio (CI)	1.08 (0.91 to 1.28)	1.04 (0.86 to 1.27)
	p-value	1	1
Hematology			
Thrombocytopenia	SARS-CoV-2 Group	600/19618.55 (0.0306)	443/14377.61 (0.0308)
	2019 Comparison Group	353/21374.12 (0.0165)	255/15661.17 (0.0163)
	Hazard Ratio (CI)	1.82 (1.46 to 2.27)	1.86 (1.44 to 2.4)
	p-value	<0.001	<0.001
Leukopenia	SARS-CoV-2 Group	192/20296.89 (0.0095)	132/14853.37 (0.0089)
	2019 Comparison Group	96/22136.37 (0.0043)	74/16188.14 (0.0046)
	Hazard Ratio (CI)	2.15 (1.42 to 3.24)	1.92 (1.19 to 3.1)
	p-value	<0.001	<0.001

Anemia	SARS-CoV-2 Group	1659/16780.08 (0.0989)	1168/12502.27 (0.0934)
	2019 Comparison Group	1207/18336.4 (0.0658)	831/13616.53 (0.0610)
	Hazard Ratio (CI)	1.49 (1.32 to 1.69)	1.52 (1.31 to 1.77)
	p-value	<0.001	<0.001
Symptom			
Myalgia	SARS-CoV-2 Group	2743/11165.02 (0.2457)	2030/8580.47 (0.2366)
	2019 Comparison Group	2539/12120.13 (0.2095)	1869/9309.34 (0.2008)
	Hazard Ratio (CI)	1.17 (1.07 to 1.28)	1.17 (1.06 to 1.31)
	p-value	<0.001	<0.001
Fatigue Diagnosis	SARS-CoV-2 Group	4144/11999.75 (0.3453)	3148/9498.04 (0.3314)
	2019 Comparison Group	2518/13088.68 (0.1924)	1780/10333.45 (0.1723)
	Hazard Ratio (CI)	1.82 (1.68 to 1.98)	1.95 (1.77 to 2.15)
	p-value	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	4100/12012.6 (0.3413)	3107/9507.39 (0.3268)
	2019 Comparison Group	2518/13102.79 (0.1922)	1780/10344.75 (0.1721)
	Hazard Ratio (CI)	1.8 (1.66 to 1.95)	1.93 (1.75 to 2.12)
	p-value	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	235/20029.17 (0.0117)	171/14657.87 (0.0117)
	2019 Comparison Group	264/21858.93 (0.0121)	197/15987.13 (0.0123)
	Hazard Ratio (CI)	0.96 (0.72 to 1.3)	0.94 (0.67 to 1.33)
	p-value	1	1
> Postviral Fatigue	SARS-CoV-2 Group	153/20496.78 (0.0075)	110/15001.38 (0.0073)
	2019 Comparison Group	14/22362.27 (0.0006)	10/16353.99 (0.0006)
	Hazard Ratio (CI)	11.52 (4.58 to 29)	11.61 (3.89 to 34.6)
	p-value	<0.001	<0.001
Anosmia	SARS-CoV-2 Group	48/20510.01 (0.0023)	40/14999.94 (0.0027)
	2019 Comparison Group	14/22375.2 (0.0006)	10/16352.06 (0.0006)
	Hazard Ratio (CI)	3.75 (1.37 to 10.25)	4.34 (1.34 to 14.03)
	p-value	<0.001	<0.001

The 2019 Comparison with Balanced Dementia Group consists of the matched SARS-CoV-2 and 2019 comparison groups already filtered based on having at least 21 days of observation from the index date and having either both none or with prior dementia comorbidity.

Denominator for incidence of each outcome is person-year for individuals at-risk starting at the start of the post-acute phase (index date + 21 days).

Confidence intervals were calculated based on the Bonferroni correction, i.e., $(1 - 0.05/N)$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5a: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

Clinical Sequelae	Category	65–74	>74	p-interaction
	Matched Group Size	40,051 vs 40,051	46,350 vs 46,350	
Hypertension				
Hypertension	SARS-CoV-2 Group	10.08	16.25	
	2020 Comparison Group	6.15	7.28	
	Risk Difference	3.93 (1.52 to 6.11)	8.96 (4.7 to 13.54)	
	p-value	<0.001	<0.001	0.03
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.71	1.26	
	2020 Comparison Group	0.37	0.85	
	Risk Difference	0.34 (0.1 to 0.57)	0.42 (0.11 to 0.74)	
	p-value	<0.001	<0.001	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	3.89	5.94	
	2020 Comparison Group	1.98	3.33	
	Risk Difference	1.91 (1.36 to 2.49)	2.61 (1.92 to 3.2)	
	p-value	<0.001	<0.001	1
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.11	3.65	
	2020 Comparison Group	1.2	2.27	
	Risk Difference	0.9 (0.52 to 1.25)	1.38 (0.88 to 1.96)	
	p-value	<0.001	<0.001	1
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.57	3.26	
	2020 Comparison Group	1.15	1.58	
	Risk Difference	1.42 (1 to 1.81)	1.68 (1.29 to 2.06)	
	p-value	<0.001	<0.001	1
> POTs				
> POTs	SARS-CoV-2 Group	0.88	1.34	

	2020 Comparison Group	0.44	0.8	
	Risk Difference	0.44 (0.2 to 0.71)	0.54 (0.22 to 0.85)	
	p-value	<0.001	<0.001	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.21	4.08	
	2020 Comparison Group	1.12	2.39	
	Risk Difference	1.09 (0.67 to 1.59)	1.69 (1.08 to 2.28)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	1.82	3.78	
	2020 Comparison Group	0.92	2.13	
	Risk Difference	0.9 (0.56 to 1.29)	1.64 (1.09 to 2.18)	
	p-value	<0.001	<0.001	0.18
> Cardiomyopathy	SARS-CoV-2 Group	1.02	1.27	
	2020 Comparison Group	0.55	0.9	
	Risk Difference	0.46 (0.17 to 0.73)	0.37 (0.02 to 0.72)	
	p-value	<0.001	<0.001	0.66
> Myocarditis	SARS-CoV-2 Group	0.04	0.04	
	2020 Comparison Group	0	0.01	
	Risk Difference	0.04 (0.01 to 0.09)	0.03 (-0.02 to 0.08)	
	p-value	<0.001	1	1
Coronary Disease	SARS-CoV-2 Group	1.3	2.09	
	2020 Comparison Group	0.63	1.07	
	Risk Difference	0.67 (0.4 to 0.95)	1.02 (0.59 to 1.43)	
	p-value	<0.001	<0.001	1
> Myocardial Infarction	SARS-CoV-2 Group	1.08	1.7	
	2020 Comparison Group	0.47	0.85	
	Risk Difference	0.61 (0.38 to 0.83)	0.85 (0.54 to 1.21)	

	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.3	2.07	
	2020 Comparison Group	0.63	1.06	
	Risk Difference	0.67 (0.39 to 1.01)	1.01 (0.66 to 1.4)	
	p-value	<0.001	<0.001	1
Cardiogenic Shock	SARS-CoV-2 Group	0.12	0.15	
	2020 Comparison Group	0.05	0.07	
	Risk Difference	0.07 (-0.01 to 0.15)	0.08 (-0.01 to 0.17)	
	p-value	0.53	0.42	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.84	4	
	2020 Comparison Group	0.92	1.42	
	Risk Difference	1.92 (1.48 to 2.3)	2.58 (2.14 to 3)	
	p-value	<0.001	<0.001	1
> Hypercoagulability	SARS-CoV-2 Group	1.99	2.75	
	2020 Comparison Group	0.72	1.02	
	Risk Difference	1.27 (0.94 to 1.67)	1.73 (1.37 to 2.18)	
	p-value	<0.001	<0.001	0.4
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.4	1.88	
	2020 Comparison Group	0.42	0.55	
	Risk Difference	0.98 (0.72 to 1.27)	1.33 (1.03 to 1.63)	
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	0.98	1.47	
	2020 Comparison Group	0.25	0.35	
	Risk Difference	0.74 (0.51 to 0.98)	1.12 (0.86 to 1.37)	
	p-value	<0.001	<0.001	1

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.33	0.43	
	2020 Comparison Group	0.15	0.23	
	Risk Difference	0.18 (0.04 to 0.34)	0.21 (0.07 to 0.36)	
	p-value	<0.001	<0.001	1
Stroke and Sequelae	SARS-CoV-2 Group	1.57	2.98	
	2020 Comparison Group	0.81	1.83	
	Risk Difference	0.76 (0.46 to 1.1)	1.15 (0.75 to 1.58)	
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.41	2.65	
	2020 Comparison Group	0.74	1.59	
	Risk Difference	0.67 (0.38 to 1.07)	1.06 (0.64 to 1.46)	
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	0.92	1.73	
	2020 Comparison Group	0.44	0.97	
	Risk Difference	0.48 (0.26 to 0.75)	0.75 (0.43 to 1.04)	
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.07	6.35	
	2020 Comparison Group	3.05	3.36	
	Risk Difference	2.02 (1.29 to 2.78)	2.99 (2.28 to 3.89)	
	p-value	<0.001	<0.001	0.39
Psychosis	SARS-CoV-2 Group	0.23	0.42	
	2020 Comparison Group	0.07	0.15	
	Risk Difference	0.17 (0.05 to 0.27)	0.27 (0.12 to 0.42)	
	p-value	<0.001	<0.001	0.12

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.01	7.28	
	2020 Comparison Group	1.46	3.19	
	Risk Difference	1.55 (1.05 to 1.99)	4.09 (3.35 to 4.8)	
	p-value	<0.001	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.43	0.23	
	2020 Comparison Group	0.35	0.18	
	Risk Difference	0.09 (-0.07 to 0.25)	0.04 (-0.08 to 0.19)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.89	0.98	
	2020 Comparison Group	0.69	0.85	
	Risk Difference	0.2 (-0.04 to 0.57)	0.13 (-0.12 to 0.37)	
	p-value	0.53	1	1
Encephalopathy	SARS-CoV-2 Group	1.75	3.62	
	2020 Comparison Group	0.49	1.25	
	Risk Difference	1.26 (0.95 to 1.53)	2.37 (1.85 to 2.86)	
	p-value	<0.001	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.42	0.62	
	2020 Comparison Group	0.17	0.31	
	Risk Difference	0.25 (0.1 to 0.43)	0.31 (0.08 to 0.54)	
	p-value	<0.001	<0.001	1
Dementia	SARS-CoV-2 Group	0.81	4.55	
	2020 Comparison Group	0.4	1.91	
	Risk Difference	0.41 (0.17 to 0.59)	2.64 (2.01 to 3.23)	
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.03	0.01	

	2020 Comparison Group	0.02	0.01	
	Risk Difference	0.02 (-0.03 to 0.06)	0 (-0.02 to 0.03)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.92	2.97	
	2020 Comparison Group	1.58	1.26	
	Risk Difference	1.34 (0.77 to 1.94)	1.71 (1.09 to 2.26)	
	p-value	<0.001	<0.001	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	2.15	1.54	
	2020 Comparison Group	1.38	1.02	
	Risk Difference	0.77 (0.31 to 1.2)	0.53 (0.19 to 0.87)	
	p-value	<0.001	<0.001	0.03
Nephrology				
Kidney Injury	SARS-CoV-2 Group	4.56	8.34	
	2020 Comparison Group	2.6	5.02	
	Risk Difference	1.96 (1.32 to 2.6)	3.32 (2.34 to 4.35)	
	p-value	<0.001	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	3.05	5.59	
	2020 Comparison Group	2.22	4.17	
	Risk Difference	0.82 (0.32 to 1.45)	1.41 (0.54 to 2.3)	
	p-value	<0.001	<0.001	0.02
> Acute Kidney Injury	SARS-CoV-2 Group	3.11	5.87	
	2020 Comparison Group	1.17	2.37	
	Risk Difference	1.94 (1.56 to 2.38)	3.5 (2.96 to 4.04)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.44	10.4	

	2020 Comparison Group	0.97	1.9	
	Risk Difference	6.46 (5.96 to 6.97)	8.51 (7.79 to 9.1)	
	p-value	<0.001	<0.001	0.11
> Acute Respiratory Failure	SARS-CoV-2 Group	6.59	9.2	
	2020 Comparison Group	0.67	1.35	
	Risk Difference	5.92 (5.47 to 6.39)	7.86 (7.28 to 8.4)	
	p-value	<0.001	<0.001	0.01
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.18	1.51	
	2020 Comparison Group	0.28	0.45	
	Risk Difference	0.9 (0.66 to 1.19)	1.06 (0.81 to 1.31)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.22	1.59	
	2020 Comparison Group	0.29	0.53	
	Risk Difference	0.93 (0.69 to 1.18)	1.06 (0.78 to 1.38)	
	p-value	<0.001	<0.001	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.3	0.25	
	2020 Comparison Group	0.23	0.21	
	Risk Difference	0.07 (-0.08 to 0.2)	0.04 (-0.12 to 0.22)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.22	0.15	
	2020 Comparison Group	0.14	0.09	
	Risk Difference	0.08 (-0.03 to 0.21)	0.06 (-0.03 to 0.18)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.1	0.09	

	2020 Comparison Group	0.03	0.05	
	Risk Difference	0.07 (-0.01 to 0.16)	0.04 (-0.03 to 0.11)	
	p-value	0.53	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.91	1.22	
	2020 Comparison Group	1.16	0.79	
	Risk Difference	0.74 (0.32 to 1.13)	0.43 (0.14 to 0.72)	
	p-value	<0.001	<0.001	0.28
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.76	1.01	
	2020 Comparison Group	0.42	0.6	
	Risk Difference	0.34 (0.13 to 0.58)	0.41 (0.14 to 0.65)	
	p-value	<0.001	<0.001	1
Leukopenia	SARS-CoV-2 Group	0.26	0.29	
	2020 Comparison Group	0.15	0.18	
	Risk Difference	0.11 (-0.04 to 0.28)	0.11 (-0.01 to 0.23)	
	p-value	0.85	0.64	1
Anemia	SARS-CoV-2 Group	2.52	3.89	
	2020 Comparison Group	1.51	2.21	
	Risk Difference	1.01 (0.44 to 1.42)	1.69 (1.12 to 2.22)	
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	7.06	9.34	
	2020 Comparison Group	5.24	5.89	
	Risk Difference	1.82 (0.89 to 2.72)	3.45 (2.38 to 4.35)	
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	8.56	13.07	
	2020 Comparison Group	3.78	6	

	Risk Difference	4.78 (3.95 to 5.56)	7.07 (5.95 to 8.17)	
	p-value	<0.001	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	8.4	12.93	
	2020 Comparison Group	3.78	5.99	
	Risk Difference	4.61 (3.75 to 5.33)	6.94 (5.96 to 8)	
	p-value	<0.001	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	0.38	0.38	
	2020 Comparison Group	0.25	0.35	
	Risk Difference	0.14 (-0.01 to 0.31)	0.03 (-0.16 to 0.22)	
	p-value	0.42	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.26	0.26	
	2020 Comparison Group	0.01	0.02	
	Risk Difference	0.26 (0.17 to 0.36)	0.24 (0.15 to 0.34)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.07	0.04	
	2020 Comparison Group	0.01	0.02	
	Risk Difference	0.06 (0 to 0.13)	0.02 (-0.03 to 0.08)	
	p-value	<0.001	1	1

Subgroups are subpopulations of the 2020 cohort.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5b: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

Clinical Sequelae	Category	White	Black	p-interaction
	Matched Group Size	67,027 vs 67,027	10,292 vs 10,292	
Hypertension				
Hypertension	SARS-CoV-2 Group	11.26	16.74	
	2020 Comparison Group	7.72	8.81	
	Risk Difference	3.54 (1.3 to 5.84)	7.92 (-4.38 to 20.77)	
	p-value	<0.001	1	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.99	1.29	
	2020 Comparison Group	0.64	0.81	
	Risk Difference	0.36 (0.14 to 0.63)	0.48 (-0.05 to 1.07)	
	p-value	<0.001	0.11	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.77	5.81	
	2020 Comparison Group	2.78	2.77	
	Risk Difference	1.98 (1.45 to 2.57)	3.03 (1.73 to 4.41)	
	p-value	<0.001	<0.001	0.04
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.9	3.48	
	2020 Comparison Group	1.86	1.73	
	Risk Difference	1.04 (0.63 to 1.48)	1.75 (0.7 to 2.73)	
	p-value	<0.001	<0.001	0.69
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.84	3.68	
	2020 Comparison Group	1.41	1.56	
	Risk Difference	1.43 (1.05 to 1.85)	2.12 (1.12 to 3.26)	
	p-value	<0.001	<0.001	0.06
> POTs				
> POTs	SARS-CoV-2 Group	1.1	1.73	

	2020 Comparison Group	0.75	0.76	
	Risk Difference	0.35 (0.13 to 0.63)	0.97 (0.35 to 1.57)	
	p-value	<0.001	<0.001	0.1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	3.17	3.65	
	2020 Comparison Group	1.71	1.92	
	Risk Difference	1.46 (1.1 to 1.87)	1.73 (0.72 to 2.88)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.79	3.4	
	2020 Comparison Group	1.48	1.8	
	Risk Difference	1.31 (0.94 to 1.66)	1.6 (0.7 to 2.64)	
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	1.15	1.34	
	2020 Comparison Group	0.74	1.03	
	Risk Difference	0.41 (0.18 to 0.64)	0.31 (-0.29 to 0.88)	
	p-value	<0.001	1	1
> Myocarditis	SARS-CoV-2 Group	0.03	0.04	
	2020 Comparison Group	0	0	
	Risk Difference	0.02 (-0.01 to 0.07)	0.04 (0 to 0.15)	
	p-value	1	<0.001	1
Coronary Disease	SARS-CoV-2 Group	1.6	1.95	
	2020 Comparison Group	0.87	0.99	
	Risk Difference	0.73 (0.48 to 1.03)	0.95 (0.23 to 1.56)	
	p-value	<0.001	<0.001	1
> Myocardial Infarction	SARS-CoV-2 Group	1.32	1.6	
	2020 Comparison Group	0.68	0.81	
	Risk Difference	0.63 (0.37 to 0.87)	0.79 (0.23 to 1.25)	

	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.6	1.93	
	2020 Comparison Group	0.86	0.99	
	Risk Difference	0.73 (0.47 to 0.97)	0.94 (0.21 to 1.65)	
	p-value	<0.001	<0.001	1
Cardiogenic Shock	SARS-CoV-2 Group	0.14	0.31	
	2020 Comparison Group	0.1	0.07	
	Risk Difference	0.04 (-0.05 to 0.13)	0.24 (0.03 to 0.47)	
	p-value	1	<0.001	0.05
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.3	4.65	
	2020 Comparison Group	1.28	1.62	
	Risk Difference	2.02 (1.7 to 2.34)	3.03 (1.95 to 4.09)	
	p-value	<0.001	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	2.3	3.29	
	2020 Comparison Group	0.98	1.22	
	Risk Difference	1.31 (1.02 to 1.69)	2.07 (1.2 to 2.9)	
	p-value	<0.001	<0.001	0.002
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.59	2.49	
	2020 Comparison Group	0.56	0.89	
	Risk Difference	1.03 (0.78 to 1.27)	1.6 (0.88 to 2.36)	
	p-value	<0.001	<0.001	0.05
> Pulmonary Embolism	SARS-CoV-2 Group	1.22	1.85	
	2020 Comparison Group	0.29	0.43	
	Risk Difference	0.93 (0.75 to 1.12)	1.42 (0.99 to 2)	
	p-value	<0.001	<0.001	0.004

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.38	0.7	
	2020 Comparison Group	0.22	0.4	
	Risk Difference	0.16 (0.02 to 0.3)	0.3 (-0.13 to 0.69)	
	p-value	<0.001	0.95	1
Stroke and Sequelae	SARS-CoV-2 Group	2.21	2.51	
	2020 Comparison Group	1.31	1.62	
	Risk Difference	0.91 (0.6 to 1.28)	0.89 (-0.03 to 1.68)	
	p-value	<0.001	0.32	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.96	2.42	
	2020 Comparison Group	1.14	1.52	
	Risk Difference	0.82 (0.49 to 1.12)	0.9 (0.15 to 1.71)	
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.34	1.47	
	2020 Comparison Group	0.68	0.93	
	Risk Difference	0.66 (0.43 to 0.96)	0.53 (-0.08 to 1.25)	
	p-value	<0.001	0.32	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	6.28	3.99	
	2020 Comparison Group	3.47	2.33	
	Risk Difference	2.81 (2.11 to 3.49)	1.66 (0.41 to 2.89)	
	p-value	<0.001	<0.001	1
Psychosis	SARS-CoV-2 Group	0.36	0.27	
	2020 Comparison Group	0.13	0.17	
	Risk Difference	0.23 (0.12 to 0.34)	0.1 (-0.11 to 0.36)	
	p-value	<0.001	1	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.1	5.72	
	2020 Comparison Group	2.53	2.32	
	Risk Difference	2.57 (2.06 to 3.01)	3.41 (2.23 to 4.73)	
	p-value	<0.001	<0.001	0.12
Migraine	SARS-CoV-2 Group	0.35	0.19	
	2020 Comparison Group	0.32	0.12	
	Risk Difference	0.02 (-0.12 to 0.18)	0.06 (-0.15 to 0.27)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	1	0.92	
	2020 Comparison Group	0.72	0.73	
	Risk Difference	0.29 (0.02 to 0.49)	0.19 (-0.35 to 0.65)	
	p-value	<0.001	1	1
Encephalopathy	SARS-CoV-2 Group	2.72	3.95	
	2020 Comparison Group	0.96	1.05	
	Risk Difference	1.76 (1.47 to 2.05)	2.9 (2 to 3.83)	
	p-value	<0.001	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.49	0.8	
	2020 Comparison Group	0.26	0.45	
	Risk Difference	0.23 (0.08 to 0.39)	0.35 (-0.04 to 0.8)	
	p-value	<0.001	0.42	1
Dementia	SARS-CoV-2 Group	2.66	2.83	
	2020 Comparison Group	1.21	1.09	
	Risk Difference	1.45 (1.08 to 1.75)	1.74 (0.87 to 2.56)	
	p-value	<0.001	<0.001	1
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.01	0.04	

	2020 Comparison Group	0.01	0.02	
	Risk Difference	0.01 (-0.01 to 0.03)	0.02 (-0.06 to 0.11)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.54	4.94	
	2020 Comparison Group	1.18	1.76	
	Risk Difference	1.36 (0.87 to 1.84)	3.19 (0.94 to 5.48)	
	p-value	<0.001	<0.001	0.07
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.71	1.89	
	2020 Comparison Group	1.12	1.44	
	Risk Difference	0.58 (0.27 to 0.88)	0.44 (-0.43 to 1.34)	
	p-value	<0.001	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.14	8.96	
	2020 Comparison Group	3.6	4.81	
	Risk Difference	2.53 (1.81 to 3.2)	4.15 (2.3 to 6.29)	
	p-value	<0.001	<0.001	0.05
> Chronic Kidney Disease	SARS-CoV-2 Group	4.13	5.79	
	2020 Comparison Group	2.96	4.07	
	Risk Difference	1.16 (0.64 to 1.68)	1.72 (0.11 to 3.49)	
	p-value	<0.001	<0.001	1
> Acute Kidney Injury	SARS-CoV-2 Group	4.16	7.17	
	2020 Comparison Group	1.81	2.61	
	Risk Difference	2.35 (1.98 to 2.83)	4.56 (3.48 to 5.73)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	8.51	10.18	

	2020 Comparison Group	1.66	1.65	
	Risk Difference	6.86 (6.4 to 7.35)	8.53 (7.33 to 9.58)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	7.56	9.53	
	2020 Comparison Group	1.18	1.33	
	Risk Difference	6.38 (5.98 to 6.81)	8.21 (7.14 to 9.19)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.35	1.47	
	2020 Comparison Group	0.4	0.38	
	Risk Difference	0.95 (0.74 to 1.16)	1.09 (0.51 to 1.59)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.35	1.4	
	2020 Comparison Group	0.45	0.41	
	Risk Difference	0.9 (0.67 to 1.15)	0.99 (0.52 to 1.49)	
	p-value	<0.001	<0.001	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.27	0.26	
	2020 Comparison Group	0.21	0.3	
	Risk Difference	0.06 (-0.08 to 0.18)	-0.04 (-0.35 to 0.19)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.2	0.22	
	2020 Comparison Group	0.15	0.19	
	Risk Difference	0.05 (-0.05 to 0.18)	0.03 (-0.19 to 0.26)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.12	0.03	

	2020 Comparison Group	0.05	0.01	
	Risk Difference	0.07 (0 to 0.16)	0.02 (-0.05 to 0.11)	
	p-value	0.11	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.61	1.48	
	2020 Comparison Group	1.01	1.24	
	Risk Difference	0.6 (0.3 to 0.91)	0.24 (-0.44 to 0.92)	
	p-value	<0.001	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.86	0.86	
	2020 Comparison Group	0.51	0.67	
	Risk Difference	0.36 (0.18 to 0.56)	0.18 (-0.34 to 0.64)	
	p-value	<0.001	1	1
Leukopenia	SARS-CoV-2 Group	0.3	0.35	
	2020 Comparison Group	0.16	0.2	
	Risk Difference	0.14 (0.04 to 0.27)	0.15 (-0.14 to 0.4)	
	p-value	<0.001	1	1
Anemia	SARS-CoV-2 Group	3.17	4.4	
	2020 Comparison Group	1.88	2.76	
	Risk Difference	1.29 (0.9 to 1.77)	1.63 (0.51 to 2.69)	
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.05	8.87	
	2020 Comparison Group	5.86	6.33	
	Risk Difference	2.2 (1.37 to 2.98)	2.54 (0.9 to 4.24)	
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	10.7	11.8	
	2020 Comparison Group	5.11	4.8	

	Risk Difference	5.59 (4.69 to 6.24)	7 (5.36 to 9.07)	
	p-value	<0.001	<0.001	0.14
> Fatigue	SARS-CoV-2 Group	10.52	11.56	
	2020 Comparison Group	5.1	4.78	
	Risk Difference	5.42 (4.66 to 6.33)	6.78 (4.98 to 8.49)	
	p-value	<0.001	<0.001	0.2
> Chronic Fatigue	SARS-CoV-2 Group	0.38	0.31	
	2020 Comparison Group	0.28	0.29	
	Risk Difference	0.1 (-0.05 to 0.23)	0.02 (-0.27 to 0.28)	
	p-value	0.64	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.26	0.27	
	2020 Comparison Group	0.01	0.03	
	Risk Difference	0.25 (0.16 to 0.34)	0.24 (0.05 to 0.46)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.07	0.07	
	2020 Comparison Group	0.02	0	
	Risk Difference	0.05 (0 to 0.1)	0.07 (0 to 0.21)	
	p-value	0.11	<0.001	1

Subgroups are subpopulations of the 2020 cohort.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5c: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

Clinical Sequelae	Category	Female	Male	p-interaction
	Matched Group Size	49,054 vs 49,054	37,503 vs 37,503	
Hypertension				
Hypertension	SARS-CoV-2 Group	10.03	12.92	
	2020 Comparison Group	6.36	6.34	
	Risk Difference	3.67 (0.89 to 6.38)	6.58 (3.03 to 9.5)	
	p-value	<0.001	<0.001	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.98	0.95	
	2020 Comparison Group	0.62	0.61	
	Risk Difference	0.36 (0.11 to 0.62)	0.34 (0.04 to 0.62)	
	p-value	<0.001	<0.001	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.23	5.63	
	2020 Comparison Group	2.38	2.6	
	Risk Difference	1.84 (1.32 to 2.35)	3.02 (2.43 to 3.73)	
	p-value	<0.001	<0.001	0.002
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.43	3.41	
	2020 Comparison Group	1.45	1.83	
	Risk Difference	0.98 (0.57 to 1.33)	1.58 (1.01 to 2.09)	
	p-value	<0.001	<0.001	0.15
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.55	3.5	
	2020 Comparison Group	1.3	1.35	
	Risk Difference	1.25 (0.81 to 1.57)	2.16 (1.62 to 2.62)	
	p-value	<0.001	<0.001	0.02
> POTs				
> POTs	SARS-CoV-2 Group	0.95	1.33	

	2020 Comparison Group	0.58	0.81	
	Risk Difference	0.37 (0.13 to 0.61)	0.53 (0.22 to 0.84)	
	p-value	<0.001	<0.001	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.79	3.66	
	2020 Comparison Group	1.41	1.98	
	Risk Difference	1.38 (0.81 to 1.81)	1.68 (1.02 to 2.21)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.46	3.17	
	2020 Comparison Group	1.31	1.7	
	Risk Difference	1.15 (0.8 to 1.52)	1.47 (0.95 to 2.09)	
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	0.9	1.48	
	2020 Comparison Group	0.45	1.06	
	Risk Difference	0.45 (0.23 to 0.67)	0.42 (0.04 to 0.8)	
	p-value	<0.001	<0.001	1
> Myocarditis	SARS-CoV-2 Group	0.05	0.03	
	2020 Comparison Group	0.01	0	
	Risk Difference	0.03 (-0.02 to 0.09)	0.03 (0 to 0.07)	
	p-value	1	0.21	1
Coronary Disease	SARS-CoV-2 Group	1.39	1.94	
	2020 Comparison Group	0.8	0.86	
	Risk Difference	0.58 (0.3 to 0.88)	1.08 (0.72 to 1.45)	
	p-value	<0.001	<0.001	0.01
> Myocardial Infarction	SARS-CoV-2 Group	1.17	1.56	
	2020 Comparison Group	0.63	0.7	
	Risk Difference	0.53 (0.34 to 0.82)	0.86 (0.55 to 1.18)	

	p-value	<0.001	<0.001	0.08
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.38	1.93	
	2020 Comparison Group	0.8	0.86	
	Risk Difference	0.58 (0.29 to 0.85)	1.07 (0.74 to 1.44)	
	p-value	<0.001	<0.001	0.01
Cardiogenic Shock	SARS-CoV-2 Group	0.09	0.18	
	2020 Comparison Group	0.08	0.1	
	Risk Difference	0.01 (-0.08 to 0.1)	0.08 (-0.04 to 0.19)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.11	3.89	
	2020 Comparison Group	1.03	1.31	
	Risk Difference	2.08 (1.63 to 2.5)	2.59 (2.09 to 3.15)	
	p-value	<0.001	<0.001	0.04
> Hypercoagulability	SARS-CoV-2 Group	2.29	2.53	
	2020 Comparison Group	0.82	0.98	
	Risk Difference	1.47 (1.15 to 1.79)	1.55 (1.17 to 1.97)	
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.65	1.71	
	2020 Comparison Group	0.47	0.51	
	Risk Difference	1.18 (0.89 to 1.44)	1.2 (0.85 to 1.46)	
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.07	1.5	
	2020 Comparison Group	0.28	0.3	
	Risk Difference	0.79 (0.58 to 1)	1.21 (0.92 to 1.45)	
	p-value	<0.001	<0.001	<0.001

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.29	0.59	
	2020 Comparison Group	0.18	0.27	
	Risk Difference	0.11 (-0.02 to 0.25)	0.32 (0.11 to 0.55)	
	p-value	0.21	<0.001	0.12
Stroke and Sequelae	SARS-CoV-2 Group	2.11	2.33	
	2020 Comparison Group	1.13	1.35	
	Risk Difference	0.98 (0.64 to 1.36)	0.98 (0.59 to 1.46)	
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.88	2.08	
	2020 Comparison Group	0.98	1.16	
	Risk Difference	0.9 (0.58 to 1.23)	0.92 (0.51 to 1.29)	
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.26	1.4	
	2020 Comparison Group	0.61	0.74	
	Risk Difference	0.65 (0.35 to 0.91)	0.66 (0.36 to 1.01)	
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	6.8	4.06	
	2020 Comparison Group	4.37	2.5	
	Risk Difference	2.43 (1.58 to 3.26)	1.55 (0.87 to 2.15)	
	p-value	<0.001	<0.001	0.21
Psychosis	SARS-CoV-2 Group	0.35	0.28	
	2020 Comparison Group	0.15	0.07	
	Risk Difference	0.19 (0.08 to 0.33)	0.2 (0.09 to 0.35)	
	p-value	<0.001	<0.001	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.05	4.91	
	2020 Comparison Group	2.4	2.19	
	Risk Difference	2.65 (2.12 to 3.18)	2.72 (2.09 to 3.39)	
	p-value	<0.001	<0.001	1
Migraine	SARS-CoV-2 Group	0.38	0.2	
	2020 Comparison Group	0.31	0.15	
	Risk Difference	0.07 (-0.09 to 0.23)	0.05 (-0.08 to 0.21)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.9	0.93	
	2020 Comparison Group	0.68	0.78	
	Risk Difference	0.23 (-0.02 to 0.47)	0.15 (-0.13 to 0.46)	
	p-value	0.21	1	1
Encephalopathy	SARS-CoV-2 Group	2.55	2.88	
	2020 Comparison Group	0.88	0.81	
	Risk Difference	1.67 (1.32 to 2.01)	2.07 (1.64 to 2.47)	
	p-value	<0.001	<0.001	0.23
Seizure	SARS-CoV-2 Group	0.51	0.55	
	2020 Comparison Group	0.29	0.25	
	Risk Difference	0.22 (0.06 to 0.37)	0.3 (0.11 to 0.52)	
	p-value	<0.001	<0.001	1
Dementia	SARS-CoV-2 Group	2.8	2.28	
	2020 Comparison Group	1.33	1.1	
	Risk Difference	1.47 (1.07 to 1.89)	1.18 (0.81 to 1.58)	
	p-value	<0.001	<0.001	1
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.03	

	2020 Comparison Group	0.01	0	
	Risk Difference	0.01 (-0.02 to 0.04)	0.03 (0 to 0.07)	
	p-value	1	<0.001	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.58	3.66	
	2020 Comparison Group	1.38	1.69	
	Risk Difference	1.21 (0.62 to 1.73)	1.97 (1.19 to 2.86)	
	p-value	<0.001	<0.001	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.76	2.03	
	2020 Comparison Group	1.2	1.37	
	Risk Difference	0.56 (0.15 to 0.9)	0.66 (0.27 to 1.09)	
	p-value	<0.001	<0.001	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	5.98	7.15	
	2020 Comparison Group	3.51	3.89	
	Risk Difference	2.47 (1.78 to 3.23)	3.25 (2.24 to 4.08)	
	p-value	<0.001	<0.001	0.04
> Chronic Kidney Disease	SARS-CoV-2 Group	4.1	4.64	
	2020 Comparison Group	2.82	3.22	
	Risk Difference	1.28 (0.64 to 1.92)	1.42 (0.59 to 2.28)	
	p-value	<0.001	<0.001	1
> Acute Kidney Injury	SARS-CoV-2 Group	3.76	5.55	
	2020 Comparison Group	1.61	2.11	
	Risk Difference	2.15 (1.68 to 2.59)	3.44 (2.88 to 4.09)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.57	10.81	

	2020 Comparison Group	1.42	1.57	
	Risk Difference	6.15 (5.59 to 6.71)	9.24 (8.47 to 9.89)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	6.72	9.52	
	2020 Comparison Group	0.95	1.14	
	Risk Difference	5.77 (5.27 to 6.17)	8.38 (7.81 to 8.92)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.28	1.48	
	2020 Comparison Group	0.32	0.35	
	Risk Difference	0.97 (0.75 to 1.22)	1.12 (0.85 to 1.41)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.15	1.68	
	2020 Comparison Group	0.52	0.48	
	Risk Difference	0.64 (0.39 to 0.91)	1.2 (0.88 to 1.53)	
	p-value	<0.001	<0.001	<0.001
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.25	0.26	
	2020 Comparison Group	0.29	0.27	
	Risk Difference	-0.04 (-0.19 to 0.09)	-0.02 (-0.19 to 0.14)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.21	0.15	
	2020 Comparison Group	0.15	0.13	
	Risk Difference	0.06 (-0.07 to 0.16)	0.02 (-0.09 to 0.15)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.1	0.09	

	2020 Comparison Group	0.05	0.02	
	Risk Difference	0.05 (-0.03 to 0.12)	0.07 (-0.02 to 0.15)	
	p-value	1	0.21	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.18	2.12	
	2020 Comparison Group	0.8	1.19	
	Risk Difference	0.38 (0.07 to 0.63)	0.92 (0.45 to 1.32)	
	p-value	<0.001	<0.001	0.86
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.65	1.32	
	2020 Comparison Group	0.43	0.74	
	Risk Difference	0.23 (0.05 to 0.43)	0.58 (0.33 to 0.91)	
	p-value	<0.001	<0.001	0.56
Leukopenia	SARS-CoV-2 Group	0.27	0.28	
	2020 Comparison Group	0.16	0.13	
	Risk Difference	0.11 (0 to 0.22)	0.15 (0.02 to 0.3)	
	p-value	<0.001	<0.001	1
Anemia	SARS-CoV-2 Group	3.25	3.1	
	2020 Comparison Group	1.96	1.94	
	Risk Difference	1.29 (0.83 to 1.79)	1.17 (0.61 to 1.81)	
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.63	7.04	
	2020 Comparison Group	6.23	5.05	
	Risk Difference	2.4 (1.31 to 3.48)	1.98 (1.17 to 3.09)	
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	10.98	10.37	
	2020 Comparison Group	5.07	4.29	

	Risk Difference	5.91 (5.03 to 6.8)	6.08 (5.23 to 7.15)	
	p-value	<0.001	<0.001	1
> Fatigue	SARS-CoV-2 Group	10.81	10.24	
	2020 Comparison Group	5.08	4.29	
	Risk Difference	5.73 (4.82 to 6.62)	5.95 (5.18 to 6.89)	
	p-value	<0.001	<0.001	1
> Chronic Fatigue	SARS-CoV-2 Group	0.42	0.31	
	2020 Comparison Group	0.32	0.22	
	Risk Difference	0.1 (-0.08 to 0.3)	0.09 (-0.07 to 0.27)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.29	0.2	
	2020 Comparison Group	0.02	0.01	
	Risk Difference	0.27 (0.18 to 0.36)	0.19 (0.1 to 0.31)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.07	0.06	
	2020 Comparison Group	0.04	0.03	
	Risk Difference	0.03 (-0.03 to 0.11)	0.03 (-0.04 to 0.12)	
	p-value	1	1	1

Subgroups are subpopulations of the 2020 cohort.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5d: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2020 Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

Clinical Sequelae	Category	Not hospitalized with COVID	Hospitalized with COVID	p-interaction
	Matched Group Size	63,690 vs 63,690	23,486 vs 23,486	
Hypertension				
Hypertension	SARS-CoV-2 Group	9.34	22.89	
	2020 Comparison Group	6.78	8.25	
	Risk Difference	2.55 (0.05 to 5.06)	14.64 (7.13 to 21.3)	
	p-value	0.11	<0.001	<0.001
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.79	1.74	
	2020 Comparison Group	0.54	0.74	
	Risk Difference	0.26 (0.07 to 0.49)	1.01 (0.52 to 1.42)	
	p-value	<0.001	<0.001	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	3.48	9.61	
	2020 Comparison Group	2.5	2.9	
	Risk Difference	0.98 (0.57 to 1.4)	6.71 (5.61 to 7.82)	
	p-value	<0.001	<0.001	<0.001
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.14	4.94	
	2020 Comparison Group	1.68	1.95	
	Risk Difference	0.46 (0.1 to 0.78)	2.99 (2.21 to 3.84)	
	p-value	<0.001	<0.001	<0.001
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	1.92	6.46	
	2020 Comparison Group	1.27	1.62	
	Risk Difference	0.66 (0.35 to 0.93)	4.84 (4.01 to 5.68)	
	p-value	<0.001	<0.001	<0.001
> POTs				
> POTs	SARS-CoV-2 Group	0.84	2.01	

	2020 Comparison Group	0.62	0.82	
	Risk Difference	0.22 (0.02 to 0.41)	1.19 (0.63 to 1.72)	
	p-value	<0.001	<0.001	<0.001
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.28	6.01	
	2020 Comparison Group	1.62	2.36	
	Risk Difference	0.67 (0.35 to 1.02)	3.66 (2.81 to 4.64)	
	p-value	<0.001	<0.001	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	2.03	5.41	
	2020 Comparison Group	1.41	2.08	
	Risk Difference	0.62 (0.3 to 0.97)	3.33 (2.53 to 4.21)	
	p-value	<0.001	<0.001	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	0.86	1.83	
	2020 Comparison Group	0.71	0.99	
	Risk Difference	0.16 (-0.05 to 0.35)	0.84 (0.37 to 1.32)	
	p-value	0.95	<0.001	0.48
> Myocarditis	SARS-CoV-2 Group	0.02	0.11	
	2020 Comparison Group	0.01	0.02	
	Risk Difference	0.01 (-0.01 to 0.04)	0.1 (-0.01 to 0.21)	
	p-value	1	0.11	0.02
Coronary Disease	SARS-CoV-2 Group	1.13	3.21	
	2020 Comparison Group	0.82	1.08	
	Risk Difference	0.31 (0.08 to 0.57)	2.12 (1.58 to 2.69)	
	p-value	<0.001	<0.001	<0.001
> Myocardial Infarction	SARS-CoV-2 Group	0.9	2.73	
	2020 Comparison Group	0.66	0.88	
	Risk Difference	0.24 (0.02 to 0.44)	1.85 (1.24 to 2.37)	

	p-value	<0.001	<0.001	<0.001
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.13	3.17	
	2020 Comparison Group	0.82	1.08	
	Risk Difference	0.31 (0.06 to 0.55)	2.09 (1.5 to 2.82)	
	p-value	<0.001	<0.001	<0.001
Cardiogenic Shock	SARS-CoV-2 Group	0.1	0.25	
	2020 Comparison Group	0.08	0.17	
	Risk Difference	0.01 (-0.06 to 0.08)	0.08 (-0.08 to 0.31)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.13	7.62	
	2020 Comparison Group	1.09	1.5	
	Risk Difference	1.04 (0.73 to 1.38)	6.12 (5.24 to 7.04)	
	p-value	<0.001	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	1.59	4.94	
	2020 Comparison Group	0.79	1	
	Risk Difference	0.8 (0.54 to 1.12)	3.94 (3.09 to 4.6)	
	p-value	<0.001	<0.001	<0.001
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.01	3.78	
	2020 Comparison Group	0.49	0.56	
	Risk Difference	0.52 (0.31 to 0.72)	3.22 (2.58 to 3.8)	
	p-value	<0.001	<0.001	<0.001
> Pulmonary Embolism	SARS-CoV-2 Group	0.63	3.22	
	2020 Comparison Group	0.25	0.35	
	Risk Difference	0.39 (0.21 to 0.55)	2.87 (2.45 to 3.37)	
	p-value	<0.001	<0.001	<0.001

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.31	0.76	
	2020 Comparison Group	0.24	0.37	
	Risk Difference	0.07 (-0.04 to 0.2)	0.38 (0.09 to 0.71)	
	p-value	1	<0.001	0.14
Stroke and Sequelae	SARS-CoV-2 Group	1.59	4.56	
	2020 Comparison Group	1.11	1.58	
	Risk Difference	0.48 (0.2 to 0.75)	2.99 (2.18 to 3.82)	
	p-value	<0.001	<0.001	<0.001
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.4	4.2	
	2020 Comparison Group	0.98	1.39	
	Risk Difference	0.42 (0.17 to 0.66)	2.8 (2.05 to 3.62)	
	p-value	<0.001	<0.001	<0.001
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.04	2.61	
	2020 Comparison Group	0.62	0.95	
	Risk Difference	0.41 (0.18 to 0.62)	1.66 (1.06 to 2.33)	
	p-value	<0.001	<0.001	<0.001
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.02	8.11	
	2020 Comparison Group	3.17	3.63	
	Risk Difference	1.85 (1.25 to 2.48)	4.48 (3.38 to 5.94)	
	p-value	<0.001	<0.001	<0.001
Psychosis	SARS-CoV-2 Group	0.23	0.67	
	2020 Comparison Group	0.1	0.22	
	Risk Difference	0.13 (0.04 to 0.24)	0.45 (0.13 to 0.72)	
	p-value	<0.001	<0.001	0.003

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.25	10.99	
	2020 Comparison Group	2	2.83	
	Risk Difference	1.25 (0.87 to 1.61)	8.16 (6.91 to 9.39)	
	p-value	<0.001	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.34	0.19	
	2020 Comparison Group	0.27	0.26	
	Risk Difference	0.07 (-0.06 to 0.21)	-0.07 (-0.29 to 0.12)	
	p-value	1	1	0.15
Peripheral Neuropathy	SARS-CoV-2 Group	0.85	1.21	
	2020 Comparison Group	0.74	0.84	
	Risk Difference	0.11 (-0.07 to 0.33)	0.37 (-0.11 to 0.83)	
	p-value	1	0.95	1
Encephalopathy	SARS-CoV-2 Group	1.41	6.82	
	2020 Comparison Group	0.72	1.17	
	Risk Difference	0.69 (0.44 to 0.94)	5.65 (4.93 to 6.72)	
	p-value	<0.001	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.37	0.92	
	2020 Comparison Group	0.2	0.24	
	Risk Difference	0.17 (0 to 0.29)	0.67 (0.28 to 1)	
	p-value	0.11	<0.001	<0.001
Dementia	SARS-CoV-2 Group	1.87	4.85	
	2020 Comparison Group	0.97	1.66	
	Risk Difference	0.9 (0.63 to 1.16)	3.19 (2.31 to 4.11)	
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.01	0.06	

	2020 Comparison Group	0	0.02	
	Risk Difference	0.01 (0 to 0.03)	0.04 (-0.02 to 0.12)	
	p-value	<0.001	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.34	5.54	
	2020 Comparison Group	1.41	1.83	
	Risk Difference	0.94 (0.47 to 1.53)	3.71 (2.41 to 4.88)	
	p-value	<0.001	<0.001	<0.001
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.62	2.24	
	2020 Comparison Group	1.29	1.24	
	Risk Difference	0.33 (0.05 to 0.6)	1 (0.29 to 1.55)	
	p-value	<0.001	<0.001	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	4.69	13.08	
	2020 Comparison Group	3.59	4.66	
	Risk Difference	1.1 (0.52 to 1.6)	8.42 (7 to 9.83)	
	p-value	<0.001	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	3.66	6.6	
	2020 Comparison Group	3.02	3.95	
	Risk Difference	0.64 (0.16 to 1.08)	2.65 (1.33 to 3.67)	
	p-value	<0.001	<0.001	<0.001
> Acute Kidney Injury	SARS-CoV-2 Group	2.52	11.13	
	2020 Comparison Group	1.56	2.35	
	Risk Difference	0.96 (0.62 to 1.31)	8.78 (7.58 to 9.88)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	3.52	26.1	

	2020 Comparison Group	1.33	2.01	
	Risk Difference	2.18 (1.82 to 2.56)	24.1 (22.77 to 25.16)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	2.73	23.8	
	2020 Comparison Group	0.92	1.48	
	Risk Difference	1.81 (1.49 to 2.09)	22.32 (21.18 to 23.54)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	0.7	3.74	
	2020 Comparison Group	0.28	0.49	
	Risk Difference	0.43 (0.29 to 0.59)	3.25 (2.64 to 3.9)	
	p-value	<0.001	<0.001	<0.001
> Interstitial Lung Disease	SARS-CoV-2 Group	0.88	2.96	
	2020 Comparison Group	0.47	0.46	
	Risk Difference	0.41 (0.23 to 0.62)	2.51 (1.96 to 3.12)	
	p-value	<0.001	<0.001	<0.001
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.28	0.25	
	2020 Comparison Group	0.23	0.22	
	Risk Difference	0.04 (-0.08 to 0.16)	0.03 (-0.18 to 0.23)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.19	0.27	
	2020 Comparison Group	0.13	0.15	
	Risk Difference	0.06 (-0.04 to 0.15)	0.12 (-0.07 to 0.34)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.09	0.1	

	2020 Comparison Group	0.05	0.02	
	Risk Difference	0.04 (-0.02 to 0.11)	0.08 (0 to 0.2)	
	p-value	0.85	0.21	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.34	2.38	
	2020 Comparison Group	1.09	1.11	
	Risk Difference	0.25 (-0.1 to 0.55)	1.27 (0.68 to 1.9)	
	p-value	0.74	<0.001	0.01
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.65	1.7	
	2020 Comparison Group	0.5	0.69	
	Risk Difference	0.15 (-0.04 to 0.34)	1.01 (0.54 to 1.47)	
	p-value	0.42	<0.001	<0.001
Leukopenia	SARS-CoV-2 Group	0.23	0.48	
	2020 Comparison Group	0.16	0.16	
	Risk Difference	0.07 (-0.05 to 0.18)	0.32 (0.1 to 0.56)	
	p-value	1	<0.001	0.02
Anemia	SARS-CoV-2 Group	2.73	5.09	
	2020 Comparison Group	1.69	2.13	
	Risk Difference	1.04 (0.61 to 1.43)	2.96 (2.11 to 3.8)	
	p-value	<0.001	<0.001	0.01
Symptom				
Myalgia	SARS-CoV-2 Group	7.36	11.12	
	2020 Comparison Group	5.54	6.19	
	Risk Difference	1.82 (1.06 to 2.6)	4.93 (3.34 to 6.81)	
	p-value	<0.001	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	7.74	20.36	
	2020 Comparison Group	4.5	5.19	

	Risk Difference	3.24 (2.57 to 3.81)	15.16 (13.24 to 16.75)	
	p-value	<0.001	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	7.6	20.06	
	2020 Comparison Group	4.5	5.19	
	Risk Difference	3.11 (2.49 to 3.86)	14.88 (13.18 to 16.62)	
	p-value	<0.001	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	0.31	0.54	
	2020 Comparison Group	0.25	0.25	
	Risk Difference	0.06 (-0.06 to 0.18)	0.28 (0.06 to 0.57)	
	p-value	1	<0.001	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.19	0.46	
	2020 Comparison Group	0.02	0.01	
	Risk Difference	0.17 (0.1 to 0.26)	0.45 (0.28 to 0.63)	
	p-value	<0.001	<0.001	<0.001
Anosmia	SARS-CoV-2 Group	0.07	0.07	
	2020 Comparison Group	0.04	0.02	
	Risk Difference	0.04 (-0.02 to 0.09)	0.05 (-0.06 to 0.16)	
	p-value	1	1	1

Subgroups are subpopulations of the 2020 cohort.

Hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals hospitalized due to COVID and individuals within the 2020 comparison group. Meanwhile, Not hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals not hospitalized due to COVID and individuals within the 2020 comparison group.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5e: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

Clinical Sequelae	Category	65–74	>74	p-interaction
	Matched Group Size	40,750 vs 40,750	47,400 vs 47,400	
Hypertension				
Hypertension	SARS-CoV-2 Group	12.08	14.81	
	2019 Comparison Group	7.62	11.01	
	Risk Difference	4.45 (1.46 to 7.52)	3.8 (-2.18 to 9.21)	
	p-value	<0.001	1	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.74	1.25	
	2019 Comparison Group	0.44	1.04	
	Risk Difference	0.31 (0.05 to 0.53)	0.21 (-0.08 to 0.5)	
	p-value	<0.001	1	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.07	5.55	
	2019 Comparison Group	2.42	4.04	
	Risk Difference	1.65 (1.17 to 2.14)	1.52 (0.84 to 2.16)	
	p-value	<0.001	<0.001	0.55
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.19	3.36	
	2019 Comparison Group	1.48	2.83	
	Risk Difference	0.71 (0.29 to 1.12)	0.52 (0.02 to 1.26)	
	p-value	<0.001	<0.001	0.33
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.71	3.29	
	2019 Comparison Group	1.38	1.79	
	Risk Difference	1.33 (0.84 to 1.76)	1.5 (1.03 to 1.94)	
	p-value	<0.001	<0.001	1
> POTs				
> POTs	SARS-CoV-2 Group	0.95	1.29	

	2019 Comparison Group	0.56	1.08	
	Risk Difference	0.39 (0.17 to 0.63)	0.21 (-0.09 to 0.51)	
	p-value	<0.001	1	0.31
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.17	4.14	
	2019 Comparison Group	1.31	2.98	
	Risk Difference	0.86 (0.43 to 1.25)	1.16 (0.65 to 1.71)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	1.82	3.77	
	2019 Comparison Group	1.1	2.74	
	Risk Difference	0.72 (0.41 to 1.1)	1.03 (0.43 to 1.57)	
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	0.98	1.29	
	2019 Comparison Group	0.62	0.95	
	Risk Difference	0.35 (0.09 to 0.7)	0.34 (-0.04 to 0.66)	
	p-value	<0.001	0.32	1
> Myocarditis	SARS-CoV-2 Group	0.04	0.04	
	2019 Comparison Group	0	0.01	
	Risk Difference	0.04 (0 to 0.09)	0.03 (-0.01 to 0.07)	
	p-value	0.21	0.64	1
Coronary Disease	SARS-CoV-2 Group	1.39	2.07	
	2019 Comparison Group	0.76	1.39	
	Risk Difference	0.63 (0.34 to 0.93)	0.67 (0.3 to 1.04)	
	p-value	<0.001	<0.001	1
> Myocardial Infarction	SARS-CoV-2 Group	1.14	1.73	
	2019 Comparison Group	0.57	1.13	
	Risk Difference	0.58 (0.29 to 0.82)	0.6 (0.22 to 0.93)	

	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.38	2.05	
	2019 Comparison Group	0.76	1.39	
	Risk Difference	0.62 (0.3 to 0.89)	0.66 (0.29 to 1.07)	
	p-value	<0.001	<0.001	1
Cardiogenic Shock	SARS-CoV-2 Group	0.13	0.14	
	2019 Comparison Group	0.08	0.1	
	Risk Difference	0.04 (-0.04 to 0.12)	0.04 (-0.04 to 0.13)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.86	3.94	
	2019 Comparison Group	1.19	1.93	
	Risk Difference	1.68 (1.27 to 2.12)	2.01 (1.54 to 2.53)	
	p-value	<0.001	<0.001	1
> Hypercoagulability	SARS-CoV-2 Group	1.92	2.8	
	2019 Comparison Group	0.91	1.47	
	Risk Difference	1.02 (0.69 to 1.35)	1.34 (0.96 to 1.75)	
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.39	1.94	
	2019 Comparison Group	0.57	0.85	
	Risk Difference	0.82 (0.51 to 1.11)	1.09 (0.79 to 1.44)	
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.06	1.36	
	2019 Comparison Group	0.26	0.38	
	Risk Difference	0.8 (0.58 to 1.02)	0.98 (0.73 to 1.22)	
	p-value	<0.001	<0.001	1

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.41	0.42	
	2019 Comparison Group	0.22	0.33	
	Risk Difference	0.19 (0.04 to 0.37)	0.09 (-0.06 to 0.28)	
	p-value	<0.001	1	1
Stroke and Sequelae	SARS-CoV-2 Group	1.47	3.05	
	2019 Comparison Group	1.02	2.29	
	Risk Difference	0.45 (0.06 to 0.82)	0.76 (0.34 to 1.24)	
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.31	2.71	
	2019 Comparison Group	0.92	2.03	
	Risk Difference	0.39 (0.06 to 0.7)	0.68 (0.21 to 1.28)	
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	0.9	1.81	
	2019 Comparison Group	0.51	1.32	
	Risk Difference	0.39 (0.15 to 0.66)	0.49 (0.12 to 0.84)	
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.14	6.58	
	2019 Comparison Group	3.67	4.52	
	Risk Difference	1.47 (0.73 to 2.18)	2.07 (1.24 to 3.04)	
	p-value	<0.001	<0.001	1
Psychosis	SARS-CoV-2 Group	0.23	0.43	
	2019 Comparison Group	0.13	0.28	
	Risk Difference	0.1 (-0.02 to 0.24)	0.16 (-0.02 to 0.35)	
	p-value	0.85	0.21	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.01	7.92	
	2019 Comparison Group	1.78	4.92	
	Risk Difference	1.23 (0.77 to 1.74)	2.99 (2.17 to 3.96)	
	p-value	<0.001	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.45	0.21	
	2019 Comparison Group	0.43	0.23	
	Risk Difference	0.02 (-0.18 to 0.23)	-0.02 (-0.17 to 0.11)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.88	1.01	
	2019 Comparison Group	0.84	1.1	
	Risk Difference	0.04 (-0.22 to 0.32)	-0.08 (-0.36 to 0.22)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	1.82	3.72	
	2019 Comparison Group	0.68	1.78	
	Risk Difference	1.14 (0.82 to 1.43)	1.94 (1.52 to 2.37)	
	p-value	<0.001	<0.001	0.02
Seizure	SARS-CoV-2 Group	0.46	0.63	
	2019 Comparison Group	0.28	0.47	
	Risk Difference	0.17 (0 to 0.36)	0.17 (-0.03 to 0.38)	
	p-value	0.11	0.53	1
Dementia	SARS-CoV-2 Group	0.86	4.79	
	2019 Comparison Group	0.4	2.45	
	Risk Difference	0.46 (0.23 to 0.68)	2.34 (1.66 to 2.95)	
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.01	0.02	

	2019 Comparison Group	0.01	0	
	Risk Difference	0.01 (-0.02 to 0.04)	0.01 (-0.02 to 0.04)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	3.11	3.1	
	2019 Comparison Group	1.57	1.66	
	Risk Difference	1.53 (0.76 to 2.26)	1.44 (0.77 to 2.12)	
	p-value	<0.001	<0.001	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	2.12	1.48	
	2019 Comparison Group	1.51	1.16	
	Risk Difference	0.61 (0.22 to 1.09)	0.32 (-0.03 to 0.66)	
	p-value	<0.001	0.21	0.02
Nephrology				
Kidney Injury	SARS-CoV-2 Group	4.79	8.91	
	2019 Comparison Group	3.29	5.93	
	Risk Difference	1.5 (0.77 to 2.26)	2.98 (2.02 to 4.06)	
	p-value	<0.001	<0.001	0.7
> Chronic Kidney Disease	SARS-CoV-2 Group	3.12	5.96	
	2019 Comparison Group	2.77	5.01	
	Risk Difference	0.35 (-0.31 to 1.03)	0.95 (0 to 1.77)	
	p-value	1	0.11	1
> Acute Kidney Injury	SARS-CoV-2 Group	3.31	5.88	
	2019 Comparison Group	1.55	2.98	
	Risk Difference	1.76 (1.33 to 2.24)	2.89 (2.16 to 3.64)	
	p-value	<0.001	<0.001	1
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.72	10.35	

	2019 Comparison Group	1.4	2.69	
	Risk Difference	6.32 (5.73 to 6.9)	7.66 (7.1 to 8.3)	
	p-value	<0.001	<0.001	1
> Acute Respiratory Failure	SARS-CoV-2 Group	6.8	9.22	
	2019 Comparison Group	0.98	1.93	
	Risk Difference	5.82 (5.36 to 6.28)	7.29 (6.77 to 7.87)	
	p-value	<0.001	<0.001	1
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.26	1.52	
	2019 Comparison Group	0.3	0.56	
	Risk Difference	0.96 (0.72 to 1.21)	0.96 (0.7 to 1.26)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.21	1.45	
	2019 Comparison Group	0.48	0.85	
	Risk Difference	0.73 (0.46 to 0.99)	0.59 (0.3 to 0.9)	
	p-value	<0.001	<0.001	0.1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.29	0.25	
	2019 Comparison Group	0.3	0.33	
	Risk Difference	-0.01 (-0.2 to 0.16)	-0.08 (-0.24 to 0.09)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.23	0.17	
	2019 Comparison Group	0.21	0.16	
	Risk Difference	0.01 (-0.13 to 0.14)	0.01 (-0.1 to 0.13)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.1	0.07	

	2019 Comparison Group	0.06	0.06	
	Risk Difference	0.04 (-0.04 to 0.13)	0.01 (-0.07 to 0.08)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.91	1.23	
	2019 Comparison Group	1.77	1.1	
	Risk Difference	0.13 (-0.3 to 0.57)	0.12 (-0.21 to 0.46)	
	p-value	1	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.78	1.01	
	2019 Comparison Group	0.44	0.69	
	Risk Difference	0.34 (0.08 to 0.58)	0.32 (0.01 to 0.55)	
	p-value	<0.001	<0.001	1
Leukopenia	SARS-CoV-2 Group	0.28	0.29	
	2019 Comparison Group	0.14	0.15	
	Risk Difference	0.14 (0.01 to 0.27)	0.14 (0 to 0.29)	
	p-value	<0.001	0.11	1
Anemia	SARS-CoV-2 Group	2.62	4.06	
	2019 Comparison Group	1.76	2.64	
	Risk Difference	0.87 (0.36 to 1.49)	1.42 (0.81 to 1.98)	
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	6.84	8.84	
	2019 Comparison Group	6.58	7.87	
	Risk Difference	0.26 (-0.66 to 1.25)	0.97 (-0.14 to 1.93)	
	p-value	1	0.21	1
Fatigue Diagnosis	SARS-CoV-2 Group	8.49	13.32	
	2019 Comparison Group	4.32	8.05	

	Risk Difference	4.17 (3.27 to 4.99)	5.27 (4.2 to 6.55)	
	p-value	<0.001	<0.001	0.13
> Fatigue	SARS-CoV-2 Group	8.34	13.16	
	2019 Comparison Group	4.31	8.06	
	Risk Difference	4.03 (3.24 to 4.97)	5.11 (3.8 to 6.27)	
	p-value	<0.001	<0.001	0.18
> Chronic Fatigue	SARS-CoV-2 Group	0.39	0.38	
	2019 Comparison Group	0.34	0.34	
	Risk Difference	0.04 (-0.14 to 0.21)	0.04 (-0.12 to 0.22)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.25	0.25	
	2019 Comparison Group	0.03	0.01	
	Risk Difference	0.22 (0.12 to 0.33)	0.24 (0.16 to 0.33)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.07	0.05	
	2019 Comparison Group	0.02	0.03	
	Risk Difference	0.05 (-0.01 to 0.13)	0.03 (-0.02 to 0.1)	
	p-value	0.85	1	1

Subgroups are subpopulations of the SARS-CoV-2 and 2019 cohorts.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5f: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

Clinical Sequelae	Category	White	Black	p-interaction
	Matched Group Size	68,009 vs 68,009	9,320 vs 9,320	
Hypertension				
Hypertension	SARS-CoV-2 Group	13.26	22.34	
	2019 Comparison Group	9.15	11.4	
	Risk Difference	4.11 (0.57 to 8.06)	10.94 (-9.81 to 27.41)	
	p-value	<0.001	1	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.96	1.16	
	2019 Comparison Group	0.85	0.98	
	Risk Difference	0.11 (-0.14 to 0.34)	0.18 (-0.47 to 0.75)	
	p-value	1	1	1
Cardiology				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.97	5.79	
	2019 Comparison Group	3.43	3.53	
	Risk Difference	1.54 (1.03 to 2.13)	2.26 (0.98 to 3.64)	
	p-value	<0.001	<0.001	1
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.99	3.55	
	2019 Comparison Group	2.4	2.38	
	Risk Difference	0.59 (0.14 to 1.02)	1.17 (0.23 to 2.23)	
	p-value	<0.001	<0.001	1
> Tachycardia	SARS-CoV-2 Group	2.95	3.67	
	2019 Comparison Group	1.61	1.77	
	Risk Difference	1.34 (0.98 to 1.79)	1.91 (0.93 to 2.86)	
	p-value	<0.001	<0.001	0.97
> POTs	SARS-CoV-2 Group	1.15	1.68	

	2019 Comparison Group	0.98	0.9	
	Risk Difference	0.17 (-0.07 to 0.4)	0.78 (0.11 to 1.56)	
	p-value	1	<0.001	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	3.13	3.66	
	2019 Comparison Group	2.36	2.52	
	Risk Difference	0.77 (0.35 to 1.18)	1.14 (0.16 to 2.19)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.81	3.49	
	2019 Comparison Group	2.13	1.99	
	Risk Difference	0.68 (0.27 to 1.09)	1.5 (0.31 to 2.56)	
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	1.16	1.24	
	2019 Comparison Group	0.89	1.03	
	Risk Difference	0.26 (0.01 to 0.55)	0.21 (-0.39 to 0.89)	
	p-value	<0.001	1	1
> Myocarditis	SARS-CoV-2 Group	0.04	0.05	
	2019 Comparison Group	0.01	0	
	Risk Difference	0.03 (-0.01 to 0.06)	0.05 (0 to 0.2)	
	p-value	1	<0.001	1
Coronary Disease	SARS-CoV-2 Group	1.73	1.87	
	2019 Comparison Group	1.22	1.2	
	Risk Difference	0.51 (0.21 to 0.8)	0.67 (-0.17 to 1.32)	
	p-value	<0.001	0.21	1
> Myocardial Infarction	SARS-CoV-2 Group	1.43	1.53	
	2019 Comparison Group	0.96	1.06	
	Risk Difference	0.47 (0.2 to 0.73)	0.47 (-0.15 to 1.21)	

	p-value	<0.001	0.85	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.72	1.86	
	2019 Comparison Group	1.22	1.2	
	Risk Difference	0.5 (0.24 to 0.82)	0.66 (-0.07 to 1.31)	
	p-value	<0.001	0.21	1
Cardiogenic Shock	SARS-CoV-2 Group	0.13	0.25	
	2019 Comparison Group	0.09	0.14	
	Risk Difference	0.04 (-0.03 to 0.12)	0.11 (-0.12 to 0.35)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.44	4.32	
	2019 Comparison Group	1.6	2.37	
	Risk Difference	1.84 (1.47 to 2.18)	1.95 (0.98 to 3.17)	
	p-value	<0.001	<0.001	1
> Hypercoagulability	SARS-CoV-2 Group	2.37	3.2	
	2019 Comparison Group	1.25	1.74	
	Risk Difference	1.12 (0.81 to 1.52)	1.46 (0.62 to 2.4)	
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.66	2.48	
	2019 Comparison Group	0.68	1.18	
	Risk Difference	0.98 (0.73 to 1.21)	1.3 (0.52 to 2.08)	
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.22	1.58	
	2019 Comparison Group	0.33	0.44	
	Risk Difference	0.88 (0.7 to 1.07)	1.14 (0.62 to 1.67)	
	p-value	<0.001	<0.001	0.03

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.39	0.61	
	2019 Comparison Group	0.27	0.41	
	Risk Difference	0.12 (-0.04 to 0.25)	0.2 (-0.22 to 0.57)	
	p-value	0.21	1	1
Stroke and Sequelae	SARS-CoV-2 Group	2.32	2.69	
	2019 Comparison Group	1.74	1.94	
	Risk Difference	0.58 (0.2 to 0.92)	0.75 (-0.07 to 1.62)	
	p-value	<0.001	0.32	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	2.07	2.57	
	2019 Comparison Group	1.52	1.9	
	Risk Difference	0.55 (0.2 to 0.85)	0.66 (-0.29 to 1.63)	
	p-value	<0.001	1	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.37	1.56	
	2019 Comparison Group	0.92	0.92	
	Risk Difference	0.44 (0.15 to 0.7)	0.64 (0.06 to 1.33)	
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	6.49	3.72	
	2019 Comparison Group	4.36	3.49	
	Risk Difference	2.13 (1.41 to 2.89)	0.24 (-1 to 1.79)	
	p-value	<0.001	1	0.001
Psychosis	SARS-CoV-2 Group	0.38	0.27	
	2019 Comparison Group	0.26	0.23	
	Risk Difference	0.12 (-0.02 to 0.28)	0.04 (-0.22 to 0.36)	
	p-value	0.32	1	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.45	6.05	
	2019 Comparison Group	3.71	3.39	
	Risk Difference	1.74 (1.22 to 2.37)	2.66 (1.28 to 3.96)	
	p-value	<0.001	<0.001	1
Migraine	SARS-CoV-2 Group	0.35	0.21	
	2019 Comparison Group	0.31	0.24	
	Risk Difference	0.03 (-0.11 to 0.16)	-0.03 (-0.32 to 0.24)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	1.01	0.82	
	2019 Comparison Group	0.98	1.07	
	Risk Difference	0.03 (-0.24 to 0.3)	-0.25 (-0.92 to 0.33)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	2.82	3.79	
	2019 Comparison Group	1.37	1.68	
	Risk Difference	1.45 (1.13 to 1.85)	2.11 (1.15 to 3.24)	
	p-value	<0.001	<0.001	0.49
Seizure	SARS-CoV-2 Group	0.52	0.74	
	2019 Comparison Group	0.4	0.65	
	Risk Difference	0.12 (-0.04 to 0.28)	0.09 (-0.38 to 0.53)	
	p-value	1	1	1
Dementia	SARS-CoV-2 Group	2.91	2.76	
	2019 Comparison Group	1.7	1.76	
	Risk Difference	1.21 (0.74 to 1.6)	1 (0 to 2.01)	
	p-value	<0.001	0.11	1
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.05	

	2019 Comparison Group	0	0.03	
	Risk Difference	0.01 (0 to 0.03)	0.02 (-0.08 to 0.14)	
	p-value	0.21	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.67	4.72	
	2019 Comparison Group	1.55	2.89	
	Risk Difference	1.12 (0.52 to 1.69)	1.83 (-0.38 to 4.05)	
	p-value	<0.001	0.53	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.7	2.08	
	2019 Comparison Group	1.34	1.6	
	Risk Difference	0.36 (0.02 to 0.63)	0.48 (-0.32 to 1.31)	
	p-value	0.11	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.38	10.02	
	2019 Comparison Group	4.92	6.43	
	Risk Difference	1.46 (0.73 to 2.29)	3.59 (1.48 to 6.03)	
	p-value	<0.001	<0.001	1
> Chronic Kidney Disease	SARS-CoV-2 Group	4.25	6.35	
	2019 Comparison Group	4.04	5.21	
	Risk Difference	0.21 (-0.35 to 0.81)	1.13 (-0.95 to 2.88)	
	p-value	1	1	1
> Acute Kidney Injury	SARS-CoV-2 Group	4.3	7.58	
	2019 Comparison Group	2.51	3.34	
	Risk Difference	1.79 (1.28 to 2.22)	4.24 (2.92 to 5.58)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	8.8	10.43	

	2019 Comparison Group	2.18	1.74	
	Risk Difference	6.62 (6.06 to 7.17)	8.69 (7.54 to 9.96)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	7.73	9.6	
	2019 Comparison Group	1.53	1.49	
	Risk Difference	6.19 (5.77 to 6.72)	8.11 (6.91 to 9.32)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.36	1.41	
	2019 Comparison Group	0.5	0.38	
	Risk Difference	0.86 (0.66 to 1.12)	1.02 (0.59 to 1.65)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.34	1.38	
	2019 Comparison Group	0.68	0.41	
	Risk Difference	0.66 (0.43 to 0.92)	0.97 (0.43 to 1.55)	
	p-value	<0.001	<0.001	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.28	0.27	
	2019 Comparison Group	0.28	0.24	
	Risk Difference	0.01 (-0.14 to 0.14)	0.03 (-0.3 to 0.38)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.2	0.21	
	2019 Comparison Group	0.19	0.2	
	Risk Difference	0.01 (-0.1 to 0.12)	0.01 (-0.22 to 0.26)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.11	0.02	

	2019 Comparison Group	0.05	0.05	
	Risk Difference	0.06 (0 to 0.12)	-0.03 (-0.15 to 0.08)	
	p-value	0.32	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.62	1.36	
	2019 Comparison Group	1.43	1.19	
	Risk Difference	0.19 (-0.17 to 0.51)	0.17 (-0.54 to 0.96)	
	p-value	1	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.89	0.86	
	2019 Comparison Group	0.59	0.64	
	Risk Difference	0.3 (0.13 to 0.51)	0.22 (-0.38 to 0.72)	
	p-value	<0.001	1	1
Leukopenia	SARS-CoV-2 Group	0.29	0.36	
	2019 Comparison Group	0.16	0.38	
	Risk Difference	0.13 (0 to 0.24)	-0.02 (-0.36 to 0.35)	
	p-value	<0.001	1	1
Anemia	SARS-CoV-2 Group	3.16	4.02	
	2019 Comparison Group	2.15	2.9	
	Risk Difference	1.01 (0.57 to 1.42)	1.12 (-0.03 to 2.37)	
	p-value	<0.001	0.11	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.12	7.89	
	2019 Comparison Group	7.14	7.78	
	Risk Difference	0.98 (0.09 to 1.98)	0.11 (-1.72 to 2.27)	
	p-value	<0.001	1	0.62
Fatigue Diagnosis	SARS-CoV-2 Group	11.11	11.5	
	2019 Comparison Group	7.19	6	

	Risk Difference	3.92 (2.9 to 4.69)	5.5 (3.45 to 8.01)	
	p-value	<0.001	<0.001	1
> Fatigue	SARS-CoV-2 Group	10.95	11.34	
	2019 Comparison Group	7.19	5.96	
	Risk Difference	3.77 (2.94 to 4.71)	5.37 (3.33 to 7.33)	
	p-value	<0.001	<0.001	1
> Chronic Fatigue	SARS-CoV-2 Group	0.39	0.32	
	2019 Comparison Group	0.37	0.28	
	Risk Difference	0.03 (-0.12 to 0.21)	0.04 (-0.33 to 0.42)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.25	0.23	
	2019 Comparison Group	0.03	0.08	
	Risk Difference	0.22 (0.13 to 0.31)	0.16 (-0.09 to 0.37)	
	p-value	<0.001	1	1
Anosmia	SARS-CoV-2 Group	0.07	0.08	
	2019 Comparison Group	0.03	0.01	
	Risk Difference	0.04 (-0.02 to 0.09)	0.06 (-0.04 to 0.2)	
	p-value	1	1	1

Subgroups are subpopulations of the SARS-CoV-2 and 2019 cohorts.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5g: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

Clinical Sequelae	Category	Female	Male	p-interaction
	Matched Group Size	49,853 vs 49,853	38,208 vs 38,208	
Hypertension				
Hypertension	SARS-CoV-2 Group	11.58	15.01	
	2019 Comparison Group	8.86	10.47	
	Risk Difference	2.72 (-0.71 to 6.25)	4.54 (-0.53 to 9.53)	
	p-value	0.85	0.11	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.98	1	
	2019 Comparison Group	0.85	0.8	
	Risk Difference	0.13 (-0.09 to 0.42)	0.2 (-0.16 to 0.48)	
	p-value	1	1	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.3	5.79	
	2019 Comparison Group	2.81	3.46	
	Risk Difference	1.49 (0.93 to 2.03)	2.32 (1.61 to 3.02)	
	p-value	<0.001	<0.001	1
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.39	3.52	
	2019 Comparison Group	1.85	2.41	
	Risk Difference	0.55 (0.15 to 0.96)	1.1 (0.55 to 1.54)	
	p-value	<0.001	<0.001	1
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.59	3.54	
	2019 Comparison Group	1.46	1.69	
	Risk Difference	1.13 (0.73 to 1.5)	1.85 (1.33 to 2.36)	
	p-value	<0.001	<0.001	0.22
> POTs				
> POTs	SARS-CoV-2 Group	1.01	1.36	

	2019 Comparison Group	0.76	0.92	
	Risk Difference	0.26 (-0.04 to 0.56)	0.44 (0.08 to 0.76)	
	p-value	0.21	<0.001	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.75	3.57	
	2019 Comparison Group	2.07	2.47	
	Risk Difference	0.67 (0.25 to 1.07)	1.1 (0.39 to 1.74)	
	p-value	<0.001	<0.001	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.46	3.16	
	2019 Comparison Group	1.87	2.25	
	Risk Difference	0.58 (0.16 to 1.04)	0.91 (0.31 to 1.58)	
	p-value	<0.001	<0.001	1
> Cardiomyopathy	SARS-CoV-2 Group	0.89	1.44	
	2019 Comparison Group	0.55	1.09	
	Risk Difference	0.34 (0.11 to 0.57)	0.34 (-0.02 to 0.74)	
	p-value	<0.001	0.11	1
> Myocarditis	SARS-CoV-2 Group	0.05	0.03	
	2019 Comparison Group	0.01	0.02	
	Risk Difference	0.04 (0 to 0.1)	0.01 (-0.03 to 0.06)	
	p-value	<0.001	1	1
Coronary Disease	SARS-CoV-2 Group	1.51	1.99	
	2019 Comparison Group	0.95	1.5	
	Risk Difference	0.56 (0.19 to 0.85)	0.49 (0.01 to 0.9)	
	p-value	<0.001	0.11	1
> Myocardial Infarction	SARS-CoV-2 Group	1.28	1.55	
	2019 Comparison Group	0.74	1.14	
	Risk Difference	0.54 (0.25 to 0.85)	0.41 (0.05 to 0.75)	

	p-value	<0.001	<0.001	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.5	1.97	
	2019 Comparison Group	0.95	1.49	
	Risk Difference	0.55 (0.26 to 0.88)	0.48 (-0.01 to 0.87)	
	p-value	<0.001	0.11	1
Cardiogenic Shock	SARS-CoV-2 Group	0.09	0.21	
	2019 Comparison Group	0.04	0.13	
	Risk Difference	0.04 (-0.02 to 0.11)	0.07 (-0.05 to 0.19)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.05	3.84	
	2019 Comparison Group	1.39	1.73	
	Risk Difference	1.66 (1.3 to 2.17)	2.11 (1.64 to 2.57)	
	p-value	<0.001	<0.001	0.12
> Hypercoagulability	SARS-CoV-2 Group	2.2	2.55	
	2019 Comparison Group	1.08	1.39	
	Risk Difference	1.12 (0.81 to 1.5)	1.16 (0.7 to 1.69)	
	p-value	<0.001	<0.001	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.58	1.73	
	2019 Comparison Group	0.64	0.78	
	Risk Difference	0.93 (0.66 to 1.26)	0.95 (0.6 to 1.26)	
	p-value	<0.001	<0.001	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.05	1.43	
	2019 Comparison Group	0.31	0.37	
	Risk Difference	0.75 (0.56 to 0.97)	1.05 (0.76 to 1.37)	
	p-value	<0.001	<0.001	0.11

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.29	0.61	
	2019 Comparison Group	0.25	0.27	
	Risk Difference	0.04 (-0.08 to 0.18)	0.34 (0.13 to 0.55)	
	p-value	1	<0.001	0.003
Stroke and Sequelae	SARS-CoV-2 Group	2.23	2.39	
	2019 Comparison Group	1.58	1.73	
	Risk Difference	0.65 (0.25 to 1.04)	0.66 (0.26 to 1.07)	
	p-value	<0.001	<0.001	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.99	2.16	
	2019 Comparison Group	1.42	1.55	
	Risk Difference	0.58 (0.2 to 0.93)	0.61 (0.14 to 1.17)	
	p-value	<0.001	<0.001	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.28	1.44	
	2019 Comparison Group	0.92	0.97	
	Risk Difference	0.35 (0.02 to 0.67)	0.47 (0.15 to 0.78)	
	p-value	<0.001	<0.001	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	6.95	4.32	
	2019 Comparison Group	5.15	3.01	
	Risk Difference	1.8 (1.02 to 2.76)	1.31 (0.7 to 2.11)	
	p-value	<0.001	<0.001	1
Psychosis	SARS-CoV-2 Group	0.36	0.34	
	2019 Comparison Group	0.27	0.19	
	Risk Difference	0.08 (-0.06 to 0.23)	0.15 (0 to 0.32)	
	p-value	1	0.32	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.61	5.19	
	2019 Comparison Group	4.04	3.06	
	Risk Difference	1.57 (0.92 to 2.27)	2.14 (1.42 to 2.9)	
	p-value	<0.001	<0.001	1
Migraine	SARS-CoV-2 Group	0.43	0.21	
	2019 Comparison Group	0.37	0.19	
	Risk Difference	0.07 (-0.1 to 0.24)	0.03 (-0.11 to 0.19)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.89	0.93	
	2019 Comparison Group	0.97	1.09	
	Risk Difference	-0.08 (-0.36 to 0.19)	-0.16 (-0.5 to 0.17)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	2.72	2.96	
	2019 Comparison Group	1.32	1.39	
	Risk Difference	1.4 (1.01 to 1.87)	1.57 (1.08 to 2.09)	
	p-value	<0.001	<0.001	1
Seizure	SARS-CoV-2 Group	0.55	0.55	
	2019 Comparison Group	0.43	0.35	
	Risk Difference	0.11 (-0.04 to 0.29)	0.2 (0.01 to 0.4)	
	p-value	1	<0.001	1
Dementia	SARS-CoV-2 Group	3.12	2.47	
	2019 Comparison Group	1.63	1.43	
	Risk Difference	1.5 (0.98 to 1.99)	1.05 (0.59 to 1.55)	
	p-value	<0.001	<0.001	0.49
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.02	

	2019 Comparison Group	0	0.01	
	Risk Difference	0.02 (0 to 0.04)	0.01 (-0.03 to 0.05)	
	p-value	<0.001	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.62	3.83	
	2019 Comparison Group	1.69	1.76	
	Risk Difference	0.94 (0.29 to 1.63)	2.07 (0.93 to 2.8)	
	p-value	<0.001	<0.001	0.04
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.71	1.91	
	2019 Comparison Group	1.27	1.41	
	Risk Difference	0.43 (0.03 to 0.84)	0.5 (0.01 to 0.96)	
	p-value	<0.001	0.11	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.05	7.6	
	2019 Comparison Group	4.6	5.26	
	Risk Difference	1.45 (0.75 to 2.2)	2.34 (1.34 to 3.2)	
	p-value	<0.001	<0.001	0.08
> Chronic Kidney Disease	SARS-CoV-2 Group	4.14	4.9	
	2019 Comparison Group	3.82	4.26	
	Risk Difference	0.32 (-0.4 to 0.93)	0.64 (-0.27 to 1.46)	
	p-value	1	1	1
> Acute Kidney Injury	SARS-CoV-2 Group	3.97	5.61	
	2019 Comparison Group	2.04	2.88	
	Risk Difference	1.93 (1.34 to 2.39)	2.74 (1.98 to 3.37)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.58	11.07	

	2019 Comparison Group	1.89	2.32	
	Risk Difference	5.69 (5.13 to 6.22)	8.75 (8.1 to 9.54)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	6.7	9.8	
	2019 Comparison Group	1.37	1.59	
	Risk Difference	5.33 (4.77 to 5.79)	8.22 (7.59 to 8.87)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.31	1.58	
	2019 Comparison Group	0.46	0.47	
	Risk Difference	0.85 (0.58 to 1.13)	1.11 (0.8 to 1.47)	
	p-value	<0.001	<0.001	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.1	1.59	
	2019 Comparison Group	0.58	0.71	
	Risk Difference	0.52 (0.26 to 0.76)	0.88 (0.54 to 1.24)	
	p-value	<0.001	<0.001	0.4
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.3	0.26	
	2019 Comparison Group	0.32	0.31	
	Risk Difference	-0.02 (-0.17 to 0.13)	-0.05 (-0.21 to 0.1)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.22	0.19	
	2019 Comparison Group	0.29	0.13	
	Risk Difference	-0.06 (-0.21 to 0.06)	0.06 (-0.05 to 0.19)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.09	0.08	

	2019 Comparison Group	0.05	0.07	
	Risk Difference	0.04 (-0.06 to 0.11)	0.02 (-0.07 to 0.1)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.14	1.99	
	2019 Comparison Group	1.19	1.78	
	Risk Difference	-0.04 (-0.39 to 0.21)	0.2 (-0.29 to 0.63)	
	p-value	1	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.66	1.28	
	2019 Comparison Group	0.47	0.78	
	Risk Difference	0.19 (0.01 to 0.38)	0.49 (0.22 to 0.82)	
	p-value	<0.001	<0.001	1
Leukopenia	SARS-CoV-2 Group	0.3	0.29	
	2019 Comparison Group	0.12	0.17	
	Risk Difference	0.19 (0.07 to 0.31)	0.12 (-0.02 to 0.27)	
	p-value	<0.001	0.42	1
Anemia	SARS-CoV-2 Group	3.42	3.29	
	2019 Comparison Group	2.24	2.17	
	Risk Difference	1.18 (0.71 to 1.64)	1.12 (0.59 to 1.81)	
	p-value	<0.001	<0.001	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.66	6.9	
	2019 Comparison Group	7.97	6.08	
	Risk Difference	0.69 (-0.3 to 1.64)	0.82 (-0.19 to 1.91)	
	p-value	1	0.42	1
Fatigue Diagnosis	SARS-CoV-2 Group	11.26	10.36	
	2019 Comparison Group	7.11	6.09	

	Risk Difference	4.16 (3.07 to 5.28)	4.27 (3.24 to 5.22)	
	p-value	<0.001	<0.001	1
> Fatigue	SARS-CoV-2 Group	11.06	10.22	
	2019 Comparison Group	7.11	6.08	
	Risk Difference	3.95 (2.95 to 5.11)	4.14 (2.94 to 5.27)	
	p-value	<0.001	<0.001	1
> Chronic Fatigue	SARS-CoV-2 Group	0.43	0.32	
	2019 Comparison Group	0.45	0.28	
	Risk Difference	-0.01 (-0.19 to 0.15)	0.04 (-0.14 to 0.2)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.28	0.21	
	2019 Comparison Group	0.02	0.01	
	Risk Difference	0.27 (0.17 to 0.37)	0.2 (0.1 to 0.28)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.06	0.06	
	2019 Comparison Group	0.02	0.03	
	Risk Difference	0.05 (0 to 0.11)	0.02 (-0.05 to 0.08)	
	p-value	0.32	1	1

Subgroups are subpopulations of the SARS-CoV-2 and 2019 cohort.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5h: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and 2019 Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

Clinical Sequelae	Category	Not hospitalized with COVID	Hospitalized with COVID	p-interaction
	Matched Group Size	64194 vs 64194	23887 vs 23887	
Hypertension				
Hypertension	SARS-CoV-2 Group	10.53	24.37	
	2019 Comparison Group	8.82	8.37	
	Risk Difference	1.71 (-1.33 to 4.59)	15.99 (6.6 to 24.92)	
	p-value	1	<0.001	<0.001
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.75	1.76	
	2019 Comparison Group	0.68	1.05	
	Risk Difference	0.07 (-0.18 to 0.28)	0.71 (0.2 to 1.15)	
	p-value	1	<0.001	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	3.47	9.4	
	2019 Comparison Group	2.8	4.18	
	Risk Difference	0.67 (0.19 to 1.09)	5.22 (4.08 to 6.37)	
	p-value	<0.001	<0.001	<0.001
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.16	4.99	
	2019 Comparison Group	1.87	2.84	
	Risk Difference	0.29 (-0.05 to 0.69)	2.15 (1.23 to 3.03)	
	p-value	0.32	<0.001	<0.001
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	1.96	6.32	
	2019 Comparison Group	1.33	2.06	
	Risk Difference	0.63 (0.25 to 0.94)	4.26 (3.4 to 5.13)	
	p-value	<0.001	<0.001	<0.001
> POTs				
> POTs	SARS-CoV-2 Group	0.85	2.07	

	2019 Comparison Group	0.72	0.94	
	Risk Difference	0.13 (-0.12 to 0.35)	1.14 (0.61 to 1.66)	
	p-value	1	<0.001	<0.001
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.26	6.18	
	2019 Comparison Group	1.91	3.06	
	Risk Difference	0.35 (-0.04 to 0.72)	3.12 (2.16 to 4.24)	
	p-value	0.21	<0.001	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	1.98	5.44	
	2019 Comparison Group	1.62	2.78	
	Risk Difference	0.36 (0.02 to 0.67)	2.66 (1.84 to 3.9)	
	p-value	<0.001	<0.001	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	0.92	1.89	
	2019 Comparison Group	0.79	1.19	
	Risk Difference	0.13 (-0.11 to 0.32)	0.7 (0.14 to 1.22)	
	p-value	1	<0.001	1
> Myocarditis	SARS-CoV-2 Group	0.02	0.11	
	2019 Comparison Group	0.01	0.01	
	Risk Difference	0.01 (-0.02 to 0.03)	0.1 (0.01 to 0.21)	
	p-value	1	<0.001	0.01
Coronary Disease	SARS-CoV-2 Group	1.19	3.28	
	2019 Comparison Group	0.95	1.52	
	Risk Difference	0.24 (0.02 to 0.45)	1.76 (1.03 to 2.36)	
	p-value	<0.001	<0.001	<0.001
> Myocardial Infarction	SARS-CoV-2 Group	0.95	2.74	
	2019 Comparison Group	0.74	1.25	
	Risk Difference	0.21 (0.01 to 0.43)	1.5 (0.95 to 2.13)	

	p-value	<0.001	<0.001	<0.001
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.18	3.23	
	2019 Comparison Group	0.95	1.51	
	Risk Difference	0.23 (-0.04 to 0.53)	1.71 (1.12 to 2.35)	
	p-value	0.11	<0.001	<0.001
Cardiogenic Shock	SARS-CoV-2 Group	0.1	0.25	
	2019 Comparison Group	0.09	0.06	
	Risk Difference	0.01 (-0.06 to 0.09)	0.19 (0.06 to 0.36)	
	p-value	1	<0.001	0.23
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.2	7.45	
	2019 Comparison Group	1.49	2.02	
	Risk Difference	0.71 (0.39 to 1.05)	5.43 (4.61 to 6.17)	
	p-value	<0.001	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	1.63	4.89	
	2019 Comparison Group	1.11	1.45	
	Risk Difference	0.52 (0.26 to 0.83)	3.44 (2.79 to 4.12)	
	p-value	<0.001	<0.001	<0.001
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.06	3.67	
	2019 Comparison Group	0.6	0.83	
	Risk Difference	0.46 (0.21 to 0.66)	2.85 (2.25 to 3.41)	
	p-value	<0.001	<0.001	<0.001
> Pulmonary Embolism	SARS-CoV-2 Group	0.63	3.05	
	2019 Comparison Group	0.32	0.51	
	Risk Difference	0.3 (0.14 to 0.48)	2.54 (2 to 2.99)	
	p-value	<0.001	<0.001	<0.001

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.31	0.76	
	2019 Comparison Group	0.24	0.34	
	Risk Difference	0.07 (-0.05 to 0.19)	0.42 (0.15 to 0.75)	
	p-value	1	<0.001	1
Stroke and Sequelae	SARS-CoV-2 Group	1.58	4.52	
	2019 Comparison Group	1.51	2.17	
	Risk Difference	0.07 (-0.22 to 0.35)	2.35 (1.42 to 3.14)	
	p-value	1	<0.001	<0.001
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.37	4.15	
	2019 Comparison Group	1.34	1.86	
	Risk Difference	0.04 (-0.25 to 0.3)	2.29 (1.52 to 3.08)	
	p-value	1	<0.001	<0.001
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.02	2.5	
	2019 Comparison Group	0.82	1.47	
	Risk Difference	0.2 (-0.04 to 0.43)	1.03 (0.57 to 1.62)	
	p-value	0.42	<0.001	<0.001
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.19	8.3	
	2019 Comparison Group	4.07	4.75	
	Risk Difference	1.12 (0.53 to 1.75)	3.55 (2.12 to 4.98)	
	p-value	<0.001	<0.001	0.02
Psychosis	SARS-CoV-2 Group	0.25	0.73	
	2019 Comparison Group	0.21	0.26	
	Risk Difference	0.04 (-0.08 to 0.15)	0.47 (0.2 to 0.8)	
	p-value	1	<0.001	<0.001

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.62	10.88	
	2019 Comparison Group	3.08	4.49	
	Risk Difference	0.55 (-0.01 to 1.12)	6.39 (5.2 to 7.75)	
	p-value	0.11	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.33	0.18	
	2019 Comparison Group	0.33	0.23	
	Risk Difference	-0.01 (-0.13 to 0.13)	-0.05 (-0.25 to 0.19)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.85	1.18	
	2019 Comparison Group	1.1	1.13	
	Risk Difference	-0.25 (-0.53 to 0)	0.05 (-0.37 to 0.55)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	1.51	7.11	
	2019 Comparison Group	1.07	2	
	Risk Difference	0.44 (0.16 to 0.7)	5.11 (4.26 to 5.91)	
	p-value	<0.001	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.38	0.96	
	2019 Comparison Group	0.35	0.48	
	Risk Difference	0.02 (-0.13 to 0.16)	0.48 (0.16 to 0.89)	
	p-value	1	<0.001	0.01
Dementia	SARS-CoV-2 Group	2.06	5.22	
	2019 Comparison Group	1.35	2.21	
	Risk Difference	0.71 (0.4 to 1.06)	3 (1.93 to 4.08)	
	p-value	<0.001	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.01	0.05	

	2019 Comparison Group	0	0	
	Risk Difference	0.01 (0 to 0.03)	0.05 (0 to 0.16)	
	p-value	<0.001	<0.001	0.28
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.24	4.97	
	2019 Comparison Group	1.6	1.64	
	Risk Difference	0.64 (0.15 to 1.19)	3.33 (2.1 to 4.59)	
	p-value	<0.001	<0.001	<0.001
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.68	2.5	
	2019 Comparison Group	1.37	1.3	
	Risk Difference	0.32 (0.01 to 0.62)	1.2 (0.61 to 1.79)	
	p-value	<0.001	<0.001	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	4.92	13.09	
	2019 Comparison Group	4.65	6.01	
	Risk Difference	0.28 (-0.4 to 0.93)	7.08 (5.31 to 8.71)	
	p-value	1	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	3.73	6.84	
	2019 Comparison Group	3.73	4.8	
	Risk Difference	0 (-0.56 to 0.52)	2.03 (0.58 to 3.4)	
	p-value	1	<0.001	0.002
> Acute Kidney Injury	SARS-CoV-2 Group	2.6	11.14	
	2019 Comparison Group	2.24	3.4	
	Risk Difference	0.36 (0.02 to 0.76)	7.75 (6.57 to 8.92)	
	p-value	<0.001	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	3.61	25.81	

	2019 Comparison Group	1.72	2.76	
	Risk Difference	1.89 (1.51 to 2.25)	23.05 (21.74 to 24.41)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	2.8	23.41	
	2019 Comparison Group	1.21	2.1	
	Risk Difference	1.59 (1.22 to 1.9)	21.31 (20.08 to 22.27)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	0.67	3.62	
	2019 Comparison Group	0.39	0.6	
	Risk Difference	0.28 (0.12 to 0.46)	3.02 (2.55 to 3.61)	
	p-value	<0.001	<0.001	<0.001
> Interstitial Lung Disease	SARS-CoV-2 Group	0.85	2.96	
	2019 Comparison Group	0.54	0.79	
	Risk Difference	0.3 (0.13 to 0.51)	2.16 (1.57 to 2.73)	
	p-value	<0.001	<0.001	<0.001
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.24	0.28	
	2019 Comparison Group	0.3	0.29	
	Risk Difference	-0.06 (-0.2 to 0.07)	-0.02 (-0.24 to 0.27)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.16	0.29	
	2019 Comparison Group	0.24	0.17	
	Risk Difference	-0.08 (-0.17 to 0.03)	0.11 (-0.07 to 0.33)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.09	0.11	

	2019 Comparison Group	0.05	0.05	
	Risk Difference	0.04 (-0.02 to 0.1)	0.06 (-0.07 to 0.18)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.33	2.37	
	2019 Comparison Group	1.31	1.54	
	Risk Difference	0.02 (-0.27 to 0.3)	0.82 (0.19 to 1.41)	
	p-value	1	<0.001	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.63	1.58	
	2019 Comparison Group	0.56	0.83	
	Risk Difference	0.07 (-0.13 to 0.28)	0.75 (0.31 to 1.13)	
	p-value	1	<0.001	<0.001
Leukopenia	SARS-CoV-2 Group	0.21	0.45	
	2019 Comparison Group	0.13	0.14	
	Risk Difference	0.09 (-0.03 to 0.18)	0.31 (0.12 to 0.55)	
	p-value	0.21	<0.001	0.28
Anemia	SARS-CoV-2 Group	2.67	5.66	
	2019 Comparison Group	1.98	2.75	
	Risk Difference	0.69 (0.3 to 1.04)	2.91 (1.71 to 3.9)	
	p-value	<0.001	<0.001	0.001
Symptom				
Myalgia	SARS-CoV-2 Group	7.4	10.98	
	2019 Comparison Group	6.89	7.17	
	Risk Difference	0.51 (-0.26 to 1.35)	3.82 (2.15 to 5.62)	
	p-value	1	<0.001	1
Fatigue Diagnosis	SARS-CoV-2 Group	8	20.89	
	2019 Comparison Group	5.99	7.42	

	Risk Difference	2.01 (1.29 to 2.76)	13.47 (11.93 to 15.37)	
	p-value	<0.001	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	7.9	20.57	
	2019 Comparison Group	5.99	7.41	
	Risk Difference	1.92 (1.14 to 2.61)	13.17 (11.31 to 15.21)	
	p-value	<0.001	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	0.33	0.51	
	2019 Comparison Group	0.3	0.36	
	Risk Difference	0.02 (-0.15 to 0.16)	0.15 (-0.15 to 0.43)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.18	0.4	
	2019 Comparison Group	0.03	0.03	
	Risk Difference	0.15 (0.08 to 0.24)	0.37 (0.21 to 0.55)	
	p-value	<0.001	<0.001	0.01
Anosmia	SARS-CoV-2 Group	0.07	0.08	
	2019 Comparison Group	0.01	0.02	
	Risk Difference	0.06 (0.01 to 0.12)	0.06 (-0.04 to 0.17)	
	p-value	<0.001	1	1

Subgroups are subpopulations of the SARS-CoV-2 and 2019 cohorts.

Hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals hospitalized due to COVID and individuals within the 2019 comparison group. Meanwhile, Not hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals not hospitalized due to COVID and individuals within the 2019 comparison group.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5i: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Age

Clinical Sequelae	Category	65–74	>74	p-interaction
	Matched Group Size	31,793 vs 31,793	40,937 vs 40,937	
Hypertension				
Hypertension	SARS-CoV-2 Group	11.96	15.28	
	Viral LRTI Comparison Group	11.1	19.22	
	Risk Difference	0.86 (-3.06 to 5.01)	-3.94 (-11.95 to 2.38)	
	p-value	1	1	0.35
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.73	1.2	
	Viral LRTI Comparison Group	1.02	1.81	
	Risk Difference	-0.3 (-0.59 to 0.04)	-0.62 (-1 to -0.26)	
	p-value	1	1	1
Cardiology				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	3.88	5.78	
	Viral LRTI Comparison Group	4.18	6.38	
	Risk Difference	-0.29 (-0.93 to 0.36)	-0.6 (-1.57 to 0.07)	
	p-value	1	1	0.59
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.18	3.52	
	Viral LRTI Comparison Group	2.38	4.09	
	Risk Difference	-0.2 (-0.71 to 0.27)	-0.57 (-1.3 to 0.08)	
	p-value	1	1	0.07
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.54	3.27	
	Viral LRTI Comparison Group	2.77	3.29	
	Risk Difference	-0.24 (-0.78 to 0.29)	-0.02 (-0.54 to 0.49)	
	p-value	1	1	1
> POTs				
> POTs	SARS-CoV-2 Group	0.93	1.3	

	Viral LRTI Comparison Group	0.86	1.51	
	Risk Difference	0.07 (-0.21 to 0.37)	-0.22 (-0.56 to 0.12)	
	p-value	1	1	0.19
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.23	3.97	
	Viral LRTI Comparison Group	3.93	7.85	
	Risk Difference	-1.7 (-2.26 to -1.08)	-3.87 (-4.5 to -3.11)	
	p-value	1	1	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	1.87	3.62	
	Viral LRTI Comparison Group	3.29	7.14	
	Risk Difference	-1.42 (-1.88 to -0.9)	-3.52 (-4.2 to -2.82)	
	p-value	1	1	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	0.88	1.21	
	Viral LRTI Comparison Group	1.71	2.01	
	Risk Difference	-0.82 (-1.17 to -0.47)	-0.8 (-1.17 to -0.47)	
	p-value	1	1	1
> Myocarditis	SARS-CoV-2 Group	0.04	0.03	
	Viral LRTI Comparison Group	0.01	0.02	
	Risk Difference	0.03 (-0.02 to 0.1)	0.02 (-0.03 to 0.06)	
	p-value	1	1	1
Coronary Disease	SARS-CoV-2 Group	1.36	1.88	
	Viral LRTI Comparison Group	1.78	2.58	
	Risk Difference	-0.43 (-0.84 to 0.03)	-0.7 (-1.12 to -0.25)	
	p-value	1	1	0.43
> Myocardial Infarction	SARS-CoV-2 Group	1.06	1.56	
	Viral LRTI Comparison Group	1.41	2.21	
	Risk Difference	-0.34 (-0.7 to 0.01)	-0.65 (-1.1 to -0.26)	

	p-value	1	1	0.85
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.34	1.87	
	Viral LRTI Comparison Group	1.78	2.58	
	Risk Difference	-0.44 (-0.81 to -0.05)	-0.7 (-1.1 to -0.3)	
	p-value	1	1	0.49
Cardiogenic Shock	SARS-CoV-2 Group	0.14	0.11	
	Viral LRTI Comparison Group	0.22	0.3	
	Risk Difference	-0.09 (-0.21 to 0.04)	-0.19 (-0.33 to -0.08)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.8	3.91	
	Viral LRTI Comparison Group	2.52	3.81	
	Risk Difference	0.28 (-0.19 to 0.85)	0.11 (-0.47 to 0.62)	
	p-value	1	1	1
> Hypercoagulability	SARS-CoV-2 Group	1.96	2.75	
	Viral LRTI Comparison Group	1.76	2.77	
	Risk Difference	0.2 (-0.22 to 0.68)	-0.02 (-0.51 to 0.49)	
	p-value	1	1	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.41	1.85	
	Viral LRTI Comparison Group	1.27	1.87	
	Risk Difference	0.14 (-0.22 to 0.47)	-0.03 (-0.4 to 0.31)	
	p-value	1	1	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.01	1.38	
	Viral LRTI Comparison Group	0.91	1.22	
	Risk Difference	0.1 (-0.18 to 0.45)	0.16 (-0.15 to 0.49)	
	p-value	1	1	1

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.39	0.45	
	Viral LRTI Comparison Group	0.4	0.51	
	Risk Difference	-0.01 (-0.24 to 0.21)	-0.06 (-0.25 to 0.17)	
	p-value	1	1	1
Stroke and Sequelae	SARS-CoV-2 Group	1.68	2.96	
	Viral LRTI Comparison Group	1.92	3.69	
	Risk Difference	-0.24 (-0.63 to 0.17)	-0.74 (-1.23 to -0.1)	
	p-value	1	1	0.08
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.52	2.61	
	Viral LRTI Comparison Group	1.74	3.3	
	Risk Difference	-0.22 (-0.58 to 0.19)	-0.69 (-1.18 to -0.23)	
	p-value	1	1	0.11
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.03	1.83	
	Viral LRTI Comparison Group	1.12	2.29	
	Risk Difference	-0.08 (-0.43 to 0.26)	-0.46 (-0.83 to 0.12)	
	p-value	1	1	0.39
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.33	6.41	
	Viral LRTI Comparison Group	5.3	6.14	
	Risk Difference	0.03 (-0.98 to 0.95)	0.27 (-0.62 to 1.2)	
	p-value	1	1	1
Psychosis	SARS-CoV-2 Group	0.27	0.41	
	Viral LRTI Comparison Group	0.18	0.4	
	Risk Difference	0.09 (-0.05 to 0.24)	0.01 (-0.16 to 0.24)	
	p-value	1	1	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.15	7.83	
	Viral LRTI Comparison Group	2.93	7.81	
	Risk Difference	0.22 (-0.32 to 0.76)	0.02 (-0.84 to 0.97)	
	p-value	1	1	1
Migraine	SARS-CoV-2 Group	0.4	0.23	
	Viral LRTI Comparison Group	0.48	0.28	
	Risk Difference	-0.08 (-0.31 to 0.12)	-0.05 (-0.2 to 0.09)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.91	0.96	
	Viral LRTI Comparison Group	0.99	1.32	
	Risk Difference	-0.08 (-0.39 to 0.23)	-0.36 (-0.67 to -0.03)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	1.82	3.75	
	Viral LRTI Comparison Group	1.5	3.52	
	Risk Difference	0.33 (0 to 0.77)	0.23 (-0.41 to 0.72)	
	p-value	0.21	1	1
Seizure	SARS-CoV-2 Group	0.42	0.62	
	Viral LRTI Comparison Group	0.43	0.69	
	Risk Difference	0 (-0.22 to 0.22)	-0.07 (-0.31 to 0.16)	
	p-value	1	1	1
Dementia	SARS-CoV-2 Group	0.97	5.07	
	Viral LRTI Comparison Group	0.78	4.04	
	Risk Difference	0.19 (-0.11 to 0.56)	1.03 (0.22 to 1.72)	
	p-value	1	<0.001	0.004
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.03	0.02	

	Viral LRTI Comparison Group	0.02	0.03	
	Risk Difference	0.01 (-0.03 to 0.07)	-0.01 (-0.05 to 0.03)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	3	3.06	
	Viral LRTI Comparison Group	2.36	2.8	
	Risk Difference	0.65 (-0.1 to 1.47)	0.26 (-0.47 to 0.98)	
	p-value	0.53	1	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	2.1	1.42	
	Viral LRTI Comparison Group	2.19	1.97	
	Risk Difference	-0.1 (-0.66 to 0.37)	-0.55 (-0.94 to -0.15)	
	p-value	1	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	4.85	9.02	
	Viral LRTI Comparison Group	4.9	9.01	
	Risk Difference	-0.05 (-0.97 to 0.79)	0.01 (-1.06 to 1.25)	
	p-value	1	1	1
> Chronic Kidney Disease	SARS-CoV-2 Group	3.09	6.07	
	Viral LRTI Comparison Group	3.64	6.29	
	Risk Difference	-0.55 (-1.13 to 0.16)	-0.22 (-1.17 to 0.83)	
	p-value	1	1	1
> Acute Kidney Injury	SARS-CoV-2 Group	3.3	5.8	
	Viral LRTI Comparison Group	3.55	6.44	
	Risk Difference	-0.25 (-0.87 to 0.38)	-0.65 (-1.54 to 0.04)	
	p-value	1	1	1
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.6	10.26	

	Viral LRTI Comparison Group	4.96	7.97	
	Risk Difference	2.64 (1.88 to 3.49)	2.28 (1.37 to 3.06)	
	p-value	<0.001	<0.001	0.02
> Acute Respiratory Failure	SARS-CoV-2 Group	6.84	9	
	Viral LRTI Comparison Group	3.57	5.75	
	Risk Difference	3.27 (2.56 to 3.85)	3.25 (2.55 to 3.86)	
	p-value	<0.001	<0.001	0.17
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.29	1.51	
	Viral LRTI Comparison Group	1.5	2.18	
	Risk Difference	-0.2 (-0.61 to 0.19)	-0.67 (-1.08 to -0.26)	
	p-value	1	1	0.59
> Interstitial Lung Disease	SARS-CoV-2 Group	1.14	1.48	
	Viral LRTI Comparison Group	1.37	2.05	
	Risk Difference	-0.23 (-0.6 to 0.15)	-0.57 (-0.91 to -0.18)	
	p-value	1	1	0.005
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.25	0.27	
	Viral LRTI Comparison Group	0.32	0.34	
	Risk Difference	-0.07 (-0.27 to 0.1)	-0.07 (-0.25 to 0.11)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.24	0.15	
	Viral LRTI Comparison Group	0.3	0.21	
	Risk Difference	-0.05 (-0.23 to 0.11)	-0.06 (-0.18 to 0.08)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.07	0.09	

	Viral LRTI Comparison Group	0.07	0.06	
	Risk Difference	0 (-0.09 to 0.1)	0.04 (-0.04 to 0.12)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.78	1.06	
	Viral LRTI Comparison Group	2.48	1.72	
	Risk Difference	-0.7 (-1.25 to -0.13)	-0.67 (-1 to -0.33)	
	p-value	1	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.8	1.01	
	Viral LRTI Comparison Group	1.02	1.07	
	Risk Difference	-0.22 (-0.54 to 0.12)	-0.06 (-0.35 to 0.22)	
	p-value	1	1	1
Leukopenia	SARS-CoV-2 Group	0.23	0.3	
	Viral LRTI Comparison Group	0.28	0.2	
	Risk Difference	-0.05 (-0.21 to 0.12)	0.1 (-0.05 to 0.25)	
	p-value	1	1	1
Anemia	SARS-CoV-2 Group	2.54	3.91	
	Viral LRTI Comparison Group	2.78	4.07	
	Risk Difference	-0.24 (-0.78 to 0.34)	-0.16 (-0.76 to 0.52)	
	p-value	1	1	1
Symptom				
Myalgia	SARS-CoV-2 Group	7.15	9.07	
	Viral LRTI Comparison Group	8.22	9.46	
	Risk Difference	-1.07 (-2.12 to 0)	-0.39 (-1.47 to 0.66)	
	p-value	1	1	1
Fatigue Diagnosis	SARS-CoV-2 Group	8.46	13.44	
	Viral LRTI Comparison Group	7.67	13.72	

	Risk Difference	0.79 (-0.18 to 1.85)	-0.28 (-1.98 to 1.1)	
	p-value	0.74	1	0.15
> Fatigue	SARS-CoV-2 Group	8.3	13.25	
	Viral LRTI Comparison Group	7.65	13.72	
	Risk Difference	0.65 (-0.67 to 1.73)	-0.48 (-1.86 to 1.12)	
	p-value	1	1	0.13
> Chronic Fatigue	SARS-CoV-2 Group	0.41	0.37	
	Viral LRTI Comparison Group	0.42	0.44	
	Risk Difference	-0.01 (-0.28 to 0.22)	-0.07 (-0.26 to 0.13)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.22	0.26	
	Viral LRTI Comparison Group	0.02	0.08	
	Risk Difference	0.21 (0.12 to 0.33)	0.18 (0.07 to 0.29)	
	p-value	<0.001	<0.001	1
Anosmia	SARS-CoV-2 Group	0.08	0.04	
	Viral LRTI Comparison Group	0.02	0.02	
	Risk Difference	0.06 (-0.02 to 0.13)	0.02 (-0.03 to 0.08)	
	p-value	0.21	1	1

Subgroups are subpopulations of the SARS-CoV-2 and viral LRTI cohorts.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5j: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Race

Clinical Sequelae	Category	White	Black	p-interaction
	Matched Group Size	56,338 vs 56,338	6,475 vs 6,475	
Hypertension				
Hypertension	SARS-CoV-2 Group	12.1	19.67	
	Viral LRTI Comparison Group	12.5	19.83	
	Risk Difference	-0.4 (-4.25 to 3.18)	-0.17 (-22.97 to 23.26)	
	p-value	1	1	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.96	1.17	
	Viral LRTI Comparison Group	1.54	1.99	
	Risk Difference	-0.57 (-0.83 to -0.24)	-0.82 (-1.67 to 0)	
	p-value	1	1	0.28
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.95	6.07	
	Viral LRTI Comparison Group	5.13	6.16	
	Risk Difference	-0.18 (-0.86 to 0.39)	-0.09 (-1.84 to 1.79)	
	p-value	1	1	1
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.85	3.78	
	Viral LRTI Comparison Group	3.36	3.37	
	Risk Difference	-0.51 (-0.91 to -0.08)	0.41 (-0.92 to 1.62)	
	p-value	1	1	1
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	2.99	3.76	
	Viral LRTI Comparison Group	2.71	4.03	
	Risk Difference	0.28 (-0.17 to 0.71)	-0.27 (-1.53 to 1.16)	
	p-value	1	1	1
> POTs				
> POTs	SARS-CoV-2 Group	1.12	1.71	

	Viral LRTI Comparison Group	1.4	1.62	
	Risk Difference	-0.27 (-0.63 to -0.02)	0.09 (-0.82 to 0.92)	
	p-value	1	1	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	3.15	3.79	
	Viral LRTI Comparison Group	6.04	6.48	
	Risk Difference	-2.89 (-3.57 to -2.29)	-2.69 (-4.37 to -1.08)	
	p-value	1	1	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.76	3.47	
	Viral LRTI Comparison Group	5.44	6.01	
	Risk Difference	-2.67 (-3.17 to -2.08)	-2.54 (-4.1 to -0.93)	
	p-value	1	1	1
> Cardiomyopathy	SARS-CoV-2 Group	1.13	1.28	
	Viral LRTI Comparison Group	1.74	2.33	
	Risk Difference	-0.6 (-0.95 to -0.29)	-1.05 (-1.9 to -0.12)	
	p-value	1	1	0.34
> Myocarditis	SARS-CoV-2 Group	0.04	0.08	
	Viral LRTI Comparison Group	0.01	0.02	
	Risk Difference	0.03 (-0.01 to 0.08)	0.06 (-0.07 to 0.22)	
	p-value	0.74	1	1
Coronary Disease	SARS-CoV-2 Group	1.7	1.84	
	Viral LRTI Comparison Group	2.14	2.57	
	Risk Difference	-0.44 (-0.81 to -0.12)	-0.73 (-1.91 to 0.42)	
	p-value	1	1	1
> Myocardial Infarction	SARS-CoV-2 Group	1.41	1.47	
	Viral LRTI Comparison Group	1.77	2.19	
	Risk Difference	-0.37 (-0.67 to -0.05)	-0.72 (-1.85 to 0.24)	

	p-value	1	1	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.69	1.84	
	Viral LRTI Comparison Group	2.14	2.53	
	Risk Difference	-0.45 (-0.8 to -0.07)	-0.69 (-1.74 to 0.24)	
	p-value	1	1	1
Cardiogenic Shock	SARS-CoV-2 Group	0.14	0.27	
	Viral LRTI Comparison Group	0.2	0.56	
	Risk Difference	-0.06 (-0.19 to 0.04)	-0.29 (-0.74 to 0.14)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	3.35	4.66	
	Viral LRTI Comparison Group	3.2	4.71	
	Risk Difference	0.15 (-0.36 to 0.54)	-0.05 (-1.91 to 1.21)	
	p-value	1	1	1
> Hypercoagulability	SARS-CoV-2 Group	2.28	3.36	
	Viral LRTI Comparison Group	2.26	3.39	
	Risk Difference	0.02 (-0.42 to 0.35)	-0.03 (-1.21 to 1.12)	
	p-value	1	1	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.61	2.6	
	Viral LRTI Comparison Group	1.47	2.48	
	Risk Difference	0.14 (-0.18 to 0.45)	0.12 (-0.87 to 1.1)	
	p-value	1	1	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.22	1.51	
	Viral LRTI Comparison Group	1.11	1.7	
	Risk Difference	0.1 (-0.15 to 0.36)	-0.19 (-1.09 to 0.59)	
	p-value	1	1	1

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.41	0.69	
	Viral LRTI Comparison Group	0.45	0.89	
	Risk Difference	-0.04 (-0.21 to 0.11)	-0.2 (-0.79 to 0.43)	
	p-value	1	1	1
Stroke and Sequelae	SARS-CoV-2 Group	2.31	2.66	
	Viral LRTI Comparison Group	2.62	3.51	
	Risk Difference	-0.31 (-0.77 to 0.11)	-0.85 (-2.24 to 0.34)	
	p-value	1	1	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	2.07	2.64	
	Viral LRTI Comparison Group	2.35	3.28	
	Risk Difference	-0.28 (-0.71 to 0.1)	-0.64 (-1.82 to 0.49)	
	p-value	1	1	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.3	1.77	
	Viral LRTI Comparison Group	1.54	2.15	
	Risk Difference	-0.23 (-0.55 to 0.07)	-0.38 (-1.34 to 0.48)	
	p-value	1	1	1
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	6.34	3.87	
	Viral LRTI Comparison Group	6.35	4.51	
	Risk Difference	0 (-0.8 to 0.78)	-0.64 (-2.3 to 0.71)	
	p-value	1	1	1
Psychosis	SARS-CoV-2 Group	0.37	0.31	
	Viral LRTI Comparison Group	0.34	0.31	
	Risk Difference	0.03 (-0.11 to 0.18)	0 (-0.38 to 0.4)	
	p-value	1	1	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.78	6.52	
	Viral LRTI Comparison Group	5.64	6.46	
	Risk Difference	0.14 (-0.45 to 0.77)	0.06 (-1.76 to 2.03)	
	p-value	1	1	1
Migraine	SARS-CoV-2 Group	0.32	0.18	
	Viral LRTI Comparison Group	0.4	0.23	
	Risk Difference	-0.08 (-0.28 to 0.07)	-0.05 (-0.41 to 0.26)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.99	0.71	
	Viral LRTI Comparison Group	1.15	1.08	
	Risk Difference	-0.16 (-0.44 to 0.1)	-0.37 (-1.38 to 0.27)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	2.7	4.27	
	Viral LRTI Comparison Group	2.68	3.81	
	Risk Difference	0.03 (-0.46 to 0.43)	0.45 (-0.99 to 1.96)	
	p-value	1	1	1
Seizure	SARS-CoV-2 Group	0.52	0.59	
	Viral LRTI Comparison Group	0.6	1.11	
	Risk Difference	-0.08 (-0.26 to 0.12)	-0.52 (-1.18 to 0.11)	
	p-value	1	1	1
Dementia	SARS-CoV-2 Group	3.09	3.6	
	Viral LRTI Comparison Group	2.38	3.08	
	Risk Difference	0.71 (0.25 to 1.13)	0.51 (-0.91 to 1.83)	
	p-value	<0.001	1	1
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0	

	Viral LRTI Comparison Group	0.01	0	
	Risk Difference	0.01 (-0.01 to 0.05)	0 (0 to 0)	
	p-value	1	<0.001	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.58	5.01	
	Viral LRTI Comparison Group	2.32	4.8	
	Risk Difference	0.25 (-0.29 to 0.78)	0.21 (-2.2 to 3.17)	
	p-value	1	1	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.69	1.76	
	Viral LRTI Comparison Group	1.81	2.1	
	Risk Difference	-0.12 (-0.5 to 0.17)	-0.34 (-1.3 to 0.53)	
	p-value	1	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.63	9.91	
	Viral LRTI Comparison Group	7.03	9.72	
	Risk Difference	-0.4 (-1.16 to 0.39)	0.19 (-2.5 to 2.39)	
	p-value	1	1	1
> Chronic Kidney Disease	SARS-CoV-2 Group	4.44	5.79	
	Viral LRTI Comparison Group	5.17	6.81	
	Risk Difference	-0.73 (-1.34 to -0.05)	-1.01 (-3.15 to 1.09)	
	p-value	1	1	1
> Acute Kidney Injury	SARS-CoV-2 Group	4.34	7.98	
	Viral LRTI Comparison Group	4.84	7.25	
	Risk Difference	-0.5 (-1.06 to 0.01)	0.73 (-1.44 to 2.5)	
	p-value	1	1	0.76
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	8.82	10.95	

	Viral LRTI Comparison Group	6.93	6.44	
	Risk Difference	1.89 (1.17 to 2.52)	4.51 (2.67 to 6.26)	
	p-value	<0.001	<0.001	0.01
> Acute Respiratory Failure	SARS-CoV-2 Group	7.74	10.52	
	Viral LRTI Comparison Group	4.95	5.46	
	Risk Difference	2.79 (2.16 to 3.43)	5.06 (3.59 to 6.5)	
	p-value	<0.001	<0.001	0.007
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.41	1.64	
	Viral LRTI Comparison Group	1.91	1.48	
	Risk Difference	-0.5 (-0.83 to -0.18)	0.16 (-0.88 to 0.94)	
	p-value	1	1	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.34	1.1	
	Viral LRTI Comparison Group	1.9	1.24	
	Risk Difference	-0.56 (-0.85 to -0.25)	-0.14 (-0.85 to 0.76)	
	p-value	1	1	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.25	0.17	
	Viral LRTI Comparison Group	0.27	0.19	
	Risk Difference	-0.02 (-0.16 to 0.1)	-0.02 (-0.34 to 0.28)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.19	0.15	
	Viral LRTI Comparison Group	0.23	0.11	
	Risk Difference	-0.04 (-0.14 to 0.1)	0.05 (-0.2 to 0.33)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.1	0	

	Viral LRTI Comparison Group	0.07	0	
	Risk Difference	0.03 (-0.05 to 0.12)	0 (0 to 0)	
	p-value	1	<0.001	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.55	1.13	
	Viral LRTI Comparison Group	2.15	2.24	
	Risk Difference	-0.6 (-1.01 to -0.19)	-1.12 (-2.04 to -0.18)	
	p-value	1	1	0.03
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.91	0.9	
	Viral LRTI Comparison Group	0.99	1.39	
	Risk Difference	-0.09 (-0.32 to 0.18)	-0.49 (-1.2 to 0.3)	
	p-value	1	1	1
Leukopenia	SARS-CoV-2 Group	0.3	0.29	
	Viral LRTI Comparison Group	0.26	0.3	
	Risk Difference	0.04 (-0.11 to 0.17)	0 (-0.37 to 0.36)	
	p-value	1	1	1
Anemia	SARS-CoV-2 Group	3.25	4.2	
	Viral LRTI Comparison Group	3.62	5.01	
	Risk Difference	-0.37 (-0.94 to 0.13)	-0.8 (-2.19 to 0.78)	
	p-value	1	1	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.05	8.03	
	Viral LRTI Comparison Group	9.23	10.2	
	Risk Difference	-1.19 (-2.18 to -0.25)	-2.16 (-4.86 to 0.78)	
	p-value	1	1	0.04
Fatigue Diagnosis	SARS-CoV-2 Group	11.16	11.49	
	Viral LRTI Comparison Group	11.19	11.22	

	Risk Difference	-0.03 (-1.2 to 0.97)	0.27 (-2.06 to 2.91)	
	p-value	1	1	1
> Fatigue	SARS-CoV-2 Group	11.01	11.25	
	Viral LRTI Comparison Group	11.17	11.18	
	Risk Difference	-0.16 (-1.32 to 0.75)	0.06 (-2.73 to 2.71)	
	p-value	1	1	1
> Chronic Fatigue	SARS-CoV-2 Group	0.39	0.37	
	Viral LRTI Comparison Group	0.42	0.38	
	Risk Difference	-0.03 (-0.24 to 0.15)	-0.01 (-0.47 to 0.39)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.25	0.29	
	Viral LRTI Comparison Group	0.03	0.12	
	Risk Difference	0.22 (0.13 to 0.31)	0.17 (-0.1 to 0.53)	
	p-value	<0.001	1	1
Anosmia	SARS-CoV-2 Group	0.07	0.07	
	Viral LRTI Comparison Group	0.01	0.11	
	Risk Difference	0.06 (0.01 to 0.11)	-0.04 (-0.27 to 0.16)	
	p-value	<0.001	1	1

Subgroups are subpopulations of the SARS-CoV-2 and viral LRTI cohorts.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5k: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by Gender

Clinical Sequelae	Category	Female	Male	p-interaction
	Matched Group Size	41,363 vs 41,363	31,941 vs 31,941	
Hypertension				
Hypertension	SARS-CoV-2 Group	10.71	16.76	
	Viral LRTI Comparison Group	13.71	16.89	
	Risk Difference	-3 (-8.73 to 1.75)	-0.13 (-5.69 to 5.12)	
	p-value	1	1	1
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.96	1.01	
	Viral LRTI Comparison Group	1.5	1.4	
	Risk Difference	-0.54 (-0.82 to -0.22)	-0.39 (-0.72 to -0.02)	
	p-value	1	1	1
Cardiology				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	4.11	5.64	
	Viral LRTI Comparison Group	4.76	6.07	
	Risk Difference	-0.64 (-1.23 to 0.17)	-0.42 (-1.48 to 0.44)	
	p-value	1	1	1
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.38	3.33	
	Viral LRTI Comparison Group	2.79	3.79	
	Risk Difference	-0.41 (-0.88 to 0.08)	-0.46 (-1.23 to 0.15)	
	p-value	1	1	1
> Tachycardia	SARS-CoV-2 Group	2.42	3.44	
	Viral LRTI Comparison Group	2.74	3.23	
	Risk Difference	-0.32 (-0.82 to 0.18)	0.21 (-0.41 to 0.87)	
	p-value	1	1	1
> POTs	SARS-CoV-2 Group	1	1.31	

	Viral LRTI Comparison Group	1.13	1.42	
	Risk Difference	-0.13 (-0.43 to 0.2)	-0.11 (-0.45 to 0.25)	
	p-value	1	1	1
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.81	3.59	
	Viral LRTI Comparison Group	5.29	6.27	
	Risk Difference	-2.48 (-3.05 to -1.91)	-2.69 (-3.37 to -1.97)	
	p-value	1	1	1
> Congestive Heart Failure	SARS-CoV-2 Group	2.57	3.22	
	Viral LRTI Comparison Group	4.82	5.66	
	Risk Difference	-2.24 (-2.83 to -1.6)	-2.44 (-3.23 to -1.63)	
	p-value	1	1	1
> Cardiomyopathy	SARS-CoV-2 Group	0.81	1.49	
	Viral LRTI Comparison Group	1.31	2.35	
	Risk Difference	-0.51 (-0.77 to -0.16)	-0.86 (-1.29 to -0.38)	
	p-value	1	1	0.1
> Myocarditis	SARS-CoV-2 Group	0.03	0.02	
	Viral LRTI Comparison Group	0.03	0.02	
	Risk Difference	0 (-0.04 to 0.06)	0 (-0.04 to 0.04)	
	p-value	1	1	1
Coronary Disease	SARS-CoV-2 Group	1.43	1.93	
	Viral LRTI Comparison Group	1.78	2.55	
	Risk Difference	-0.35 (-0.73 to 0.06)	-0.62 (-1.11 to -0.21)	
	p-value	1	1	1
> Myocardial Infarction	SARS-CoV-2 Group	1.21	1.53	
	Viral LRTI Comparison Group	1.47	2.09	
	Risk Difference	-0.26 (-0.65 to 0)	-0.56 (-1.01 to -0.1)	

	p-value	1	1	1
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.42	1.92	
	Viral LRTI Comparison Group	1.78	2.54	
	Risk Difference	-0.36 (-0.71 to -0.03)	-0.61 (-1.14 to -0.16)	
	p-value	1	1	1
Cardiogenic Shock	SARS-CoV-2 Group	0.1	0.19	
	Viral LRTI Comparison Group	0.15	0.34	
	Risk Difference	-0.05 (-0.15 to 0.05)	-0.15 (-0.31 to 0.04)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.99	3.83	
	Viral LRTI Comparison Group	3.04	3.83	
	Risk Difference	-0.05 (-0.55 to 0.48)	0 (-0.61 to 0.64)	
	p-value	1	1	1
> Hypercoagulability	SARS-CoV-2 Group	2.18	2.54	
	Viral LRTI Comparison Group	2.11	2.69	
	Risk Difference	0.06 (-0.3 to 0.48)	-0.16 (-0.72 to 0.35)	
	p-value	1	1	1
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.6	1.75	
	Viral LRTI Comparison Group	1.46	1.8	
	Risk Difference	0.14 (-0.23 to 0.5)	-0.05 (-0.47 to 0.39)	
	p-value	1	1	1
> Pulmonary Embolism	SARS-CoV-2 Group	1.04	1.35	
	Viral LRTI Comparison Group	1.05	1.21	
	Risk Difference	-0.02 (-0.25 to 0.24)	0.15 (-0.15 to 0.57)	
	p-value	1	1	1

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.31	0.6	
	Viral LRTI Comparison Group	0.41	0.66	
	Risk Difference	-0.1 (-0.28 to 0.09)	-0.06 (-0.33 to 0.19)	
	p-value	1	1	1
Stroke and Sequelae	SARS-CoV-2 Group	2.21	2.39	
	Viral LRTI Comparison Group	2.46	3.07	
	Risk Difference	-0.25 (-0.67 to 0.27)	-0.68 (-1.38 to -0.08)	
	p-value	1	1	1
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.95	2.12	
	Viral LRTI Comparison Group	2.19	2.68	
	Risk Difference	-0.24 (-0.61 to 0.14)	-0.56 (-1.12 to -0.02)	
	p-value	1	1	1
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	1.34	1.46	
	Viral LRTI Comparison Group	1.41	2.1	
	Risk Difference	-0.06 (-0.37 to 0.28)	-0.64 (-1.07 to -0.15)	
	p-value	1	1	0.2
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	7.02	4.32	
	Viral LRTI Comparison Group	6.47	4.3	
	Risk Difference	0.54 (-0.38 to 1.47)	0.02 (-0.79 to 0.81)	
	p-value	1	1	1
Psychosis	SARS-CoV-2 Group	0.37	0.35	
	Viral LRTI Comparison Group	0.33	0.34	
	Risk Difference	0.04 (-0.13 to 0.2)	0.01 (-0.15 to 0.23)	
	p-value	1	1	1

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	5.73	5.3	
	Viral LRTI Comparison Group	5.46	5.66	
	Risk Difference	0.27 (-0.56 to 1.04)	-0.36 (-1.26 to 0.6)	
	p-value	1	1	1
Migraine	SARS-CoV-2 Group	0.36	0.19	
	Viral LRTI Comparison Group	0.45	0.21	
	Risk Difference	-0.08 (-0.27 to 0.09)	-0.02 (-0.19 to 0.15)	
	p-value	1	1	1
Peripheral Neuropathy	SARS-CoV-2 Group	0.93	1.01	
	Viral LRTI Comparison Group	1.08	1.12	
	Risk Difference	-0.15 (-0.41 to 0.15)	-0.1 (-0.43 to 0.24)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	2.64	2.9	
	Viral LRTI Comparison Group	2.41	2.99	
	Risk Difference	0.23 (-0.25 to 0.7)	-0.09 (-0.72 to 0.38)	
	p-value	1	1	1
Seizure	SARS-CoV-2 Group	0.54	0.55	
	Viral LRTI Comparison Group	0.58	0.59	
	Risk Difference	-0.04 (-0.24 to 0.15)	-0.04 (-0.3 to 0.2)	
	p-value	1	1	1
Dementia	SARS-CoV-2 Group	3.26	2.68	
	Viral LRTI Comparison Group	2.24	2.39	
	Risk Difference	1.02 (0.39 to 1.56)	0.29 (-0.26 to 0.86)	
	p-value	<0.001	1	0.2
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.03	

	Viral LRTI Comparison Group	0.01	0.02	
	Risk Difference	0.01 (-0.03 to 0.05)	0.02 (-0.03 to 0.07)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.77	3.42	
	Viral LRTI Comparison Group	2.28	3.14	
	Risk Difference	0.49 (-0.23 to 1.11)	0.28 (-0.59 to 1.18)	
	p-value	1	1	1
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.64	1.91	
	Viral LRTI Comparison Group	2.01	2.43	
	Risk Difference	-0.37 (-0.74 to 0.04)	-0.52 (-0.97 to 0.02)	
	p-value	1	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	6.01	7.88	
	Viral LRTI Comparison Group	6.18	7.5	
	Risk Difference	-0.17 (-0.99 to 0.79)	0.39 (-0.76 to 1.42)	
	p-value	1	1	1
> Chronic Kidney Disease	SARS-CoV-2 Group	4.02	5.01	
	Viral LRTI Comparison Group	4.66	5.27	
	Risk Difference	-0.64 (-1.31 to 0.01)	-0.26 (-1.14 to 0.73)	
	p-value	1	1	1
> Acute Kidney Injury	SARS-CoV-2 Group	3.92	5.6	
	Viral LRTI Comparison Group	4.07	5.82	
	Risk Difference	-0.16 (-0.65 to 0.38)	-0.21 (-1.05 to 0.53)	
	p-value	1	1	1
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	7.61	10.92	

	Viral LRTI Comparison Group	5.99	7.33	
	Risk Difference	1.63 (0.94 to 2.24)	3.59 (2.63 to 4.57)	
	p-value	<0.001	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	6.66	9.78	
	Viral LRTI Comparison Group	4.28	5.39	
	Risk Difference	2.38 (1.74 to 2.97)	4.39 (3.63 to 5.07)	
	p-value	<0.001	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	1.33	1.61	
	Viral LRTI Comparison Group	1.7	1.87	
	Risk Difference	-0.38 (-0.74 to -0.05)	-0.26 (-0.66 to 0.18)	
	p-value	1	1	1
> Interstitial Lung Disease	SARS-CoV-2 Group	1.16	1.56	
	Viral LRTI Comparison Group	1.51	2	
	Risk Difference	-0.35 (-0.68 to -0.01)	-0.44 (-0.86 to 0)	
	p-value	1	1	1
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.27	0.24	
	Viral LRTI Comparison Group	0.3	0.34	
	Risk Difference	-0.03 (-0.18 to 0.11)	-0.1 (-0.3 to 0.07)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.21	0.15	
	Viral LRTI Comparison Group	0.36	0.12	
	Risk Difference	-0.15 (-0.33 to -0.01)	0.03 (-0.1 to 0.15)	
	p-value	1	1	0.44
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.07	0.08	

	Viral LRTI Comparison Group	0.08	0.03	
	Risk Difference	-0.01 (-0.08 to 0.07)	0.05 (-0.02 to 0.13)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.17	1.94	
	Viral LRTI Comparison Group	1.83	2.73	
	Risk Difference	-0.66 (-1 to -0.3)	-0.79 (-1.36 to -0.15)	
	p-value	1	1	1
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.63	1.22	
	Viral LRTI Comparison Group	0.86	1.33	
	Risk Difference	-0.22 (-0.5 to 0.03)	-0.1 (-0.5 to 0.26)	
	p-value	1	1	1
Leukopenia	SARS-CoV-2 Group	0.29	0.28	
	Viral LRTI Comparison Group	0.22	0.32	
	Risk Difference	0.07 (-0.07 to 0.22)	-0.04 (-0.21 to 0.15)	
	p-value	1	1	1
Anemia	SARS-CoV-2 Group	3.34	3.18	
	Viral LRTI Comparison Group	3.49	3.56	
	Risk Difference	-0.16 (-0.7 to 0.39)	-0.38 (-0.96 to 0.32)	
	p-value	1	1	1
Symptom				
Myalgia	SARS-CoV-2 Group	8.87	7	
	Viral LRTI Comparison Group	9.47	7.92	
	Risk Difference	-0.6 (-1.79 to 0.65)	-0.92 (-2.08 to 0.24)	
	p-value	1	1	1
Fatigue Diagnosis	SARS-CoV-2 Group	11.41	10.74	
	Viral LRTI Comparison Group	11.4	10.53	

	Risk Difference	0 (-1.17 to 1.14)	0.21 (-0.98 to 1.53)	
	p-value	1	1	1
> Fatigue	SARS-CoV-2 Group	11.27	10.6	
	Viral LRTI Comparison Group	11.38	10.49	
	Risk Difference	-0.11 (-1.4 to 1.05)	0.11 (-0.98 to 1.67)	
	p-value	1	1	1
> Chronic Fatigue	SARS-CoV-2 Group	0.42	0.3	
	Viral LRTI Comparison Group	0.5	0.31	
	Risk Difference	-0.09 (-0.3 to 0.11)	-0.01 (-0.22 to 0.16)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.27	0.19	
	Viral LRTI Comparison Group	0.04	0.07	
	Risk Difference	0.23 (0.12 to 0.34)	0.13 (-0.01 to 0.24)	
	p-value	<0.001	0.11	0.31
Anosmia	SARS-CoV-2 Group	0.07	0.06	
	Viral LRTI Comparison Group	0.04	0.02	
	Risk Difference	0.03 (-0.03 to 0.1)	0.04 (-0.03 to 0.13)	
	p-value	1	1	1

Subgroups are subpopulations of the SARS-CoV-2 and viral LRTI cohorts.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 5I: Cumulative Incidence and Risk Difference per 100 Individuals of the SARS-CoV-2 and Viral LRTI Comparison Group for Clinical Sequelae in the Post-Acute Phase by COVID Hospitalization

Clinical Sequelae	Category	Not hospitalized with COVID	Hospitalized with COVID	p-interaction
	Matched Group Size	50,512 vs 50,512	22,861 vs 22,861	
Hypertension				
Hypertension	SARS-CoV-2 Group	11.01	23.06	
	Viral LRTI Comparison Group	15.47	15.69	
	Risk Difference	-4.46 (-8.14 to -0.37)	7.37 (-3.39 to 16.69)	
	p-value	1	1	0.97
Pulmonary Hypertension				
Pulmonary Hypertension	SARS-CoV-2 Group	0.73	1.73	
	Viral LRTI Comparison Group	1.52	1.98	
	Risk Difference	-0.78 (-1.04 to -0.52)	-0.25 (-0.8 to 0.26)	
	p-value	1	1	1
Cardiology				
Cardiac Rhythm Disorders				
Cardiac Rhythm Disorders	SARS-CoV-2 Group	3.34	9.5	
	Viral LRTI Comparison Group	5.35	6.47	
	Risk Difference	-2.01 (-2.57 to -1.38)	3.03 (1.67 to 4.09)	
	p-value	1	<0.001	<0.001
> Cardiac Arrhythmia				
> Cardiac Arrhythmia	SARS-CoV-2 Group	2.03	5.05	
	Viral LRTI Comparison Group	3.1	4.26	
	Risk Difference	-1.06 (-1.56 to -0.61)	0.79 (-0.18 to 1.84)	
	p-value	1	0.42	<0.001
> Tachycardia				
> Tachycardia	SARS-CoV-2 Group	1.88	6.24	
	Viral LRTI Comparison Group	2.97	3.44	
	Risk Difference	-1.09 (-1.49 to -0.72)	2.79 (2 to 3.68)	
	p-value	1	<0.001	<0.001
> POTs				
> POTs	SARS-CoV-2 Group	0.77	2.08	

	Viral LRTI Comparison Group	1.2	1.52	
	Risk Difference	-0.43 (-0.67 to -0.21)	0.57 (0.02 to 1.13)	
	p-value	1	<0.001	0.04
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	2.14	6.27	
	Viral LRTI Comparison Group	5.4	6.91	
	Risk Difference	-3.26 (-3.76 to -2.55)	-0.65 (-1.79 to 0.48)	
	p-value	1	1	<0.001
> Congestive Heart Failure	SARS-CoV-2 Group	1.9	5.67	
	Viral LRTI Comparison Group	4.78	6.21	
	Risk Difference	-2.88 (-3.34 to -2.41)	-0.54 (-1.51 to 0.66)	
	p-value	1	1	<0.001
> Cardiomyopathy	SARS-CoV-2 Group	0.78	1.96	
	Viral LRTI Comparison Group	1.76	2.19	
	Risk Difference	-0.98 (-1.32 to -0.67)	-0.23 (-0.81 to 0.52)	
	p-value	1	1	1
> Myocarditis	SARS-CoV-2 Group	0.01	0.11	
	Viral LRTI Comparison Group	0.02	0.01	
	Risk Difference	0 (-0.04 to 0.03)	0.1 (0 to 0.22)	
	p-value	1	0.11	0.006
Coronary Disease	SARS-CoV-2 Group	1.15	3.42	
	Viral LRTI Comparison Group	2.08	2.83	
	Risk Difference	-0.93 (-1.27 to -0.63)	0.59 (-0.11 to 1.38)	
	p-value	1	0.74	<0.001
> Myocardial Infarction	SARS-CoV-2 Group	0.91	3	
	Viral LRTI Comparison Group	1.66	2.52	
	Risk Difference	-0.74 (-1.01 to -0.45)	0.48 (-0.14 to 1.12)	

	p-value	1	1	<0.001
> Acute Coronary Syndrome	SARS-CoV-2 Group	1.14	3.38	
	Viral LRTI Comparison Group	2.08	2.81	
	Risk Difference	-0.94 (-1.29 to -0.65)	0.57 (-0.1 to 1.22)	
	p-value	1	0.32	<0.001
Cardiogenic Shock	SARS-CoV-2 Group	0.08	0.3	
	Viral LRTI Comparison Group	0.17	0.35	
	Risk Difference	-0.09 (-0.17 to 0)	-0.05 (-0.29 to 0.22)	
	p-value	1	1	1
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	2.11	7.46	
	Viral LRTI Comparison Group	3.19	4.19	
	Risk Difference	-1.08 (-1.53 to -0.69)	3.27 (2.32 to 4.31)	
	p-value	1	<0.001	<0.001
> Hypercoagulability	SARS-CoV-2 Group	1.59	5.06	
	Viral LRTI Comparison Group	2.28	2.99	
	Risk Difference	-0.69 (-1.03 to -0.37)	2.07 (1.2 to 2.84)	
	p-value	1	<0.001	<0.001
> Deep Vein Thrombosis	SARS-CoV-2 Group	1.06	3.79	
	Viral LRTI Comparison Group	1.59	2.03	
	Risk Difference	-0.53 (-0.82 to -0.25)	1.76 (1.12 to 2.35)	
	p-value	1	<0.001	<0.001
> Pulmonary Embolism	SARS-CoV-2 Group	0.62	3	
	Viral LRTI Comparison Group	1.08	1.27	
	Risk Difference	-0.46 (-0.7 to -0.23)	1.73 (1.17 to 2.2)	
	p-value	1	<0.001	<0.001

> Peripheral Arterial Occlusions	SARS-CoV-2 Group	0.26	0.75	
	Viral LRTI Comparison Group	0.44	0.76	
	Risk Difference	-0.18 (-0.33 to -0.03)	-0.01 (-0.32 to 0.35)	
	p-value	1	1	1
Stroke and Sequelae	SARS-CoV-2 Group	1.63	4.54	
	Viral LRTI Comparison Group	2.57	3.29	
	Risk Difference	-0.95 (-1.32 to -0.64)	1.25 (0.55 to 2.11)	
	p-value	1	<0.001	<0.001
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	1.44	4.13	
	Viral LRTI Comparison Group	2.31	2.91	
	Risk Difference	-0.88 (-1.22 to -0.54)	1.21 (0.43 to 2.14)	
	p-value	1	<0.001	<0.001
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	0.99	2.66	
	Viral LRTI Comparison Group	1.51	2.08	
	Risk Difference	-0.52 (-0.78 to -0.21)	0.59 (0.03 to 1.17)	
	p-value	1	<0.001	<0.001
Mental Health				
Mental Health Diagnosis	SARS-CoV-2 Group	5.1	8.28	
	Viral LRTI Comparison Group	5.83	6.53	
	Risk Difference	-0.72 (-1.38 to -0.05)	1.76 (0.6 to 3.48)	
	p-value	1	<0.001	0.03
Psychosis	SARS-CoV-2 Group	0.25	0.67	
	Viral LRTI Comparison Group	0.29	0.43	
	Risk Difference	-0.04 (-0.17 to 0.09)	0.24 (-0.08 to 0.56)	
	p-value	1	1	0.56

Neurologic				
Amnesia/Memory Difficulty	SARS-CoV-2 Group	3.64	11.47	
	Viral LRTI Comparison Group	5.12	6.89	
	Risk Difference	-1.48 (-2 to -0.98)	4.58 (3.11 to 5.81)	
	p-value	1	<0.001	<0.001
Migraine	SARS-CoV-2 Group	0.36	0.18	
	Viral LRTI Comparison Group	0.34	0.33	
	Risk Difference	0.02 (-0.15 to 0.21)	-0.15 (-0.38 to 0.08)	
	p-value	1	1	0.19
Peripheral Neuropathy	SARS-CoV-2 Group	0.84	1.17	
	Viral LRTI Comparison Group	1.09	1.34	
	Risk Difference	-0.24 (-0.49 to 0.04)	-0.17 (-0.61 to 0.36)	
	p-value	1	1	1
Encephalopathy	SARS-CoV-2 Group	1.45	7.07	
	Viral LRTI Comparison Group	2.24	3.57	
	Risk Difference	-0.79 (-1.15 to -0.44)	3.5 (2.6 to 4.55)	
	p-value	1	<0.001	<0.001
Seizure	SARS-CoV-2 Group	0.41	0.99	
	Viral LRTI Comparison Group	0.51	0.73	
	Risk Difference	-0.1 (-0.26 to 0.09)	0.26 (-0.18 to 0.63)	
	p-value	1	1	1
Dementia	SARS-CoV-2 Group	2.2	5.32	
	Viral LRTI Comparison Group	2.15	3.23	
	Risk Difference	0.06 (-0.32 to 0.49)	2.09 (1.29 to 3.14)	
	p-value	1	<0.001	<0.001
Guillain-Barre Syndrome	SARS-CoV-2 Group	0.02	0.04	

	Viral LRTI Comparison Group	0.01	0.01	
	Risk Difference	0.01 (-0.01 to 0.04)	0.03 (-0.03 to 0.1)	
	p-value	1	1	1
Diabetes				
Type 2 Diabetes	SARS-CoV-2 Group	2.39	5.27	
	Viral LRTI Comparison Group	2.38	2.79	
	Risk Difference	0.01 (-0.67 to 0.56)	2.47 (0.98 to 4.01)	
	p-value	1	<0.001	<0.001
Liver				
Liver Test Abnormality	SARS-CoV-2 Group	1.55	2.19	
	Viral LRTI Comparison Group	1.96	2.32	
	Risk Difference	-0.4 (-0.79 to -0.06)	-0.14 (-0.76 to 0.58)	
	p-value	1	1	1
Nephrology				
Kidney Injury	SARS-CoV-2 Group	5.06	13.53	
	Viral LRTI Comparison Group	6.7	8.68	
	Risk Difference	-1.64 (-2.42 to -0.89)	4.84 (3.04 to 6.63)	
	p-value	1	<0.001	<0.001
> Chronic Kidney Disease	SARS-CoV-2 Group	3.82	7.17	
	Viral LRTI Comparison Group	5.05	6.49	
	Risk Difference	-1.22 (-1.92 to -0.59)	0.68 (-0.77 to 2)	
	p-value	1	1	0.57
> Acute Kidney Injury	SARS-CoV-2 Group	2.52	11.54	
	Viral LRTI Comparison Group	4.56	6.41	
	Risk Difference	-2.05 (-2.62 to -1.62)	5.13 (3.85 to 6.45)	
	p-value	1	<0.001	<0.001
Respiratory				
Respiratory Failure	SARS-CoV-2 Group	3.63	26.09	

	Viral LRTI Comparison Group	6.39	8.21	
	Risk Difference	-2.76 (-3.36 to -2.2)	17.88 (16.51 to 19.22)	
	p-value	1	<0.001	<0.001
> Acute Respiratory Failure	SARS-CoV-2 Group	2.81	23.81	
	Viral LRTI Comparison Group	4.62	6.24	
	Risk Difference	-1.8 (-2.32 to -1.35)	17.57 (16.39 to 18.67)	
	p-value	1	<0.001	<0.001
> Chronic Respiratory Failure	SARS-CoV-2 Group	0.73	3.72	
	Viral LRTI Comparison Group	1.62	2.33	
	Risk Difference	-0.89 (-1.17 to -0.6)	1.39 (0.66 to 2.1)	
	p-value	1	<0.001	<0.001
> Interstitial Lung Disease	SARS-CoV-2 Group	0.83	2.93	
	Viral LRTI Comparison Group	1.7	1.99	
	Risk Difference	-0.87 (-1.17 to -0.6)	0.95 (0.17 to 1.64)	
	p-value	1	<0.001	<0.001
Dermatologic				
Atopic Dermatitis	SARS-CoV-2 Group	0.27	0.28	
	Viral LRTI Comparison Group	0.37	0.29	
	Risk Difference	-0.09 (-0.22 to 0.06)	-0.01 (-0.26 to 0.18)	
	p-value	1	1	1
Urticaria	SARS-CoV-2 Group	0.15	0.27	
	Viral LRTI Comparison Group	0.28	0.24	
	Risk Difference	-0.13 (-0.26 to -0.02)	0.03 (-0.18 to 0.25)	
	p-value	1	1	1
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	0.07	0.08	

	Viral LRTI Comparison Group	0.05	0.04	
	Risk Difference	0.02 (-0.04 to 0.08)	0.04 (-0.06 to 0.13)	
	p-value	1	1	1
Others				
Sleep Apnea	SARS-CoV-2 Group	1.19	2.36	
	Viral LRTI Comparison Group	2.14	2.42	
	Risk Difference	-0.95 (-1.27 to -0.59)	-0.06 (-0.74 to 0.67)	
	p-value	1	1	0.18
Hematology				
Thrombocytopenia	SARS-CoV-2 Group	0.65	1.69	
	Viral LRTI Comparison Group	0.99	1.22	
	Risk Difference	-0.34 (-0.55 to -0.09)	0.47 (-0.02 to 0.99)	
	p-value	1	0.11	<0.001
Leukopenia	SARS-CoV-2 Group	0.19	0.47	
	Viral LRTI Comparison Group	0.2	0.33	
	Risk Difference	0 (-0.11 to 0.11)	0.15 (-0.11 to 0.38)	
	p-value	1	1	0.56
Anemia	SARS-CoV-2 Group	2.52	5.2	
	Viral LRTI Comparison Group	3.43	4.16	
	Risk Difference	-0.91 (-1.51 to -0.38)	1.04 (-0.01 to 1.98)	
	p-value	1	0.11	0.01
Symptom				
Myalgia	SARS-CoV-2 Group	7.09	11.16	
	Viral LRTI Comparison Group	8.42	10.36	
	Risk Difference	-1.33 (-2.27 to -0.25)	0.81 (-0.84 to 2.79)	
	p-value	1	1	1
Fatigue Diagnosis	SARS-CoV-2 Group	8	21.15	
	Viral LRTI Comparison Group	10.76	12.29	

	Risk Difference	-2.76 (-3.59 to -1.98)	8.86 (6.96 to 11.11)	
	p-value	1	<0.001	<0.001
> Fatigue	SARS-CoV-2 Group	7.9	20.9	
	Viral LRTI Comparison Group	10.72	12.25	
	Risk Difference	-2.82 (-3.75 to -1.93)	8.65 (6.29 to 10.52)	
	p-value	1	<0.001	<0.001
> Chronic Fatigue	SARS-CoV-2 Group	0.32	0.62	
	Viral LRTI Comparison Group	0.42	0.47	
	Risk Difference	-0.1 (-0.24 to 0.05)	0.15 (-0.14 to 0.47)	
	p-value	1	1	1
> Post-viral Fatigue	SARS-CoV-2 Group	0.16	0.46	
	Viral LRTI Comparison Group	0.05	0.07	
	Risk Difference	0.11 (0.04 to 0.17)	0.38 (0.2 to 0.59)	
	p-value	<0.001	<0.001	0.009
Anosmia	SARS-CoV-2 Group	0.06	0.07	
	Viral LRTI Comparison Group	0.03	0.02	
	Risk Difference	0.03 (-0.03 to 0.09)	0.05 (-0.04 to 0.16)	
	p-value	1	1	1

Subgroups are subpopulations of the SARS-CoV-2 and viral LRTI cohorts.

Hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals hospitalized due to COVID and individuals within the viral LRTI comparison group. Meanwhile, Not hospitalized with COVID subpopulation compares SARS-CoV-2 infected individuals not hospitalized due to COVID and individuals within the viral LRTI comparison group.

Cumulative incidence was obtained by Kaplan-Meier estimator at 120 days after the start of the post-acute phase (141 days after index date).

Confidence intervals were calculated based on Bonferroni correction, i.e., $(1 - 0.05/(N \times \text{number of subgroup levels}))$ confidence interval.

Individuals were excluded if they had less than 21 days of observation from the index date, had already been diagnosed with the outcome of interest prior to acute phase, or their matched pair was excluded for the same reasons.

Table 6a: Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and 2020 Comparison Group

Clinical Sequelae	Category	Total at Risk	Total with Post-acute Outcome	Persistent	New Onset
Hypertension					
Hypertension	SARS-CoV-2 Group	5,664	513	178 (35%)	335 (65%)
	2020 Comparison Group	5,664	347	38 (11%)	309 (89%)
Pulmonary Hypertension					
Pulmonary Hypertension	SARS-CoV-2 Group	82,315	577	85 (15%)	492 (85%)
	2020 Comparison Group	82,315	420	36 (8.6%)	384 (91%)
Cardiology					
Cardiac Rhythm Disorders					
Cardiac Rhythm Disorders	SARS-CoV-2 Group	67,540	2,387	541 (23%)	1,846 (77%)
	2020 Comparison Group	67,540	1,370	110 (8%)	1,260 (92%)
> Cardiac Arrhythmia					
> Cardiac Arrhythmia	SARS-CoV-2 Group	73,765	1,494	251 (17%)	1,243 (83%)
	2020 Comparison Group	73,765	1,021	76 (7.4%)	945 (93%)
> Tachycardia					
> Tachycardia	SARS-CoV-2 Group	77,356	1,640	320 (20%)	1,320 (80%)
	2020 Comparison Group	77,356	813	50 (6.2%)	763 (94%)
> POTs					
> POTs	SARS-CoV-2 Group	82,748	688	93 (14%)	595 (86%)
	2020 Comparison Group	82,748	436	20 (4.6%)	416 (95%)
CHF Cardiomyopathy Myocarditis					
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	68,327	1,558	516 (33%)	1,042 (67%)
	2020 Comparison Group	68,327	936	129 (14%)	807 (86%)

> Congestive Heart Failure	SARS-CoV-2 Group	71,721	1,454	476 (33%)	978 (67%)
	2020 Comparison Group	71,721	854	113 (13%)	741 (87%)
> Cardiomyopathy	SARS-CoV-2 Group	79,362	624	158 (25%)	466 (75%)
	2020 Comparison Group	79,362	464	65 (14%)	399 (86%)
> Myocarditis	SARS-CoV-2 Group	87,311	25	9 (36%)	16 (64%)
	2020 Comparison Group	87,311	5	0 (0%)	5 (100%)
Coronary Disease	SARS-CoV-2 Group	81,458	1,016	349 (34%)	667 (66%)
	2020 Comparison Group	81,458	532	33 (6.2%)	499 (94%)
> Myocardial Infarction	SARS-CoV-2 Group	82,925	854	321 (38%)	533 (62%)
	2020 Comparison Group	82,925	425	30 (7.1%)	395 (93%)
> Acute Coronary Syndrome	SARS-CoV-2 Group	81,484	1,007	343 (34%)	664 (66%)
	2020 Comparison Group	81,484	528	33 (6.2%)	495 (94%)
Cardiogenic Shock	SARS-CoV-2 Group	87,038	89	12 (13%)	77 (87%)
	2020 Comparison Group	87,038	51	3 (5.9%)	48 (94%)
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	77,100	2,087	734 (35%)	1,353 (65%)
	2020 Comparison Group	77,100	708	73 (10%)	635 (90%)
> Hypercoagulability	SARS-CoV-2 Group	79,515	1,420	338 (24%)	1,082 (76%)
	2020 Comparison Group	79,515	538	49 (9.1%)	489 (91%)

> Deep Vein Thrombosis	SARS-CoV-2 Group	82,588	1,035	271 (26%)	764 (74%)
	2020 Comparison Group	82,588	310	38 (12%)	272 (88%)
> Pulmonary Embolism	SARS-CoV-2 Group	84,869	882	441 (50%)	441 (50%)
	2020 Comparison Group	84,869	182	24 (13%)	158 (87%)
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	85,755	260	45 (17%)	215 (83%)
	2020 Comparison Group	85,755	148	18 (12%)	130 (88%)
Stroke and Sequelae	SARS-CoV-2 Group	76,384	1,324	463 (35%)	861 (65%)
	2020 Comparison Group	76,384	744	87 (12%)	657 (88%)
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	77,154	1,194	411 (34%)	783 (66%)
	2020 Comparison Group	77,154	674	78 (12%)	596 (88%)
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	80,975	838	302 (36%)	536 (64%)
	2020 Comparison Group	80,975	443	70 (16%)	373 (84%)
Mental Health					
Mental Health Diagnosis	SARS-CoV-2 Group	55,291	2,326	386 (17%)	1,940 (83%)
	2020 Comparison Group	55,291	1,469	147 (10%)	1,322 (90%)
Psychosis	SARS-CoV-2 Group	85,892	207	36 (17%)	171 (83%)
	2020 Comparison Group	85,892	84	4 (4.8%)	80 (95%)
Neurologic					

Amnesia/Memory Difficulty	SARS-CoV-2 Group	69,029	2,545	774 (30%)	1,771 (70%)
	2020 Comparison Group	69,029	1,245	108 (8.7%)	1,137 (91%)
Migraine	SARS-CoV-2 Group	85,038	198	20 (10%)	178 (90%)
	2020 Comparison Group	85,038	181	9 (5%)	172 (95%)
Peripheral Neuropathy	SARS-CoV-2 Group	81,313	574	50 (8.7%)	524 (91%)
	2020 Comparison Group	81,313	498	45 (9%)	453 (91%)
Encephalopathy	SARS-CoV-2 Group	81,193	1,773	661 (37%)	1,112 (63%)
	2020 Comparison Group	81,193	569	46 (8.1%)	523 (92%)
Seizure	SARS-CoV-2 Group	84,216	338	73 (22%)	265 (78%)
	2020 Comparison Group	84,216	170	16 (9.4%)	154 (91%)
Dementia	SARS-CoV-2 Group	70,963	1,302	410 (31%)	892 (69%)
	2020 Comparison Group	70,963	624	68 (11%)	556 (89%)
Guillain-Barre Syndrome	SARS-CoV-2 Group	87,281	15	7 (47%)	8 (53%)
	2020 Comparison Group	87,281	3	0 (0%)	3 (100%)
Diabetes					
Type 2 Diabetes	SARS-CoV-2 Group	35,386	732	158 (22%)	574 (78%)
	2020 Comparison Group	35,386	417	32 (7.7%)	385 (92%)
Liver					
Liver Test Abnormality	SARS-CoV-2 Group	78,201	1,006	102 (10%)	904 (90%)

	2020 Comparison Group	78,201	755	35 (4.6%)	720 (95%)
Nephrology					
Kidney Injury	SARS-CoV-2 Group	50,421	2,516	1,072 (43%)	1,444 (57%)
	2020 Comparison Group	50,421	1,487	162 (11%)	1,325 (89%)
> Chronic Kidney Disease	SARS-CoV-2 Group	53,146	1,632	454 (28%)	1,178 (72%)
	2020 Comparison Group	53,146	1,305	150 (11%)	1,155 (89%)
> Acute Kidney Injury	SARS-CoV-2 Group	74,924	2,813	1,398 (50%)	1,415 (50%)
	2020 Comparison Group	74,924	1,055	89 (8.4%)	966 (92%)
Respiratory					
Respiratory Failure	SARS-CoV-2 Group	75,899	5,925	4,564 (77%)	1,361 (23%)
	2020 Comparison Group	75,899	849	68 (8%)	781 (92%)
> Acute Respiratory Failure	SARS-CoV-2 Group	80,457	5,685	4,534 (80%)	1,151 (20%)
	2020 Comparison Group	80,457	647	50 (7.7%)	597 (92%)
> Chronic Respiratory Failure	SARS-CoV-2 Group	83,978	848	187 (22%)	661 (78%)
	2020 Comparison Group	83,978	202	18 (8.9%)	184 (91%)
> Interstitial Lung Disease	SARS-CoV-2 Group	83,433	778	109 (14%)	669 (86%)
	2020 Comparison Group	83,433	276	12 (4.3%)	264 (96%)
Dermatologic					
Atopic Dermatitis	SARS-CoV-2 Group	85,629	161	8 (5%)	153 (95%)

	2020 Comparison Group	85,629	185	10 (5.4%)	175 (95%)
Urticaria	SARS-CoV-2 Group	86,291	119	6 (5%)	113 (95%)
	2020 Comparison Group	86,291	76	6 (7.9%)	70 (92%)
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	86,998	46	0 (0%)	46 (100%)
	2020 Comparison Group	86,998	26	0 (0%)	26 (100%)
Others					
Sleep Apnea	SARS-CoV-2 Group	71,054	749	118 (16%)	631 (84%)
	2020 Comparison Group	71,054	542	77 (14%)	465 (86%)
Hematology					
Thrombocytopenia	SARS-CoV-2 Group	83,309	594	130 (22%)	464 (78%)
	2020 Comparison Group	83,309	367	22 (6%)	345 (94%)
Leukopenia	SARS-CoV-2 Group	86,276	203	38 (19%)	165 (81%)
	2020 Comparison Group	86,276	101	1 (1%)	100 (99%)
Anemia	SARS-CoV-2 Group	71,891	1,657	256 (15%)	1,401 (85%)
	2020 Comparison Group	71,891	1,095	144 (13%)	951 (87%)
Symptom					
Myalgia	SARS-CoV-2 Group	51,331	2,918	315 (11%)	2,603 (89%)
	2020 Comparison Group	51,331	2,353	158 (6.7%)	2,195 (93%)
Fatigue Diagnosis	SARS-CoV-2 Group	55,138	4,400	1,542 (35%)	2,858 (65%)

	2020 Comparison Group	55,138	2,115	167 (7.9%)	1,948 (92%)
> Fatigue	SARS-CoV-2 Group	55,189	4,348	1,524 (35%)	2,824 (65%)
	2020 Comparison Group	55,189	2,116	167 (7.9%)	1,949 (92%)
> Chronic Fatigue	SARS-CoV-2 Group	85,443	235	21 (8.9%)	214 (91%)
	2020 Comparison Group	85,443	170	5 (2.9%)	165 (97%)
> Postviral Fatigue	SARS-CoV-2 Group	87,159	151	19 (13%)	132 (87%)
	2020 Comparison Group	87,159	8	0 (0%)	8 (100%)
Anosmia	SARS-CoV-2 Group	87,212	41	8 (20%)	33 (80%)
	2020 Comparison Group	87,212	23	2 (8.7%)	21 (91%)

Total at Risk counts the number of individuals without the outcome of interest prior to acute phase and whose (and their matched pairs') observation period from the index date are at least 21 days.

Table 6b: Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and 2019 Comparison Group

Clinical Sequelae	Category	Total at Risk	Total with Post-acute Outcome	Persistent	New Onset
Hypertension					
Hypertension	SARS-CoV-2 Group	3,670	357	120 (34%)	237 (66%)
	2019 Comparison Group	3,670	213	27 (13%)	186 (87%)
Pulmonary Hypertension					
Pulmonary Hypertension	SARS-CoV-2 Group	83,090	594	83 (14%)	511 (86%)
	2019 Comparison Group	83,090	539	39 (7.2%)	500 (93%)
Cardiology					
Cardiac Rhythm Disorders					
Cardiac Rhythm Disorders	SARS-CoV-2 Group	68,071	2,385	568 (24%)	1,817 (76%)
	2019 Comparison Group	68,071	1,672	115 (6.9%)	1,557 (93%)
> Cardiac Arrhythmia					
> Cardiac Arrhythmia	SARS-CoV-2 Group	74,497	1,524	264 (17%)	1,260 (83%)
	2019 Comparison Group	74,497	1,252	75 (6%)	1,177 (94%)
> Tachycardia					
> Tachycardia	SARS-CoV-2 Group	78,036	1,641	329 (20%)	1,312 (80%)
	2019 Comparison Group	78,036	936	59 (6.3%)	877 (94%)
> POTs					
> POTs	SARS-CoV-2 Group	83,542	699	101 (14%)	598 (86%)
	2019 Comparison Group	83,542	549	21 (3.8%)	528 (96%)
CHF Cardiomyopathy Myocarditis					
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	68,862	1,561	521 (33%)	1,040 (67%)
	2019 Comparison Group	68,862	1,143	165 (14%)	978 (86%)

> Congestive Heart Failure	SARS-CoV-2 Group	72,126	1,460	483 (33%)	977 (67%)
	2019 Comparison Group	72,126	1,102	159 (14%)	943 (86%)
> Cardiomyopathy	SARS-CoV-2 Group	80,232	618	158 (26%)	460 (74%)
	2019 Comparison Group	80,232	502	47 (9.4%)	455 (91%)
> Myocarditis	SARS-CoV-2 Group	88,052	27	9 (33%)	18 (67%)
	2019 Comparison Group	88,052	9	0 (0%)	9 (100%)
Coronary Disease	SARS-CoV-2 Group	82,259	1,051	340 (32%)	711 (68%)
	2019 Comparison Group	82,259	722	66 (9.1%)	656 (91%)
> Myocardial Infarction	SARS-CoV-2 Group	83,770	891	316 (35%)	575 (65%)
	2019 Comparison Group	83,770	580	57 (9.8%)	523 (90%)
> Acute Coronary Syndrome	SARS-CoV-2 Group	82,278	1,045	335 (32%)	710 (68%)
	2019 Comparison Group	82,278	716	65 (9.1%)	651 (91%)
Cardiogenic Shock	SARS-CoV-2 Group	87,811	88	18 (20%)	70 (80%)
	2019 Comparison Group	87,811	69	3 (4.3%)	66 (96%)
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	77,455	2,102	744 (35%)	1,358 (65%)
	2019 Comparison Group	77,455	953	87 (9.1%)	866 (91%)
> Hypercoagulability	SARS-CoV-2 Group	80,000	1,433	352 (25%)	1,081 (75%)
	2019 Comparison Group	80,000	761	68 (8.9%)	693 (91%)

> Deep Vein Thrombosis	SARS-CoV-2 Group	83,208	1,043	271 (26%)	772 (74%)
	2019 Comparison Group	83,208	465	48 (10%)	417 (90%)
> Pulmonary Embolism	SARS-CoV-2 Group	85,580	902	445 (49%)	457 (51%)
	2019 Comparison Group	85,580	215	22 (10%)	193 (90%)
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	86,436	278	52 (19%)	226 (81%)
	2019 Comparison Group	86,436	181	11 (6.1%)	170 (94%)
Stroke and Sequelae	SARS-CoV-2 Group	75,633	1,334	442 (33%)	892 (67%)
	2019 Comparison Group	75,633	982	128 (13%)	854 (87%)
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	76,547	1,203	394 (33%)	809 (67%)
	2019 Comparison Group	76,547	879	113 (13%)	766 (87%)
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	80,621	852	299 (35%)	553 (65%)
	2019 Comparison Group	80,621	615	89 (14%)	526 (86%)
Mental Health					
Mental Health Diagnosis	SARS-CoV-2 Group	52,651	2,196	374 (17%)	1,822 (83%)
	2019 Comparison Group	52,651	1,634	186 (11%)	1,448 (89%)
Psychosis	SARS-CoV-2 Group	86,129	242	38 (16%)	204 (84%)
	2019 Comparison Group	86,129	147	9 (6.1%)	138 (94%)
Neurologic					

Amnesia/Memory Difficulty	SARS-CoV-2 Group	64,113	2,585	761 (29%)	1,824 (71%)
	2019 Comparison Group	64,113	1,759	156 (8.9%)	1,603 (91%)
Migraine	SARS-CoV-2 Group	85,739	193	18 (9.3%)	175 (91%)
	2019 Comparison Group	85,739	201	19 (9.5%)	182 (91%)
Peripheral Neuropathy	SARS-CoV-2 Group	81,805	572	47 (8.2%)	525 (92%)
	2019 Comparison Group	81,805	612	51 (8.3%)	561 (92%)
Encephalopathy	SARS-CoV-2 Group	80,637	1,807	672 (37%)	1,135 (63%)
	2019 Comparison Group	80,637	848	80 (9.4%)	768 (91%)
Seizure	SARS-CoV-2 Group	84,615	354	73 (21%)	281 (79%)
	2019 Comparison Group	84,615	280	29 (10%)	251 (90%)
Dementia	SARS-CoV-2 Group	62,571	1,326	412 (31%)	914 (69%)
	2019 Comparison Group	62,571	756	103 (14%)	653 (86%)
Guillain-Barre Syndrome	SARS-CoV-2 Group	88,007	15	6 (40%)	9 (60%)
	2019 Comparison Group	88,007	3	2 (67%)	1 (33%)
Diabetes					
Type 2 Diabetes	SARS-CoV-2 Group	32,624	709	150 (21%)	559 (79%)
	2019 Comparison Group	32,624	451	47 (10%)	404 (90%)
Liver					
Liver Test Abnormality	SARS-CoV-2 Group	78,790	1,019	113 (11%)	906 (89%)

	2019 Comparison Group	78,790	875	49 (5.6%)	826 (94%)
Nephrology					
Kidney Injury	SARS-CoV-2 Group	48,691	2,549	1,051 (41%)	1,498 (59%)
	2019 Comparison Group	48,691	1,757	197 (11%)	1,560 (89%)
> Chronic Kidney Disease	SARS-CoV-2 Group	51,816	1,669	448 (27%)	1,221 (73%)
	2019 Comparison Group	51,816	1,551	183 (12%)	1,368 (88%)
> Acute Kidney Injury	SARS-CoV-2 Group	74,827	2,874	1,416 (49%)	1,458 (51%)
	2019 Comparison Group	74,827	1,422	117 (8.2%)	1,305 (92%)
Respiratory					
Respiratory Failure	SARS-CoV-2 Group	76,155	6,004	4,588 (76%)	1,416 (24%)
	2019 Comparison Group	76,155	1,230	114 (9.3%)	1,116 (91%)
> Acute Respiratory Failure	SARS-CoV-2 Group	80,953	5,768	4,589 (80%)	1,179 (20%)
	2019 Comparison Group	80,953	960	84 (8.8%)	876 (91%)
> Chronic Respiratory Failure	SARS-CoV-2 Group	84,758	859	188 (22%)	671 (78%)
	2019 Comparison Group	84,758	288	33 (11%)	255 (89%)
> Interstitial Lung Disease	SARS-CoV-2 Group	84,074	818	120 (15%)	698 (85%)
	2019 Comparison Group	84,074	411	25 (6.1%)	386 (94%)
Dermatologic					
Atopic Dermatitis	SARS-CoV-2 Group	86,366	158	9 (5.7%)	149 (94%)

	2019 Comparison Group	86,366	195	11 (5.6%)	184 (94%)
Urticaria	SARS-CoV-2 Group	87,032	111	6 (5.4%)	105 (95%)
	2019 Comparison Group	87,032	132	13 (9.8%)	119 (90%)
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	87,739	49	0 (0%)	49 (100%)
	2019 Comparison Group	87,739	46	0 (0%)	46 (100%)
Others					
Sleep Apnea	SARS-CoV-2 Group	71,832	755	119 (16%)	636 (84%)
	2019 Comparison Group	71,832	751	98 (13%)	653 (87%)
Hematology					
Thrombocytopenia	SARS-CoV-2 Group	84,040	602	135 (22%)	467 (78%)
	2019 Comparison Group	84,040	353	24 (6.8%)	329 (93%)
Leukopenia	SARS-CoV-2 Group	86,998	192	38 (20%)	154 (80%)
	2019 Comparison Group	86,998	96	6 (6.2%)	90 (94%)
Anemia	SARS-CoV-2 Group	72,106	1,664	257 (15%)	1,407 (85%)
	2019 Comparison Group	72,106	1,211	132 (11%)	1,079 (89%)
Symptom					
Myalgia	SARS-CoV-2 Group	47,963	2,749	319 (12%)	2,430 (88%)
	2019 Comparison Group	47,963	2,542	195 (7.7%)	2,347 (92%)
Fatigue Diagnosis	SARS-CoV-2 Group	51,450	4,153	1,492 (36%)	2,661 (64%)

	2019 Comparison Group	51,450	2,521	200 (7.9%)	2,321 (92%)
> Fatigue	SARS-CoV-2 Group	51,499	4,109	1,478 (36%)	2,631 (64%)
	2019 Comparison Group	51,499	2,521	200 (7.9%)	2,321 (92%)
> Chronic Fatigue	SARS-CoV-2 Group	85,926	235	24 (10%)	211 (90%)
	2019 Comparison Group	85,926	264	13 (4.9%)	251 (95%)
> Postviral Fatigue	SARS-CoV-2 Group	87,890	153	16 (10%)	137 (90%)
	2019 Comparison Group	87,890	14	0 (0%)	14 (100%)
Anosmia	SARS-CoV-2 Group	87,934	48	10 (21%)	38 (79%)
	2019 Comparison Group	87,934	14	1 (7.1%)	13 (93%)

Total at Risk counts the number of individuals without the outcome of interest prior to acute phase and whose (and their matched pairs') observation period from the index date are at least 21 days.

Table 6c: Clinical Event Counts by Persistent and New Onset Outcomes of the Matched SARS-CoV-2 Group and Viral LRTI Comparison Group

Clinical Sequelae	Category	Total at Risk	Total with Post-acute Outcome	Persistent	New Onset
Hypertension					
Hypertension	SARS-CoV-2 Group	3,410	402	147 (37%)	255 (63%)
	Viral LRTI Comparison Group	3,410	374	154 (41%)	220 (59%)
Pulmonary Hypertension					
Pulmonary Hypertension	SARS-CoV-2 Group	69,475	521	72 (14%)	449 (86%)
	Viral LRTI Comparison Group	69,475	880	174 (20%)	706 (80%)
Cardiology					
Cardiac Rhythm Disorders					
Cardiac Rhythm Disorders	SARS-CoV-2 Group	58,069	2,136	504 (24%)	1,632 (76%)
	Viral LRTI Comparison Group	58,069	2,437	575 (24%)	1,862 (76%)
> Cardiac Arrhythmia					
> Cardiac Arrhythmia	SARS-CoV-2 Group	63,063	1,343	225 (17%)	1,118 (83%)
	Viral LRTI Comparison Group	63,063	1,619	285 (18%)	1,334 (82%)
> Tachycardia					
> Tachycardia	SARS-CoV-2 Group	65,796	1,433	287 (20%)	1,146 (80%)
	Viral LRTI Comparison Group	65,796	1,502	304 (20%)	1,198 (80%)
> POTs					
> POTs	SARS-CoV-2 Group	69,943	604	94 (16%)	510 (84%)
	Viral LRTI Comparison Group	69,943	721	76 (11%)	645 (89%)
CHF Cardiomyopathy Myocarditis					
CHF Cardiomyopathy Myocarditis	SARS-CoV-2 Group	58,232	1,436	486 (34%)	950 (66%)
	Viral LRTI Comparison Group	58,232	2,619	1,250 (48%)	1,369 (52%)

> Congestive Heart Failure	SARS-CoV-2 Group	60,761	1,346	442 (33%)	904 (67%)
	Viral LRTI Comparison Group	60,761	2,460	1,162 (47%)	1,298 (53%)
> Cardiomyopathy	SARS-CoV-2 Group	67,424	560	143 (26%)	417 (74%)
	Viral LRTI Comparison Group	67,424	944	297 (31%)	647 (69%)
> Myocarditis	SARS-CoV-2 Group	73,472	17	7 (41%)	10 (59%)
	Viral LRTI Comparison Group	73,472	12	0 (0%)	12 (100%)
Coronary Disease	SARS-CoV-2 Group	68,872	854	284 (33%)	570 (67%)
	Viral LRTI Comparison Group	68,872	1,240	489 (39%)	751 (61%)
> Myocardial Infarction	SARS-CoV-2 Group	70,052	724	271 (37%)	453 (63%)
	Viral LRTI Comparison Group	70,052	1,040	448 (43%)	592 (57%)
> Acute Coronary Syndrome	SARS-CoV-2 Group	68,896	844	277 (33%)	567 (67%)
	Viral LRTI Comparison Group	68,896	1,235	485 (39%)	750 (61%)
Cardiogenic Shock	SARS-CoV-2 Group	73,271	75	13 (17%)	62 (83%)
	Viral LRTI Comparison Group	73,271	139	31 (22%)	108 (78%)
Hypercoagulability DVT PE PAO	SARS-CoV-2 Group	65,065	1,803	630 (35%)	1,173 (65%)
	Viral LRTI Comparison Group	65,065	1,734	598 (34%)	1,136 (66%)
> Hypercoagulability	SARS-CoV-2 Group	67,118	1,247	300 (24%)	947 (76%)
	Viral LRTI Comparison Group	67,118	1,280	350 (27%)	930 (73%)

> Deep Vein Thrombosis	SARS-CoV-2 Group	69,588	893	231 (26%)	662 (74%)
	Viral LRTI Comparison Group	69,588	901	271 (30%)	630 (70%)
> Pulmonary Embolism	SARS-CoV-2 Group	71,480	745	366 (49%)	379 (51%)
	Viral LRTI Comparison Group	71,480	645	320 (50%)	325 (50%)
> Peripheral Arterial Occlusions	SARS-CoV-2 Group	72,173	222	43 (19%)	179 (81%)
	Viral LRTI Comparison Group	72,173	271	43 (16%)	228 (84%)
Stroke and Sequelae	SARS-CoV-2 Group	63,886	1,179	379 (32%)	800 (68%)
	Viral LRTI Comparison Group	63,886	1,447	467 (32%)	980 (68%)
> Ischemic Stroke and Sequelae	SARS-CoV-2 Group	64,568	1,068	335 (31%)	733 (69%)
	Viral LRTI Comparison Group	64,568	1,274	389 (31%)	885 (69%)
> Hemorrhagic Stroke and Sequelae	SARS-CoV-2 Group	67,907	758	257 (34%)	501 (66%)
	Viral LRTI Comparison Group	67,907	936	353 (38%)	583 (62%)
Mental Health					
Mental Health Diagnosis	SARS-CoV-2 Group	45,771	2,023	368 (18%)	1,655 (82%)
	Viral LRTI Comparison Group	45,771	2,093	378 (18%)	1,715 (82%)
Psychosis	SARS-CoV-2 Group	72,164	204	36 (18%)	168 (82%)
	Viral LRTI Comparison Group	72,164	175	21 (12%)	154 (88%)
Neurologic					

Amnesia/Memory Difficulty	SARS-CoV-2 Group	55,791	2,418	725 (30%)	1,693 (70%)
	Viral LRTI Comparison Group	55,791	2,447	753 (31%)	1,694 (69%)
Migraine	SARS-CoV-2 Group	71,645	170	16 (9.4%)	154 (91%)
	Viral LRTI Comparison Group	71,645	213	21 (9.9%)	192 (90%)
Peripheral Neuropathy	SARS-CoV-2 Group	68,552	486	43 (8.8%)	443 (91%)
	Viral LRTI Comparison Group	68,552	651	66 (10%)	585 (90%)
Encephalopathy	SARS-CoV-2 Group	67,876	1,545	560 (36%)	985 (64%)
	Viral LRTI Comparison Group	67,876	1,418	489 (34%)	929 (66%)
Seizure	SARS-CoV-2 Group	70,853	315	70 (22%)	245 (78%)
	Viral LRTI Comparison Group	70,853	346	96 (28%)	250 (72%)
Dementia	SARS-CoV-2 Group	55,765	1,277	367 (29%)	910 (71%)
	Viral LRTI Comparison Group	55,765	1,057	350 (33%)	707 (67%)
Guillain-Barre Syndrome	SARS-CoV-2 Group	73,441	9	4 (44%)	5 (56%)
	Viral LRTI Comparison Group	73,441	10	6 (60%)	4 (40%)
Diabetes					
Type 2 Diabetes	SARS-CoV-2 Group	29,247	698	135 (19%)	563 (81%)
	Viral LRTI Comparison Group	29,247	593	130 (22%)	463 (78%)
Liver					
Liver Test Abnormality	SARS-CoV-2 Group	66,469	881	88 (10%)	793 (90%)

	Viral LRTI Comparison Group	66,469	1,070	171 (16%)	899 (84%)
Nephrology					
Kidney Injury	SARS-CoV-2 Group	42,309	2,328	977 (42%)	1,351 (58%)
	Viral LRTI Comparison Group	42,309	2,365	948 (40%)	1,417 (60%)
> Chronic Kidney Disease	SARS-CoV-2 Group	45,030	1,530	421 (28%)	1,109 (72%)
	Viral LRTI Comparison Group	45,030	1,828	563 (31%)	1,265 (69%)
> Acute Kidney Injury	SARS-CoV-2 Group	63,023	2,527	1,249 (49%)	1,278 (51%)
	Viral LRTI Comparison Group	63,023	2,571	1,088 (42%)	1,483 (58%)
Respiratory					
Respiratory Failure	SARS-CoV-2 Group	63,459	5,061	3,870 (76%)	1,191 (24%)
	Viral LRTI Comparison Group	63,459	3,462	1,739 (50%)	1,723 (50%)
> Acute Respiratory Failure	SARS-CoV-2 Group	67,705	4,888	3,885 (79%)	1,003 (21%)
	Viral LRTI Comparison Group	67,705	2,714	1,435 (53%)	1,279 (47%)
> Chronic Respiratory Failure	SARS-CoV-2 Group	70,547	762	161 (21%)	601 (79%)
	Viral LRTI Comparison Group	70,547	971	263 (27%)	708 (73%)
> Interstitial Lung Disease	SARS-CoV-2 Group	70,052	687	96 (14%)	591 (86%)
	Viral LRTI Comparison Group	70,052	957	218 (23%)	739 (77%)
Dermatologic					
Atopic Dermatitis	SARS-CoV-2 Group	72,124	153	5 (3.3%)	148 (97%)

	Viral LRTI Comparison Group	72,124	185	12 (6.5%)	173 (94%)
Urticaria	SARS-CoV-2 Group	72,649	113	5 (4.4%)	108 (96%)
	Viral LRTI Comparison Group	72,649	140	6 (4.3%)	134 (96%)
Herpesviral Vesicular Dermatitis	SARS-CoV-2 Group	73,211	48	0 (0%)	48 (100%)
	Viral LRTI Comparison Group	73,211	41	3 (7.3%)	38 (93%)
Others					
Sleep Apnea	SARS-CoV-2 Group	60,991	644	98 (15%)	546 (85%)
	Viral LRTI Comparison Group	60,991	1,053	207 (20%)	846 (80%)
Hematology					
Thrombocytopenia	SARS-CoV-2 Group	70,289	481	95 (20%)	386 (80%)
	Viral LRTI Comparison Group	70,289	584	127 (22%)	457 (78%)
Leukopenia	SARS-CoV-2 Group	72,646	166	31 (19%)	135 (81%)
	Viral LRTI Comparison Group	72,646	157	12 (7.6%)	145 (92%)
Anemia	SARS-CoV-2 Group	61,005	1,492	235 (16%)	1,257 (84%)
	Viral LRTI Comparison Group	61,005	1,602	318 (20%)	1,284 (80%)
Symptom					
Myalgia	SARS-CoV-2 Group	40,418	2,415	291 (12%)	2,124 (88%)
	Viral LRTI Comparison Group	40,418	2,842	360 (13%)	2,482 (87%)
Fatigue Diagnosis	SARS-CoV-2 Group	43,201	3,651	1,273 (35%)	2,378 (65%)

	Viral LRTI Comparison Group	43,201	3,711	1,234 (33%)	2,477 (67%)
> Fatigue	SARS-CoV-2 Group	43,262	3,610	1,259 (35%)	2,351 (65%)
	Viral LRTI Comparison Group	43,262	3,707	1,231 (33%)	2,476 (67%)
> Chronic Fatigue	SARS-CoV-2 Group	71,738	207	18 (8.7%)	189 (91%)
	Viral LRTI Comparison Group	71,738	244	10 (4.1%)	234 (96%)
> Postviral Fatigue	SARS-CoV-2 Group	73,336	128	14 (11%)	114 (89%)
	Viral LRTI Comparison Group	73,336	33	2 (6.1%)	31 (94%)
Anosmia	SARS-CoV-2 Group	73,379	37	7 (19%)	30 (81%)
	Viral LRTI Comparison Group	73,379	29	3 (10%)	26 (90%)

Total at Risk counts the number of individuals without the outcome of interest prior to acute phase and whose (and their matched pairs') observation period from the index date are at least 21 days.